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Abstract 
 
 Many currently relevant diseases such as cancer arise from altered biological 
pathways that rely on protein-protein interactions.  The proteins involved in these 
interactions contain certain functional domains that are responsible for the protein’s 
biological activities.  These domains consist of secondary structural elements such as α-
helices and β-sheets which are at the heart of the protein’s biological activity.  Therefore, 
designing drugs that inhibit protein-protein interactions by binding to these key 
secondary structural elements should provide an effective treatment for many diseases.  
Presented in this dissertation are the designs, syntheses, and biological evaluations for 
both novel α-helix and novel β-sheet mimics. 
 The α-helix mimics were designed to inhibit the interactions between the tumor 
suppressor protein p53 and its inhibitor protein, MDM2.  We also targeted the 
interactions between the Bak/Bcl-xL proteins.  Using the knowledge gained from 
Hamilton’s 1,4-terphenylene scaffold, we designed our inhibitors to be non-peptidic 
small molecule α-helix mimics.  These molecules were designed to bind to the NH2-
terminal domain of MDM2 protein thus preventing it from binding to the p53 protein 
thereby allowing p53 to induce apoptosis.  The α-helix mimetic scaffold is designed 
around a central functionalized pyridazine ring while maintaining the appropriate 
distances between the ith, ith + 4, and ith + 7 positions of a natural alpha helix. 
xxiv 
 
The β-sheet mimics were designed as inhibitors for the integrin mediated 
extracellular matrix cell adhesion found in Multiple Myeloma.  We have designed, 
synthesized, and incorporated novel β-turns to induce the formation of β-hairpins as well 
as to cyclize the peptides in order to increase their binding affinities and reduce 
proteolytic cleavage.  Given that many protein-protein interactions occur through 
hydrophobic interactions; our primary β-turn promoter was designed with the ability to 
alter the β-hairpin’s hydrophobicity depending on the sulfonyl group used in the turn.  
The synthesis of several different sulfonyl chlorides for use in our β-turn promoter is 
included in this section.  We have also provided a detailed structural analysis and 
characterization of these new cyclic peptides via NMR and CD spectrometry.  Using 
standard 2D NMR methods, we have elucidated the 3D conformation of several peptides 
in solution.  We have also studied the structure activity relationships (SAR) for these 
cyclic peptides and then correlated these results with those obtained from the NMR 
studies. 
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Chapter One: 
Design and Synthesis of Pyridazine Based Non-Peptidic α-Helix Trimer Mimetics 
1.1 Introduction 
1.1.1 Overview of Amino Acids, Peptides and Proteins 
  
 All naturally occurring amino acids consist of the same basic backbone structure 
with varying side chains or R-groups.  As shown in Figure 1.1, there is an amine group 
(red) which is attached to the α-carbon (black) that is connected to both the R-group side 
chain (black) as well as to the carboxylic acid group (blue).  As indicated, the absolute 
stereochemistry of the α-carbon in naturally occurring amino acids is (S), but they can 
also be referred to as L-amino acids. 
 
 
Figure 1.1: Generic amino acid structure 
 
 These amino acids can be joined together through amide bond formation (Figure 
1.2) to create a string of amino acids which are linked together by the newly created 
peptide bonds (green).  The term peptide is used when this string contains a number of 
amino acids, usually between 2 and 100 with a combined weight of up to 10 KDa.  
H2N (S)
OH
O
R
2 
 
Proteins on the other hand generally consist of longer strings of amino acids, commonly 
referred to as residues, and have more well defined structures.  The number of different 
proteins that can be formed from the 20 naturally occurring amino acids is truly 
astronomical.  While the smallest naturally occurring protein known to date, which is 
found in Gila monster saliva, is only 39 amino acids along
1
, the average protein length in 
humans is about 361 amino acids
2
.  Therefore, to gain a sense of the scope of the total 
number of possible proteins, let’s look at an example of a large peptide with 100 amino 
acids.  For this peptide, there are a total of 20
100
 possible sequences which equals 
1.268*10
130
 (a number larger than a googol) structurally different molecules. 
 
 
Figure 1.2: Synthesis of peptide bonds 
 
 A protein’s biological activity depends on its three dimensional structure and its 
ability to slightly alter this structure, or conformation.  The structures of proteins are 
categorized into 4 distinct categories; primary (1°), secondary (2°), tertiary (3°), and 
quaternary (4°).  The primary structure refers to the linear sequence of amino acids 
bonded together by peptide bonds.  The secondary structure of the protein is usually 
directly related to the primary structure.  There are three general types of secondary 
structures; the α-helix, the β-sheet and the β-turn.  These secondary structures are a result 
of the geometry of the bond angles between residues and the hydrogen bonds between 
H2N (S)
OH
O
R
H2N (S) OH
O
R1
H2N ( S)
N
H
(S)
OH
O
OR
R1
- H2O
Newly Created
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backbone residues.  The tertiary structure describes what the three dimensional structure 
of the protein looks like by describing how its secondary structures are organized and 
related to one another through space.  It is this tertiary structure that controls the basic 
functionality of the protein.  Quaternary structures are when groups of proteins, called 
subunits, combine and work cooperatively to create a larger functional protein complex.  
These three dimensional structures are all stabilized by interactions such as Van der 
Waals interactions, hydrogen bonds, disulfide bonds, hydrophobic effects and by the 
formation of salt bridges.   
Another commonality between proteins is the fact that they all have locations 
called active sites, or recognition sites.  It is at these recognition sites where reactions are 
catalyzed and protein-protein interactions occur.  These protein-protein interactions are 
exceptionally important because of their role in many crucial cellular processes such as 
DNA replication, gene expression, metabolism, and programmed cell death commonly 
called apoptosis.  Often, these interactions are key integral components to a variety of 
diseases such as cancer
3
 and Alzheimer’s4.  Therefore, these interactions can potentially 
be exploited to assist in the treatment and cure of the disease. 
 
1.1.2 Protein-Protein Interactions as Potential Drug Targets 
 
 By preventing specific protein-protein interactions, we hope to prevent the 
proliferation and potentially cure diseases such as cancer and Alzheimer’s.  The generic 
concept of protein-protein interactions can be thought of as a lock and key type of 
4 
 
interaction where the lock is a protein binding site of interest while the key is a different 
protein that fits into the specific binding site of the first protein (Figure 1.3).   
 
Figure 1.3: Generic formation of protein-protein interactions 
 
Our goal is to replace this key with something else in order to prevent the protein 
complex from forming.  While a variety of other keys (compounds in this analogy) may 
fit into the lock, it is much more difficult to find a new key that successfully opens the 
lock (binds to the protein of interest) (Figure 1.4).  While there are many approaches to 
this problem, our group has approached the problem from a small molecule point of view. 
 
 
Figure 1.4: Use of alternate compounds to prevent protein-protein interactions    
 
 
Protein 1
"Lock"
Protein 2
"Key"
Protein Complex
Protein 1 Compound 1 Binding Unsuccessful
Compound 2 Binding Successful
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1.1.3 Targeting α-Helices Involved in Protein-Protein Interactions  
 
 Comprising about 40% of the total structure of naturally occurring proteins, the α-
helix is the most abundant secondary structure found in nature
5.  α-Helices are crucial 
components for many of the domains involved in protein-protein interactions, protein-
RNA and protein-DNA interactions
6
.  There are lots protein-protein interactions that 
include α-helices, many of these interactions are part of critical disease pathways7 as 
shown in Table 1.1. 
  
Table 1.1: Critical disease pathways involving α-helices 
Interaction Disease Motif 
p53/MDM2 Cancer i, i + 4, i + 7 
smMLCK/CaM Cancer i, i + 4, i + 7 
Rac1/Tiam1 Cancer i, i + 4, i + 7 
GRIP/Era Cancer i, i + 3, i + 7 
Vav Cancer i, i + 1, i + 4 
Bak/Bcl-xL Cancer i, i + 4, i + 7, i + 11 
Tachykinin Receptors/peptide Neurological Disorders i, i + 4 
NaIP Bacterial Infections i, i + 4, i + 7 
gp41 HIV i, i + 3, i + 4, i + 7 
 
 Given that the primary sequences of these α-helices are known, it could be 
possible to manually recreate them using current peptide synthesis technology.  However, 
previous experiments
8
 have shown that when α-helices are synthesized independently of 
their parent protein in a lab setting, they do not retain their secondary structure.  
6 
 
Furthermore, in vivo, these peptides were no longer able to bind to their target protein and 
take place in the same protein-protein interaction as they did when incorporated into the 
full protein.  Therefore, our lab and many others have invested significant amounts of 
time researching the design and synthesis of novel α-helix mimics. 
 The α-helix consists of amino acid residues configured in a right-handed helix and 
this helix is stabilized by intramolecular hydrogen bonds as shown in Figure 1.5
9
.  These 
intramolecular hydrogen bonds exist between the carbonyl oxygen of the ith residue and 
the amide N-H of the i + 4 residue.  There are 3.6 residues per turn of the helix which 
corresponds to a distance of 5.4 Å between each turn and a rise of 1.5 Å per residue. 
 
 
Figure 1.5: Standard α-helix 
 
i + 3 
i +7 
i + 4 
i  
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 Specific residues on the α-helix have also been labeled in Figure 1.5.  These 
residues correspond to the general binding motifs that have been observed for α-helices.  
When α-helices bind as part of a protein-protein interaction, they bind along a specific 
face using residues in one of the following three motifs; i, i + 3, i + 4; i, i + 3, i + 7; or i, i 
+ 4, i + 7.  Therefore, novel compounds can be designed around these α-helix binding 
motifs such that the final product displays the appropriate amino acid side chains at the 
appropriate position relative to the natural α-helix. 
 
1.1.4 Cancer, Apoptosis, and the p53/MDM2 Interaction 
 
 The U.S. national library of medicine defines cancer as the uncontrolled growth of 
abnormal cells in the body
10
.  While the transformation processes from normal cells to 
cancer cells is lengthy and complicated, it may not be identical for all types of cancer
11
.  
However, there are six essential cellular alterations that hallmark the more than 100 
different types of cancer cells
5b
.  The first of which is that they are self-sufficient in 
growth signals.  Unlike normal healthy cells, cancer cells do not need extracellular 
growth signals because they manufacture their own signals.  Second, cancer cells are 
unaffected by anti-growth signals.  When normal cells receive these signals, they stop 
replication either temporarily or permanently depending on the signal.  Cancer cells 
ignore such signals by blowing their respective pathways.  Third, cancer cells are able to 
invade surrounding tissue and metastasize.  This occurs when the main collection of 
cancer cells, called a tumor, sends cancer cells out to occupy new parts of the body.  The 
fourth of which is the ability to induce and sustain angiogenesis.  Angiogenesis is the 
8 
 
formation and growth of new blood vessels.  While normal cells exit the angiogenesis 
phase once fully formed, cancer cells do not.  This ensures an ever growing supply of 
oxygen and nutrients vital to continued growth and expansion.  The fifth is that they 
display the ability for limitless replication potential.  While normal cells display a 
capacity for 60-70 doublings before dying, cancer cells do not show a capacity for 
replication and do not die, thus having been dubbed as immortal cells.  The sixth and 
final hallmark of cancer cells is their ability to evade apoptosis.  The term apoptosis 
describes the programmed cell death that occurs when enough damage is detected to 
warrant killing the cell.  Since the ability to elude apoptosis is arguably the most 
important aspect of cancer cells, we have focused our attention on this issue.  Finding an 
efficient and complete way to induce cellular death in these cancer cells effectively 
removes them from the patient thus curing the patient altogether. 
 The apoptosis process is highly regulated by several pathways.  While some of 
these pathways control pro-apoptotic factors such as p53, other pathways control anti-
apoptotic factors such as Bcl-xL and Bcl-2 as shown in Figure 1.6.  The pathway most 
often compromised and associated with tumor formation (tumorigenesis) is the tumor 
suppressor protein 53 signaling pathway.  Often, this protein is referred to as p53.  The 
purpose of this pathway is to induce cell cycle arrest at appropriate times to allow for 
repairs or to promote apoptosis if necessary when the cell is damaged beyond repair
12
. 
 In normal cells, p53 is activated when the cell becomes stressed due to stressors 
such as DNA damage, UV radiation, hypoxia or toxins
13
.  In the nucleus, p53 acts as a 
sequence specific transcription factor and is responsible for the regulation of expression 
for over one hundred different targets
3
.  However, if the damage is severe enough, p53 
9 
 
can transcriptionally stimulate pro-apoptotic proteins such as the Bcl-2-associated x 
protein (Bax) which then interact with mitochondrial membrane proteins Bcl-2 and Bcl-
xL to allow for the release of cytochrome c.  This, combined with the release of other 
proteins from the mitochondria and the activation of specific cysteinyl aspartate proteases 
(caspases), ultimately results in cell death
14
.   
 
 
Figure 1.6: Cellular pathways leading to apoptosis 
 
 However, when normal cells are not stressed, p53’s transcriptional activity 
becomes dormant and its turnover rate is decreased by the binding of the regulatory 
protein MDM2.  MDM2 inhibits p53 accumulation by inhibiting phosphorylation
15
 and 
10 
 
targeting it for ubiquitination and proteasomal degradation
16
.  This is the main regulatory 
mechanism for p53.  MDMX, a different protein homolog of MDM2 can also bind to p53 
and suppress the activation of its target genes.  However, it is not the main regulatory 
mechanism since it does not promote the degradation of p53 the way MDM2 does nor is 
it transcriptionally induced by p53
17
. 
 If repairs are to be made to normal cells following stress signals, then p53’s 
actions must be closely monitored by MDM2 to prevent p53 from inducing apoptosis in 
addition to repairing the damage.  Following the stress signal, excess p53 is produced 
which then upregulates the synthesis of MDM2 as shown in Figure 1.7.  While the stress 
signal stimulates the phosphorylation of serine residues in the active site of p53, the 
newly created MDM2 proteins mop up the excess p53 proteins
18
.  The serine 
phosphorylation now prevents MDM2 from binding and deactivating p53. 
 
 
Figure 1.7: MDM2 regulation of p53 
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 p53 is then activated by induction of the ADP ribosylation factor (ARF) which 
binds to MDM2, further inhibiting the MDM2’s ability to ubiquitinate p5315.  Now p53 
can induce cell cycle arrest and initiate the necessary genes to fix the stressor damage.  
Once finished with these tasks, p53 is dephosphorylated and then destroyed by the 
MDM2 that has accumulated in the cell.  
 Cancer cells gain their last hallmark, immortality, by evading apoptosis.  While 
there are many ways in which this can happen, the most common way is through a 
mutation of the p53 gene which results in deactivation of the p53 protein.  These 
mutations usually occur in the sequence-specific DNA binding domain (residues 102-
292)
19
. This results in the loss of DNA binding capabilities of the protein thus rendering it 
useless.  More than 50% of human cancers gained their immortality though gene 
mutation.  The remaining cancers displayed inhibited wild type p53 functions due to 
MDM2 binding.  While some showed standard cellular concentrations of MDM2, the 
majority displayed an overexpression of MDM2
20
.  Thus, inhibition of the excess MDM2 
in cancer cells with wt p53 should enable p53 to induce apoptosis and kill the cancer cell. 
 Structurally, wt p53 is a nuclear phosphoprotein containing 393 amino acids and 
is comprised of several structural and functional domains
3
.  The N-terminus contains the 
transactivation domain (residues 1-42) which is responsible for the transactivation 
activity as well as interacting with and binding to the MDM2 protein.  It also contains the 
proline-rich region (residues 61-94) which is responsible for MDM2 regulated stability of 
p53.  Deletion of this regions increases p53’s susceptibility to degradation by MDM2.  
The central core contains the DNA-binding domain (residues 102-292) which is 
necessary for sequence-specific DNA binding.  It is also the most highly conserved 
12 
 
region of the entire protein.  The C-terminus contains the tetramerization domain 
(residues 324-355) which is necessary for p53 dimerization and tetramerization.  It also 
contains the regulatory domain (residues 363-393) which is responsible for the negative 
regulation of DNA binding.  This regulatory domain has also been connected to the 
initiation of apoptosis.  Figure 1.8 shows p53 interacting with DNA through an α-helix. 
 
Figure 1.8: Tumor suppressor p53 complexed with DNA (PDB structure 1TUP) 
 
 Structurally, MDM2 is a small globular protein which contains the p53 binding 
pocket as a small hydrophobic cleft on one face as shown in Figure 1.9a
21
.  This cleft is 
formed by two sets of α-helices and a pair of three-stranded β-sheets as shown in Figure 
1.10.  One set of α-helices forms the sides while the other shorter set forms the bottom of 
the cleft.  The β-sheets then close off each end of the cleft.   
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Figure 1.9: a) MDM2 binding cleft; b) Crystal structure of p53 binding to MDM2 
 
 
Figure 1.10: Schematic diagram depicting MDM2 binding cleft 
 
 As seen in the crystal structure shown in Figure 1.9b, the active binding portion of 
p53 is an α-helix which binds to the MDM2 cleft using hydrophobic residues 18 to 26.  
Of these, only three (Phe19, Trp23, and Leu26) have been shown to be key binding 
residues
21
.  These residues follow the binding motif i, i + 4, i + 7.  This α-helix forms 
very strong Van der Waals interactions with the hydrophobic residues in the cleft of 
MDM2. 
 
a) 
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1.1.5 Cancer, Apoptosis, and the Bcl2 Family of Proteins 
 
 As briefly mentioned in the previous section, the Bcl-2 family of proteins plays an 
important role in the regulation of apoptosis.  This family contains both pro-apoptotic 
(Bak, Bax, Bim, Bid) and anti-apoptotic (Bcl-2, Bcl-xL, Bcl-W) proteins.  These proteins 
all share one or more specifically conserved sequence regions referred to as Bcl-2 
homology (BH) BH1, BH2, BH3, and BH4 domains
22
.  The type of apoptotic signal will 
determine which proteins in the Bcl-2 family are responsible for causing apoptosis.  If the 
pro-apoptotic Bak and Bax proteins are responsible, then they will homo-oligomerize to 
create aggregates in the outer memebrane of the mitochondria.  As a result of these 
aggregates, pores form in this membrane which activates the release of cytochrome c to 
cause apoptosis.  If however, one or both of the anti-apoptotic Bcl-2 and Bcl-xL proteins 
heterodimerize with the BH3 domain, the death promoting region, of Bak and Bax then 
their pro-apoptotic activity will be neutralized and the cell will not enter into apoptosis.  
Therefore, just as in the p53/MDM2 situation, the balance between these pro-apoptotic 
and anti-apoptotic proteins controls the cell’s ability to enter into apoptosis. 
 Bak and Bcl-xL binding studies performed by NMR show that the BH3 binding 
domain of Bak is an α-helix.  Similar to the p53/MDM2 example, Bak interacts using 
hydrophobic residues 72 to 87 which fit into the hydrophobic cleft of the Bcl-xL protein 
as shown in Figure 1.11
23
.  The key binding residues were found to be Val74, Leu78, 
Ile81, and Ile85.  These residues follow the binding motif i, i + 4, i + 7, i + 11.  
Additionally, electrostatic interactions between oppositely charged side chains of Bak 
and Bcl-xL helped to stabilize this binding interaction. 
15 
 
 
Figure 1.11: Crystal structure of Bak binding to Bcl-xL 
 
1.1.6 Previous Non-Peptidic α-Helix Mimics  
 
 To date, there have been a number of non-peptidic α-helix mimics synthesized to 
disrupt the p53/MDM2 interaction as well as the Bax/Bcl-xL interaction.  Some examples 
include the many scaffolds developed by Rebek and coworkers
6a, 24
, the trans-fused 
polycyclic ether scaffolds
25
 , the nutlin scaffolds
26
, and the 1,4-benzodiazepine-2,5-dione 
scaffolds
27
 as shown in Figure 1.12.   
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Figure 1.12: a) Two examples of Rebek scaffolds; b) trans-fused polycyclic ether 
scaffold; c) nutlin scaffold; d) benzodiazepine scaffold 
 
However, the Hamilton 1,4-terphenylene scaffold
9, 15, 28
 was the first of this type 
and derivatives of these initial scaffolds display some of the best biological activity of all 
the non-peptidic α-helix mimics.  This 1,4-terphenylene scaffold places the side chains 
the same distance apart as they would be found in a natural α-helix displaying the motif 
of i, i + 4, i + 7 (Figure 1.13).  The scaffold also allows for some conformational 
flexibility between the phenyl rings so that the side chains can move to better fit the 
binding pocket. 
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Figure 1.13: a) Hamilton’s first 1,4-terphenylene scaffold; b) Terphenylene scaffold 
based on natural α-helix 
 
 One drawback to the terphenylene scaffold is its high degree of hydrophobicity 
which, in the case of one prominent example, has been demonstrated to provide the 
compound of interest with inadequate biological activity due to its poor solubility thus 
inhibiting it from becoming a potential drug candidate.  The terphenyl derivative 1.A 
(Figure 1.14) was shown to inhibit the p53/MDM2 interaction reasonably well in vitro 
(182 nM)
28a, b
 by binding to MDM2’s hydrophobic cleft.  However, when ELISA assays 
were used, compound 1.A was considerably less effective with an IC50 value of 130 
μM15. 
O
CO2H
O
CO2H
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Figure 1.14: Terphenylene showing most activity towards p53/MDM2 
 
1.2 Results and Discussion for the Pyridazine Scaffold 
1.2.1 Design of Novel Pyridazine Scaffold 
 
Based on the results from previous work done in Hamilton’s and other groups, it 
was clear to us that the scaffold should be one that incorporated a reasonably hydrophilic 
element to it in order to make the molecule more drug-like.  Previously
29
, our group has 
incorporated pyrimidine rings into the core of the scaffold as a way of introducing 
hydrophilic character into the molecule.  Based on the positive structural results yet 
negative biological results obtained from the pyrimidine studies our group carried out, we 
became interested in using pyridazines instead of pyrimidines as the backbone bone for 
our scaffold.  This change will allow us to create a “wet edge” of the scaffold that can be 
rich in hydrogen bond donors and acceptors while still presenting a hydrophobic surface 
CO2H
O
CO2H
1.A
p53/MDM2 K
i
= 182 nM
ELISA IC50 = 130 M
no p53 activation
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(Figure 1.15) necessary for recognition at the protein interaction site.  Furthermore, using 
a pyridazine backbone should allow for the relatively easy synthesis of a large library of 
target compounds. 
 
 
Figure 1.15: Representation of both the “wet edge” and hydrophobic binding domain 
 
 We decided that working with 3,6-dichloropyridazine A would give us a 
relatively easy place to start from rather than trying to synthesize the pyridazine ring from 
diketones/diacids
30
 or tetrazines
31
.  It would also allow us to use a wide variety of 
nucleophiles for the SNAr reactions and give us control over position substitution as 
shown in Scheme 1.1.  Furthermore, there are several known examples which 
demonstrate the addition of various alkyl groups to occupy the R2 position of 3,6-
dichloropyridazine B.  Finally, it is a relatively inexpensive starting material (100g 98% 
for 69.30 USD
32
) that can easily be purchased in large amounts from any commercial 
chemical supply company. 
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Scheme 1.1: General synthesis of pyridazine based α-helix mimics 
 
1.2.2  Retrosynthesis of Pyridazine Scaffold 
 
Working outward from the central pyridazine ring, we reasoned that both chirality 
and side chains could be introduced in the form of L-amino acids to create compounds 
with potentially enhanced binding capabilities.  These amino acids could be introduced 
one by one in a specific manner as to vary the R- groups in the final product as shown in 
the retrosynthetic strategy in Scheme 1.2.  Using the amino group of an amino acid as the 
nucleophile and using steric hindrance as our position director, we planned to easily 
attach 2 different amino acids one at a time to produce A.  We planned to use metalation 
reactions to attach R2 to 3,6-dichloropyridazine giving us C.  The benefit here is that 
depending on which metalation reaction conditions we used (discussed further below), 
we could incorporate stereochemistry at the R2 position if we so desired.  We believed 
this overall plan to be a very easy way of creating a trimeric α-helix mimic while 
maintaining strict control over stereochemistry. 
 
N N
ClCl Conditions
N N
ClCl
R2
A B
Conditions
N N
Cl
R1
R2
Nu
NuR1
R3 Nu
Conditions
C
N N
Nu
R2
NuR1 R3
D
21 
 
 
Scheme 1.2: Retrosynthesis of 3,6-diaminopyridazines 
 
1.2.3 Use of Knochel Base and Lithium Metalation Reactions to Synthesize 4-
Substituted Pyridazines 
 
 I started the synthesis of 4-substituted pyridazines using directed zincation 
reactions, otherwise known as Knochel base
33
 reactions.  2,2,6,6-Tetramethylpiperidide 
zinc chloride lithium chloride (TMPZnCl·LiCl) (G) was synthesized (Scheme 1.3) 
according to published methods as the selective base for these types of reactions.  It was 
then used in combination with 3,6-dichloropyridazine and a variety of reported conditions 
in an attempt to synthesize product 1.1 as shown in Scheme 1.4 and described in Table 
1.2.  However, none of these reactions successfully produced product and so were 
abandoned in favor of a different type of metalation reaction.  
 
 
Scheme 1.3: Synthesis of (TMPZnCl·LiCl), G 
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Scheme 1.4: Attempted synthesis of 1.1 using Knochel Base 
 
Table 1.2: Assorted conditions used in Knochel base reactions 
Entry Conditions Electrophile Result 
1 CuCN·2LiCN, Anhyd. THF, -20°C BnCl NR 
2 CuCN·2LiCN, Anhyd. THF, -20°C PhCHO† NR 
3 Pd2(dba3), P(o-furyl)3, Anhyd. THF BnCl NR 
4 Pd2(dba3), PPh3, Anhyd. THF BnCl NR 
†
This would give (3,6-dichloropyridazin-4-yl)(phenyl)methanol as the product 
 This new and more direct type of metalation reaction, what I will refer to as 
lithium metalation reactions, has been shown to add alkyl groups of interest to 3,6-
disubstituted pyridazines in reasonable yields
34
.  As shown in Scheme 1.5, pyridazine is 
first lithiated with LDA at low temperatures to produce the nucleophile H which is then 
reacted with different aldehyde electrophiles to produce 4-substituted pyridazines in 
moderate yields (Table 1.3).  However, despite the moderately decent yields of this 
reaction, it creates a new problem for us in that it non-selectively produces enantiomers 
as its products.  These enantiomers will need to be separated before moving on to the 
next step.  More than likely, this separation will require the use of HPLC to obtain a pure 
product containing a single enantiomer which will increase the total overall cost of 
producing the end trimer.  
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Scheme 1.5: Lithium metalation synthesis of 4-substituted pyridazines 
 
Table 1.3: Products of lithiation reactions 
Entry R Group Yield (%) 
1 i-Bu 44 
2 Ph 54 
3 Bn 27 
4 2,4-NO2Ph NR 
 
An attempt was made to expand the scope of this reaction’s applicability beyond 
aldehydes to halogenated alkyl compounds by using benzyl chloride as the electrophile, 
similar to the Knochel base reactions discussed above.  Therefore, the product of this new 
reaction will avoid the enantiomer issue entirely and give us a single product.  However, 
replacing the aldehyde with an alkyl chloride drastically reduced the overall yield of the 
reaction to an unacceptable 4% (Scheme 1.6).  From here, I incorporated a bit of the 
Knochel base idea but rather than using a zinc salt, I combined 2,2,6,6-
tetramethylpiperidine with nBuLi to create a new lithiating agent LTMP (lithium 2,2,6,6-
tetramethylpiperidide)
34a
.  This was then used in combination with benzaldehyde to give 
the 4-substituted product in a 38% yield.  This same product was produced in a 54% yield 
by the lithium metalation reaction mentioned above (Table 1.3, entry 2).  Obviously, 
incorporating the piperidine did nothing beneficial for this reaction.  A final attempt to 
N N
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ClCl
Li
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H
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create a single non-enantiomeric product was made using LTMP followed by benzoyl 
chloride as the electrophile.  However, this reaction failed to produce any of the product 
containing the ketone and so these methods were discontinued in favor of potentially 
higher yielding and non-enantiomer producing reactions. 
 
 
Scheme 1.6: Lithium metalation reaction using benzyl chloride 
 
1.2.4 Free Radical Synthesis of Substituted Pyridazines 
 
 Given the problems found in the metalation reactions, I began looking for an 
easier method to attach alkyl groups to pyridazines.  What I found was a reasonably 
simple free radical reaction utilizing silver-catalyzed oxidative decarboxylation of 
carboxylic acids to produce alkyl free radicals that would add to 3,6-dichloropyridazine 
in pretty high yields
24, 35
.  These reactions did not create new stereo centers in their 
products and were fairly easy to do.  Scheme 1.7 describes the generic reaction for the 
addition of any R- group to 3,6-dichloropyridazine.  We incorporated the side chains of 
the amino acids leucine, valine and phenylalanine into the different R- groups added to 
allow for the construction of a focused library.  Based on the information from 
Hamilton’s terphenylene scaffolds, we also incorporated a 2-methylnapthyl substituent as 
part of our library.  The respective yields of the reactions are listed in Table 1.4.  Analysis 
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of this table shows that when the R- group is an alkyl one, the yield is very high.  
However, as the R- group becomes more aromatic, the reaction yield decreases.  This 
analysis agrees with the published reaction mechanism
36
 which states the reaction is 
occurring via a free radical process.  Therefore, as the R- groups become more aromatic, 
their ability to spread the radical around increases thus resulting in a higher percentage of 
unwanted side products. 
 
  
Scheme 1.7: Free radical synthesis of substituted pyridazines via persulfates 
 
Table 1.4: Products of alkyl free radical addition reactions 
Product R2 Group Yield (%) 
1.1 Bn 52 
1.2 i-Pr 91 
1.4 i-Bu 100 
1.5 2-MeNpth 12 
 
1.2.5 Dimer and Trimer Synthesis via Addition of Amino Acids to Substituted 
Pyridazines  
 
Using these 4-substituted pyridazines as the center piece of our scaffold, I then 
attempted to selectively attach amino acids to the pyridazines one at a time (Scheme 1.8).  
While the substitution/addition of one amino acid to a pyridazine ring has never been 
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published, there is a reasonable amount of literature precedent for using alkyl amines as 
nucleophiles in this SNAr reaction
37
 (henceforth referred to as an addition reaction).  
Using these various reaction conditions, I was able to selectively add a single amino acid 
to the central pyridazine scaffold using the amine nitrogen as the nucleophile.  By using 
pyridazines with sterically hindered 3 positions, I gained a reasonable amount of 
selectivity for addition to the 6 position over that of the 3 position.  However, as shown in 
Table 1.5, the yields of these reactions were simply abysmal.  In an attempt to increase 
the reaction yield and rule out any possibility of negative steric interaction between the 
amino acids and the R1- groups in the 4 position of the pyridazines, I tried the reactions 
again using unsubstituted dichloropyridazines.  However, the reaction yield did not 
greatly improve and despite trying a variety of experimental conditions as shown, the 
yield never rose above 18%. 
 
 
Scheme 1.8: Addition of amino acid to 4-substitued pyridazines 
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Table 1.5: Assorted conditions used for single substitution reactions with pyridazines 
Entry R1 Group R2 Group Conditions Yield (%) 
1 Bn i-AmOH Abs. EtOH, Pressure Tube, TEA, 100°C 10 
2 Bn i-AmOH Dry MeOH, Microwave, 20 min., TEA, 150°C <1-2 
3 Bn H Abs. EtOH, Pressure Tube, TEA, 120°C 4
a
 
4 Bn H Abs. EtOH, Microwave, 20 min., 150°C 18
a,b
 
5 Bn H MeOH, Microwave, 45 min., 150°C 5 
6 Bn H MeOH, Microwave, 90 min., 160°C <1-2 
7 Bn H CuCl, Ethylene Glycol, K
3
PO
4
, DMF, 95°C 1.7 
8 Bn H CuI, K
3
PO
4
, DMF, 95°C 3 
9 i-Bu PhEtOH MeOH, Microwave, 20 min., TEA, 150°C <1-2 
10 i-Bu BnOH MeOH, Microwave, 20 min., TEA, 150°C <1-2 
11 i-Bu BnOH MeOH, Microwave, 20 min., 150°C 2.4 
12 i-Bu Bn MeOH, Microwave, 60 min., 150°C 8.2 
13 i-Bu Bn MeOH, Microwave, 90 min., 130°C 7 
aEthyl ester product bAmino acid with free carboxylic acid used 
 Given the exceedingly low yields of the monosubstituted products, we were 
pessimistic about the addition of a second amino acid but became cautiously optimistic 
by the small amount of literature precedent found for the addition of 2 amine groups onto 
pyridazine rings
38
.  Using the small amount of product isolated from the monoaddition of 
an amino acid to the substituted pyridazine, I attempted to add another amino acid to the 
other side of the pyridazine again using the amino nitrogen as the nucleophile and the 
same microwave reaction conditions as before as shown in Scheme 1.9.  However, this 
failed to give product 1.7a and so we began thinking of alternative nucleophiles that we 
could use in place of amino nitrogen’s. 
28 
 
 
 
Scheme 1.9: Second addition of amino acid to α-helix mimic 
 
1.2.6 Dimer Synthesis via Addition of Oxygen Nucleophiles to Substituted 
Pyridazines 
 
 As a way to potentially retain our desired “wet edge” of the molecule while still 
incorporating the hydrophobic side chains, we looked into using alkoxy nucleophiles.  
These oxygen nucleophiles are more nucleophilic than the amine groups from amino 
acids so they should provide us with a much larger yield.  Furthermore, after addition, 
one of the two lone pairs of electrons on the oxygen can serve as hydrogen bond 
acceptors as part of the “wet edge”.  As before, I planned to add the alkoxide 
nucleophiles to the substituted pyridazine one at a time in a stepwise fashion as shown in 
Scheme 1.10.  While symmetric dual alkoxide additions to substituted pyridazines have 
been shown before
39
, mono alkoxide additions to substituted pyridazines have not.  It was 
expected that these single alkoxide additions would be selective due to the same steric 
hindrance effects seen for the addition of amino acids.  The alcohols chosen for these 
reactions incorporated the side chains of the amino acids leucine, valine and 
phenylalanine. 
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Scheme 1.10: General addition of alkoxy groups to substituted pyridazines 
 
Synthesis of the dimers was accomplished by dissolving the appropriately 
substituted pyridazine (1.1, 1.2, 1.4 or 1.5) with a suitable solvent (either Dioxane or 
anhydrous THF) in a pressure tube followed by the addition of a strong base and then the 
dropwise addition of the appropriate alcohol (Scheme 1.11).   
 
 
Scheme 1.11: Pyridazine scaffold dimer synthesis 
 
Following the addition of the alcohol, the pressure tube was sealed and then 
heated overnight at temperatures ranging from 80°C – 100°C to yield a library of nine 
pyridazine scaffold dimer analogs as shown in Table 1.6.  The two procedures used here 
and their differences will be discussed in greater detail later in this thesis. 
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Table 1.6: Library of synthesized pyridazine scaffold dimers 
Product R1 R2 Conditions
†
 Yield (%) 
1.9 i-Pr i-Pr A 71 
1.10 Bn i-Pr A 64 
1.11 i-Bu i-Pr A 61 
1.22 i-Pr Bn A 12 
1.22 i-Pr Bn B 56 
1.23 Bn Bn A 44 
1.24 i-Bu Bn A 25 
1.35 i-Pr i-Bu A 42 
1.36 Bn i-Bu A 52 
1.37 i-Bu i-Bu B 68 
†A = Method A using KOtBu, B = Method B using NaH 
 
 The results from the monosubstitution reactions show that when either R1 or R2 is 
Bn, there is enough steric hindrance to prevent addition to the 3- position thus allowing 
for an excellent selective addition to the 6- position.  However, when either R- group is 
iPr or iBu, there is not enough hindrance between the two groups to prevent addition to 
both sides of the pyridazine.  This can be clearly seen in the LCMS traces of the crude 
reaction mixtures shown in Figure 1.16 and 1.17 and is supported by the 
1
H NMR of 
these products.  Figure 1.16 shows a single peak in the LCMS trace for the product’s 
mass which corresponds exclusively to product 1.10.  However, the LCMS trace in 
Figure 1.17 shows two peaks for the monosubstituted product’s mass; one for the 6- 
substituted product 1.9 and one for the 3- substituted product 1.9a. 
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Figure 1.16: LCMS trace for product 1.10’s mass 
 
 
 
Figure 1.17: LCMS trace for product 1.9’s mass 
 
The polarity of these two isomers is extremely similar and so the separation of 
these two products cannot be accomplished by simple flash chromatography to any 
appreciable extent.  These two isomers can however be separated using HPLC 
techniques.  As mentioned before, this deviates from our goal of synthesizing cheap α-
helix mimics by adding a further substantial cost to the overall preparation and 
purification of the trimers.  However, running a single HPLC at this point provides two 
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pure dimer isomers which can then potentially be used in the synthesis of a large number 
of different pure trimers as shown in Scheme 1.12. 
 
 
Scheme 1.12: Single HPLC purification followed by divergent synthesis  
 
 Unfortunately, during the time I was synthesizing these dimers (in addition to the 
trimers), the funding situation in our lab was such that I was unable to utilize a prep-
HPLC to completely purify the dimers and non-symmetrical trimers.  As a result, the 
yields of such dimers and non-symmetrical trimers are combinations of both the 3- and 6- 
substituted products.  However, the majority of the reported yield is due to the stated 
product in each of these cases.  It should also be mentioned that the reported NMR 
chemical shifts for each product are correct for the stated product and are not a 
combination of both potential isomers.  In cases where both isomers existed in the NMR 
sample, the specific NMR chemical shifts for the isomer of interest were extracted using 
a combination of the advanced 1 dimensional NMR techniques 1D NOE and 1D TOCSY 
and by using prior knowledge of specific chemical shift locations.  These 1D NOE and 
1D TOCSY NMR spectra can be located in Appendix A following their respective 
1
H 
and 
13
C spectra. 
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 Given this addition site selection problem, I investigated the possibility of 
selectively adding the R2 group on after adding both the R1 and the R3 group.  While this 
has been done before
40
, neither of these reported reactions displayed any type of 
selectivity for one position over another on the pyridazine ring.  It was also determined 
that trying to use the free radical procedure mentioned above would also not allow for 
any selectivity.  Furthermore, another downfall for the free radical procedure is that it 
would more than likely also add to one of the alkoxy R- groups already on the pyridazine 
ring giving us a slew of different products.  Therefore, I believe that our current method 
of synthesizing these substituted pyridazines is the best despite the fact that it will be 
necessary to purify some of the intermediate products via HPLC. 
  
1.2.7 Non-Symmetrical Trimer Synthesis via Addition of Oxygen Nucleophiles to 
Substituted Pyridazines 
 
 The exact same process to synthesize the dimers was also used to synthesize the 
non-symmetrical pyridazine scaffold trimers as shown in Scheme 1.13.  A library of 
eighteen non-symmetrical pyridazine scaffold trimer analogs were synthesized by the 
addition of the appropriate alkoxide to the monosubstituted pyridazines (Table 1.7).   
 
 
Scheme 1.13: Non-symmetrical pyridazine scaffold trimer synthesis 
 
N N
ClO
R2
Dioxane or Anhyd. THF
KOtBu or NaH, 80-100C
N N
OR3
R2
OH OR1R1 R3
34 
 
Table 1.7: Library of synthesized non-symmetrical pyridazine scaffold trimers 
Product R1 R2 R3 Conditions
†
 Yield (%) 
1.13 i-Pr i-Pr i-Bu C 73 
1.14 i-Pr i-Pr Bn C 72 
1.16 Bn i-Pr i-Pr C 45 
1.17 Bn i-Pr i-Bu C 12 
1.19 i-Bu i-Pr i-Pr C 71 
1.20 i-Bu i-Pr Bn C 44 
1.26 i-Pr Bn i-Bu D 47 
1.27 i-Pr Bn Bn D 47 
1.29 Bn Bn i-Pr D 73 
1.30 Bn Bn i-Bu D 39 
1.32 i-Bu Bn i-Pr D 53 
1.33 i-Bu Bn Bn D 12 
1.39 i-Pr i-Bu i-Bu C 82 
1.40 i-Pr i-Bu Bn C 58 
1.42 Bn i-Bu i-Pr D 75 
1.43 Bn i-Bu i-Bu D 63 
1.45 i-Bu i-Bu i-Pr D 24 
1.46 i-Bu i-Bu Bn D 56 
†C = Method C using KOtBu, D = Method D using NaH 
 
 In general, the reaction yields for the synthesis of these non-symmetric trimers 
decreases as the alcohols used become increasingly sterically hindered.  The average 
yield for the addition of i-PrOH is 56.83% which then decreases to 52.67% for i-BuOH.  
As expected, the average yield for the addition of BnOH is the lowest of the three 
alcohols at 48.16%. 
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1.2.8 Symmetrical Trimer Synthesis via Addition of Oxygen Nucleophiles to 
Substituted Pyridazines 
 
A process extremely similar to the one used to synthesize the dimers was used to 
synthesize the symmetrical pyridazine scaffold trimers (Scheme 1.14).  However, the 
equivalence of alcohol used was more than 2-fold in excess to ensure complete 
symmetrical dual alkoxide additions to the pyridazines.   
 
 
Scheme 1.14: Symmetrical pyridazine scaffold trimer synthesis 
 
A library of fifteen symmetrical pyridazine scaffold trimer analogs were 
synthesized as shown in Table 1.8.   
 As expected for the three standard alcohols, iPrOH, iBuOH and BnOH, the yields 
for these dual symmetric addition reactions decreases as the R2 group on the pyridazine 
increases in size and thus in steric hindrance.  However, the yields for 1-
napthalenemethanol follow the opposite trend; as the R2 group increases in size, the yield 
increases as well.  This may be due to favorable attractive interactions between the R2 
groups (both iBu
41
 and Bn) and the aromatic naphthalene rings.  These attractive 
interactions could bring the naphthalene alkoxide close enough to the pyridazine ring for 
a long enough time to allow for the addition reactions to occur thus increasing the yield. 
N N
ClCl
R2
Dioxane or Anhyd. THF
KOtBu or NaH, 80-100C
N N
OR1
R2
OH OR1 R1
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Table 1.8: Library of synthesized symmetrical pyridazine scaffold trimers 
Product R1 R2 Conditions
†
 Yield (%) 
1.12 i-Pr i-Pr E 62 
1.12 i-Pr i-Pr F 77 
1.15 Bn i-Pr E 72 
1.18 i-Bu i-Pr E 80 
1.21 1-MeNpth i-Pr E 62 
1.21 1-MeNpth i-Pr F 79 
1.25 i-Pr Bn E 40 
1.28 Bn Bn E 52 
1.31 i-Bu Bn E 65 
1.34 1-MeNpth Bn F 87 
1.38 i-Pr i-Bu E 52 
1.41 Bn i-Bu E 69 
1.44 i-Bu i-Bu E 63 
1.47 1-MeNpth i-Bu F 87 
1.48 i-Pr 2-MeNpth F 36 
1.49 i-Bu 2-MeNpth F 33 
1.50 Bn 2-MeNpth F 27 
†E = Method E using KOtBu, F = Method F using NaH 
 
1.2.9 Optimization of Reaction Conditions for the Addition of Oxygen 
Nucleophiles 
 
 There were two general procedures used for the alkoxide addition reactions.  The 
first of which consisted of using KOtBu in Dioxane and heating the pressure tube to 90°C 
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– 100°C.  The second used sodium hydride in anhydrous THF and then heated the 
pressure tube to a slightly cooler 80°C – 90°C.  The workup for both procedures was 
identical and consisted of quenching the reaction with DI H2O, extracting the product 
using EtOAc and then purifying it with flash column chromatography.  
Since the literature concerning these types of reactions showed good yield for a 
wide variety of solvents, my primary focus for the optimization of these reactions was 
centered on investigating the use of different strong bases.  While I began using KOtBu 
as a strong and hindered base for these reactions, I learned that the OtBu alkoxide was 
actually acting as a nucleophile in these pressure reactions and creating new side products 
while driving down the intended product’s yield.  The LCMS traces and corresponding 
compounds for a few key side products are shown in Figure 1.18.  Given that the tBu 
group is not a side chain in normally occurring amino acids nor has it been identified as 
part of any key binding interaction as discussed in the introduction, these products were 
not isolated or tested for biological activity.  
Knowing that the alkoxide base was actually in fact adding to the pyridazine, I 
assumed that this was also a potential danger with other strong heteroatom bases (i.e 
KOH and NaNH2).  Therefore, I began using sodium hydride as my strong base since it 
has been shown
42
 to work well for these types of reactions.  For my initial test reaction 
using sodium hydride, I synthesized product 1.12 due to the vastly decreased amount of 
hassle in identifying and purifying the product over a monosubstituted product such as 
1.9.  The results for these two different reaction conditions (Scheme 1.14) is shown in 
Table 1.9 clearly illustrate that the sodium hydride is indeed the far superior base for this 
reaction.  The dramatic 24% increase in the yield can in part be explained by the fact that 
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since the sodium hydride cannot add to the pyridazine the way that KOtBu can, there are 
less side products produced which leaves more pyridazine available to react with the 
isopropanol allowing for a larger percentage of product to be produced.   
 
 
 
 
 
Figure 1.18: Representative LCMS traces of side products 
 
Table 1.9: Symmetric dual alkoxide addition variations 
Product R1 R2 Base Yield (%) 
1.12 i-Pr i-Pr KOtBu 62 
1.12 i-Pr i-Pr NaH 77 
1.21 1-MeNpth i-Pr KOtBu 62 
1.21 1-MeNpth i-Pr NaH 79 
N N
ClO
1.1a
N N
OO
1.2a
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 Given these positive results for the synthesis of 1.12, I tried the reaction again 
with a much larger and bulkier alkoxide; 1-methylnapthyl.  Just as before, the yield of the 
reaction dramatically increased, this time by 27% (Table 1.9).  These two nearly identical 
results alone demonstrate the efficiency with which the reaction works when using the 
non-nucleophilic sodium hydride as the base.  However, it is also important to mention 
the astonishing yield increase for the monosubstitution reaction leading to product 1.22 
when the reaction was repeated with sodium hydride (Scheme 1.15 and Table 1.10).   
 
 
Scheme 1.15: Monoaddition of isopropanol to product 1.1 
 
Table 1.10: Base dependent monoaddition yields 
 
Product Base Yield (%) 
1.22 KOtBu 12 
1.22 NaH 56 
 
There is an astonishing 367% increase in the reaction yield when using sodium 
hydride.  While the LCMS trace reveals the presence of some side product 1.1a for the 
reaction employing KOtBu, it does not show that enough side product was formed to 
N N
ClO
N N
ClCl
BaseOH
1.221.1
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explain this gigantic increase in product yield.  Currently, it is not clear as to what, if any, 
other factors contribute to this drastic increase in product yield.   
 
1.2.10 Biological Activity Results 
 
 These trimer products were tested using FP assays against both the GST-Mcl 
1/Bim-FITC interaction and the GST-Bcl-XL/Bak-FITC interaction.  Unfortunately, none 
of our trimers showed any activity against these two interactions.  We have also 
submitted the trimers to be tested against the p53/MDM2 interaction and are currently 
waiting on the results of these assays. 
 
1.3 Experimental Section 
1.3.1 Materials and Methods 
 
All starting materials, organic and inorganic reagents (ACS grade), and solvents 
were obtained from commercial sources and used as received unless otherwise noted.  All 
deuterated solvents were purchased from Cambridge Isotopes.  Moisture- and air-
sensitive reactions were carried out in oven dried glassware and under an atmosphere of 
argon.  Thin layer chromatography (TLC) was performed on glass plates (EMD or 
Whatman) precoated with 0.25 mm thickness of silica gel (60Å F-254) and visualized 
with ultraviolet light (254 nm).  Column chromatographic purifications were performed 
using silica gel 60Å, 63-200 μm mesh (Dynamic Adsorbents).  Organic solutions were 
concentrated under reduced pressure on a Büchi rotary evaporator.  
1
H NMR and 
13
C 
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NMR spectra were obtained using either a 400 MHz Varian INOVA equipped with a 5-
mm B.B. rt probe with Z-axis PFGs, a 500 MHz Varian INOVA equipped with a 3-mm 
B.B. rt probe with Z-axis PFGs or a 600 MHz Varian INOVA instrument equipped with a 
5-mm I.D. rt probe with Z-axis PFGs running VnmrJ 2.2D software at 25 °C in CDCl3 
unless otherwise specified.  Spectra were then analyzed using ACD labs NMR Manager 
version 11.0.  Chemical shifts (δ) are reported in parts per million ppm (ppm) relative to 
residual solvent signal; either chloroform (δ 7.24) or DMSO (δ 2.50) for 1H NMR and 
either chloroform (δ 77.16) or DMSO (δ 39.52) for 13C NMR.  1H 1D NOE experiments 
were performed using a 500 ms mixing time while 
1
H 1D TOCSY experiments were 
performed using an 80 ms mixing time.  Multiplicity is expressed as (s = singlet, br s = 
broad singlet, d = doublet, t = triplet, q = quartet, p = pentet, spt = septet, or m = 
multiplet) and the values of the coupling constants (J) are given in Hertz (Hz) followed 
by the integration.  Mass Spectrometry (MS) spectra and LCMS spectra were carried out 
on an Agilent LC/MSD VL single quadrupole system.  Microwave synthesis was 
performed in a Biotage Initiator I microwave reactor.  
 
1.3.2 Experimental Procedures 
1.3.2.1 General Synthesis of 4-Substituted 3,6-Dichloropyridazines via Silver Nitrate 
 
This generic procedure has previously been reported for the synthesis of such 
compounds
35a,37b
.  To a 200 mL RBF was added 3,6-dichloropyridazine (2 g, 13.42 
mmol, 1 eq.) followed by 60 mL DI H2O and then conc. sulfuric acid (1.43 mL, 26.84 
mmol, 2 eq.).  The RBF was heated to 70°C and then the appropriate carboxylic acid 
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(14.76 mmol, 1.1 eq.) was added followed by silver nitrate (0.46 g, 2.684 mmol, 0.2 eq.) 
and the reaction became milky white.  Ammonium persulfate (6.12g, 26.84 mmol, 2 eq.) 
dissolved in 25 – 30 mL DI H2O was then added dropwise to the reaction and allowed to 
react for 1.5 hrs.  After which, the reaction was poured onto crushed ice and the pH was 
adjusted to 9 – 10 with concentrated NH4OH.  The reaction was then extracted 2x with 
DCM and the combined organic layers were dried over anhydrous Na2SO4 and 
evaporated under reduced pressure.  The crude product was then purified by column 
chromatography on silica gel. 
 
1.3.2.2 Synthesis of Unsymmetrical Dioxy Pyridazines 
1.3.2.2.1 Part 1 
1.3.2.2.1.1 Method A
39b
 
 
To an oven dried 35 mL cylindrical pressure tube (Chemglass Catalog # CG-1880-02) 
was added 1.05 eq. 4-substituted dichloropyridazine, 10-15 mL Dioxane and then 1.2 eq. 
KOtBu.  These reagents were then stirred vigorously for 5 minutes followed by the slow 
dropwise addition of 1 eq. of the appropriate alcohol.  Once the addition was complete, 
the pressure tube was sealed and the reaction was heated to 90 – 100°C for 12 hours.  
Then the reaction was allowed to cool to rt before slowly opening the pressure vessel.  
After which, the reaction was quenched with DI H2O and extracted 2x with EtOAc.  The 
combined organic layers were dried over anhydrous Na2SO4, and evaporated under 
reduced pressure.  The crude product was then purified by column chromatography on 
silica gel. 
43 
 
 
1.3.2.2.1.2 Method B 
 
To an oven dried 35 mL cylindrical pressure tube (Chemglass Catalog # CG-1880-02) 
was added 1.1 eq. 4-substituted dichloropyridazine, 10-15 mL anhydrous THF and then 
1.5 eq. NaH.  These reagents were then stirred vigorously for 5 minutes followed by the 
slow dropwise addition of 1 eq. of the appropriate alcohol.  Once the addition was 
complete, the pressure tube was allowed to sit for 5 minutes until the vigorous bubbling 
subsided before it was sealed and then heated to 80 – 90°C for 12 hours.  After allowing 
the reaction to cool to rt, the pressure vessel was slowly opened behind the hood’s shield 
(*Note* There remains a substantial amount of pressure in the tube after this reaction in 
comparison with Method A).  The reaction was then quenched slowly with DI H2O and 
extracted 2x with EtOAc.  The combined organic layers were dried over anhydrous 
Na2SO4, and evaporated under reduced pressure.  The crude product was then purified by 
column chromatography on silica gel. 
 
1.3.2.2.2 Part 2 
1.3.2.2.2.1 Method C 
 
To an oven dried 15mL cylindrical pressure tube (Chemglass Catalog # CG-1880-01) 
was added 1 eq. 6-monosubstituted chloropyridazine, 5-10mL Dioxane and then 1.4 eq. 
KOtBu.  These reagents were then stirred vigorously for 5 minutes followed by the 
addition of 1.2 eq. of the appropriate alcohol.  Once the addition was complete, the 
44 
 
pressure tube was sealed and the reaction was heated to 90 – 100°C for 12 hours.  Upon 
cooling to rt, the reaction was worked up in the same manner as Method A. 
 
1.3.2.2.2.2 Method D 
 
To an oven dried 15 mL cylindrical pressure tube (Chemglass Catalog # CG-1880-01) 
was added 1 eq. 6-monosubstituted chloropyridazine, 5-10 mL anhydrous THF and then 
1.5 eq. NaH.  These reagents were then stirred vigorously for 5 minutes followed by the 
slow dropwise addition of 1.2 eq. of the appropriate alcohol.  Once the addition was 
complete, the pressure tube was allowed to sit for 5 minutes until the vigorous bubbling 
subsided before it was sealed and then heated to 80 – 90°C for 12 hours.  Upon cooling to 
rt, the reaction was worked up in the same manner as Method B. 
 
1.3.2.2.3 Synthesis of Symmetrical Dioxy Pyridazines 
1.3.2.2.3.1 Method E 
 
To an oven dried 15mL cylindrical pressure tube (Chemglass Catalog # CG-1880-01) 
was added 1 eq. 4-substituted dichloropyridazine, 5-10mL Dioxane and then 2.5 eq. 
KOtBu.  These reagents were then stirred vigorously for 5 minutes followed by the 
addition of 2.1 eq. of the appropriate alcohol.  Once the addition was complete, the 
pressure tube was sealed and the reaction was heated to 90 – 100°C for 12 hours.  Upon 
cooling to rt, the reaction was worked up in the same manner as Method A. 
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1.3.2.2.3.2 Method F 
 
To an oven dried 15mL cylindrical pressure tube (Chemglass Catalog # CG-1880-01) 
was added 1 eq. 4-substituted dichloropyridazine, 5-10mL anhydrous THF and then 2.5 
eq. NaH.  These reagents were then stirred vigorously for 5 minutes followed by the 
semi-slow addition of 2.5 eq. of the appropriate alcohol.  Once the addition was 
complete, the pressure tube was allowed to sit for 5 minutes until the vigorous bubbling 
subsided before it was sealed and then heated to 80 – 90°C for 12 hours.  Upon cooling to 
rt, the reaction was worked up in the same manner as Method B. 
 
 
4-Benzyl-3,6-dichloropyridazine (1.1):  Following the general synthesis via silver nitrate 
and starting with 2 g 3,6-dichloropyridazine, the crude product was then purified by 
column chromatography on silica gel (1:9, EtOAc/hexanes) to afford 1.1 as a yellow-
orange sticky solid (1.66 g, 52%).  Rƒ = 0.56 (1:3 EtOAc/hexanes) UV TLC 
visualization.  
1
H NMR (400 MHz, CDCl3)  ppm 7.28 - 7.39 (m, 3 H), 7.17 (d, J=6.78 
Hz, 2 H), 7.07 (br. s., 1 H), 4.03 (br. s., 2 H).  
13
C NMR (100 MHz, CDCl3)  ppm 
156.86, 156.17, 143.69, 134.61, 129.61, 129.41, 129.38, 127.85, 38.29. m/z 241.0 
(M+H)
+
. 
 
N N
ClCl
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3,6-Dichloro-4-isopropylpyridazine (1.2):  Following the general synthesis via silver 
nitrate and starting with 10 g 3,6-dichloropyridazine, the crude product was not further 
purified.  Product (11.68 g, 91%) is a darker orange oil, Rƒ = 0.51 (1:4 EtOAc/hexanes) 
UV TLC visualization.  
1
H NMR (400 MHz, CDCl3)  ppm 7.33 (s, 1 H), 3.16 (spt, 
J=6.78 Hz, 1 H), 1.22 (d, J=6.78 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 156.54, 
156.25, 149.85, 126.77, 30.24, 21.14.  m/z 192.0 (M+H)
+
. 
 
 
1-(3,6-Dichloropyridazin-4-yl)-3-methylbutan-1-ol (1.3):  Following a general published 
procedure for Knochel base reactions
34a
, a 100 mL RBF containing 1.22M LDA (4.6 mL, 
5.64 mmol, 1.2 eq.) was chilled to -78°C and then 3,6-dichloropyridazine (0.7 g, 4.7 
mmol, 1 eq.) dissolved in 10 mL anhydrous THF was added dropwise to the reaction.  
The reaction was allowed to stir for 1 hr. then 3-methylbutyraldehyde (0.76 mL, 7.05 
mmol, 1.5 eq.) was added dropwise and allowed to react for an hour.  The reaction was 
then quenched by the addition of 15 mL of a solution containing 1:4:5 conc. HCl: abs. 
EtOH: THF and then allowing the reaction to warm up to rt.  The pH was then made 
slightly basic with saturated aqueous NaHCO3 followed by evaporating the solvent under 
reduced pressure.  The resulting goo was then extracted 2x from DI H2O with DCM.  The 
combined organic layers were then dried over anhydrous MgSO4 and the solvent was 
NN
Cl Cl
N N
ClCl
HO
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removed under reduced pressure.  The crude product was then purified by column 
chromatography on silica gel (gradient of 1:6  1:5, EtOAc/hexanes) to afford 1.3 as a 
yellow-orange sticky solid (0.48 g, 44%).  Rƒ = 0.60 (1:2 EtOAc/hexanes) UV TLC 
visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.79 (s, 1 H), 4.98 (dd, J=9.37, 2.34 
Hz, 1 H), 1.96 - 1.97 (m, 1 H), 1.47 - 1.50 (m, 2 H), 0.99 (d, J=6.45 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 156.88, 155.68, 153.91, 127.53, 67.82, 46.00, 23.78, 21.38.  
m/z 236.0 (M+H)
+
. 
 
 
3,6-Dichloro-4-isobutylpyridazine (1.4):  Following the general synthesis via silver 
nitrate and starting with 2.5 g 3,6-dichloropyridazine, the crude product was not further 
purified.  Product 1.4 is a light-brown crystalline solid (3.54 g, 100%).  Rƒ = 0.49 (1:4 
EtOAc/hexanes) UV TLC visualization.  
1
H NMR (250 MHz, CDCl3)  ppm 7.29 (s, 1 
H), 2.50 (d, J=7.11 Hz, 2 H), 1.84 - 2.01 (m, 1 H), 0.85 (d, J=6.63 Hz, 6 H).  
13
C NMR 
(63 MHz, CDCl3)  ppm 157.10, 155.52, 143.52, 130.01, 41.15, 27.65, 22.06.  m/z 206.0 
(M+H)
+
. 
 
 
N N
ClCl
N N
ClCl
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3,6-Dichloro-4-(naphthalen-2-ylmethyl)pyridazine (1.5):  Following the general synthesis 
via silver nitrate and starting with 2 g 3,6-dichloropyridazine, the crude product was then 
purified by column chromatography on silica gel (gradient of 3:97  1:9, 
EtOAc/hexanes) to afford 1.5 as a white crystalline solid (0.48 g, 12%).  Rƒ = 0.49 (1:4 
EtOAc/hexanes) UV TLC visualization.  This product can also be purified from its 
starting material through recrystallization with EtOAc/hexanes where the solid that 
crashes out is the product of interest.  
1
H NMR (400 MHz, CDCl3) ppm 7.84 - 7.88 (m, 
2 H), 7.78 - 7.82 (m, 1 H), 7.64 (br. s., 1 H), 7.49 - 7.53 (m, 2 H), 7.25 (dd, J=8.20, 1.95 
Hz, 1 H), 7.07 (t, J=0.98 Hz, 1 H), 4.20 (s, 2 H).  
1
H NMR (400 MHz, DMSO-d6)  ppm 
7.96 (s, 1 H), 7.88 - 7.92 (m, 3 H), 7.76 (br. s., 1 H), 7.49 - 7.52 (m, 2 H), 7.44 (dd, 
J=8.40, 1.76 Hz, 1 H), 4.29 (s, 2 H).  
13
C NMR (125 MHz, DMSO-d6)  ppm 156.83, 
155.68, 143.68, 133.42, 133.03, 131.94, 131.08, 128.34, 127.55, 127.54, 127.25, 126.33, 
125.97, 123.24, 37.40.  m/z 290.7 (M+H)
+
. 
 
 
(S)-Ethyl 2-(6-chloropyridazin-3-ylamino)-3-phenylpropanoate (1.6):  Based on previous 
reactions
43
, L-phenylalanine (0.22 g, 1.34 mmol, 1 eq.) and 3,6-dichloropyridazine (0.2 g, 
1.34 mmol, 1 eq.) were added to a 5 mL microwave vial along with 2 mL absolute 
ethanol.  The vial was microwaved at 150°C for 20 minutes and then the solvent was 
removed under reduced pressure.  The product was purified by column chromatography 
N N
O
H
N
O
Cl
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on silica gel (gradient of 1:3  1:1, EtOAc/hexanes) which afforded 1.6 as a milky-white 
gooey solid (0.07 g, 18%).  Rƒ = 0.43 (1:1 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (400 MHz, CDCl3)  ppm 7.21 - 7.28 (m, 3 H), 7.09 - 7.14 (m, 2 H), 7.12 (d, 
J=9.16 Hz, 1 H), 6.61 (d, J=9.34 Hz, 1 H), 5.02 - 5.08 (m, 2 H), 4.18 (q, J=7.14 Hz, 2 H), 
3.15 - 3.34 (m, 2 H), 1.24 (t, J=7.14 Hz, 3 H).  
13
C NMR (100 MHz, CDCl3)  ppm 
172.44, 156.77, 147.82, 136.26, 129.53, 129.18, 128.68, 127.21, 117.90, 61.73, 55.17, 
37.63, 14.29.  m/z 306.1 (M+H)
+
. 
 
 
(S)-Methyl 2-(5-benzyl-6-chloropyridazin-3-ylamino)-4-methylpentanoate (1.7):  The 
product was synthesized in a similar manner as described for the preparation of 1.6, the 
reaction was microwaved at 150°C for 1 hr. in methanol and starting with L-Leucine 
methyl ester HCl (0.23 g, 1.25 mmol, 1 eq.).  The crude product was purified by column 
chromatography on silica gel (gradient of 1:4  1:2, EtOAc/hexanes) which afforded 
pure 1.7 as a thick viscous orange oil (0.071 g, 8%).  Rƒ = 0.32 (1:3 EtOAc/hexanes) UV 
TLC visualization.  
1
H NMR (400 MHz, CDCl3)  ppm 7.28 - 7.35 (m, 3 H), 7.16 (d, 
J=7.14 Hz, 2 H),  6.19 (s, 1 H), 4.70 - 4.78 (m, 2 H), 3.89 (br. s., 2 H), 3.68 (s, 3 H), 1.67 
- 1.71 (m, 1 H), 1.54 - 1.61 (m, 2 H), 0.91 (t, J=5.68 Hz, 6 H).  
13
C NMR (100 MHz, 
CDCl3)  ppm 174.76, 158.02, 141.52, 135.93, 129.66, 129.43, 129.14, 127.41, 116.81, 
52.78, 41.80, 38.29, 25.06, 22.95, 22.14.  m/z 348.16 (M+H)
+
. 
N N
Cl
O
H
N
O
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(S)-Methyl 2-(5-benzyl-6-chloropyridazin-3-ylamino)-3-phenylpropanoate (1.8):  The 
product was synthesized in a similar manner as described for the preparation of 1.6, the 
reaction was microwaved at 130°C for 2 hrs. in methanol and starting with L-
Phenylalanine methyl ester HCl (0.23 g, 1.05 mmol, 1 eq.).  The crude product was 
purified by column chromatography on silica gel (gradient of 1:5  1:3, EtOAc/hexanes) 
which afforded pure 1.8 as an orange solid (0.036 g, 4%).  Rƒ = 0.23 (1:3 
EtOAc/hexanes) UV TLC visualization.  
1
H NMR (400 MHz, CDCl3)  ppm 7.26 - 7.38 
(m, 6 H), 7.12 (d, J=6.84 Hz, 2 H), 7.07 (d, J=6.84 Hz, 2 H), 6.18 (s, 1 H), 5.04 (dd, 
J=13.37, 5.86 Hz, 1 H), 4.77 (d, J=7.33 Hz, 1 H), 3.90 (s, 2 H), 3.70 (s, 3 H), 3.27 (dd, 
J=14.10, 5.68 Hz, 1 H), 3.12 (dd, J=13.92, 6.04 Hz, 1 H).  
13
C NMR (125 MHz, CDCl3) 
 ppm 172.79, 157.27, 148.69, 142.26, 136.12, 135.67, 129.51, 129.38, 129.11, 128.67, 
127.43, 127.17, 117.42, 55.42, 52.54, 38.33, 37.75.  m/z 382.1 (M+H)
+
. 
 
 
3-Chloro-6-isopropoxy-4-isopropylpyridazine (1.9):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (gradient of 5:95  1:8, EtOAc/hexanes) which afforded pure 1.9 as a light 
NN
Cl
O
H
N
O
NN
O Cl
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yellow oil (0.78 g, 71%).  Rƒ = 0.68 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (400 MHz, CDCl3)  ppm 6.75 (s, 1 H), 5.48 (spt, J=6.25 Hz, 1 H), 3.15 (spt, 
J=7.03 Hz, 1 H), 1.37 (d, J=5.86 Hz, 6 H), 1.23 (d, J=7.03 Hz, 6 H).  
13
C NMR (100 
MHz, CDCl3)  ppm 164.72, 149.58, 126.06, 116.26, 70.27, 29.86, 21.81, 21.35. m/z 
215.9 (M+H)
+
. 
 
 
6-(Benzyloxy)-3-chloro-4-isopropylpyridazine (1.10):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (1:9, EtOAc/hexanes) which afforded pure 1.10 as a semi-viscous yellow oil 
(0.86 g, 64%).  Rƒ = 0.61 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 
MHz, CDCl3)  ppm 7.47 (d, J=7.32 Hz, 2 H), 7.38 (dd, J=7.81, 6.84 Hz, 2 H), 7.34 (t, 
J=6.84 Hz, 1 H), 6.88 (s, 1 H), 5.50 (s, 2 H), 3.17 (spt, J=6.67 Hz, 1 H), 1.24 (d, J=6.84 
Hz, 7 H). 
13
C NMR (125 MHz, CDCl3)  ppm 165.06, 152.29, 150.06, 136.25, 128.73, 
128.70, 128.51, 116.14, 69.56, 30.14, 21.53.  m/z 262.9 (M+H)
+
. 
 
 
3-Chloro-6-isobutoxy-4-isopropylpyridazine (1.11):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (1:9, EtOAc/hexanes) which afforded pure 1.11 as a very light yellow oil (0.72 
N N
ClO
N N
ClO
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g, 61%).  Rƒ = 0.62 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (600 MHz, 
CDCl3)  ppm 6.81 (s, 1 H), 4.21 (d, J=7.03 Hz, 2 H), 3.15 (spt, J=7.03 Hz, 1 H), 2.09 
(spt, J=7.03 Hz, 1 H), 1.24 (d, J=7.03 Hz, 6 H), 1.00 (d, J=7.03 Hz, 6 H).  
13
C NMR (100 
MHz, CDCl3)  ppm 165.54, 151.83, 149.76, 115.95, 73.99, 30.07, 28.04, 21.53, 19.28.  
m/z 228.9 (M+H)
+
.  
 
 
3,6-Diisopropoxy-4-isopropylpyridazine (1.12):  Synthesized using Method E and 
starting with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography 
on silica gel (gradient of 1:9  1:8, EtOAc/hexanes) which afforded pure 1.12 as a bright 
yellow oil (0.39 g, 62%).  Rƒ = 0.71 (1:4 EtOAc/hexanes) UV TLC visualization.  Using 
Method F significantly increased production of product (0.48 g, 77%).  
1
H NMR (500 
MHz, CDCl3)  ppm 6.62 (s, 1 H), 5.40 (spt, J=6.35 Hz, 1 H), 5.35 (spt, J=6.35 Hz, 1 H), 
2.99 (spt, J=6.92 Hz, 1 H), 1.33 (d, J=4.88 Hz, 6 H), 1.32 (d, J=4.88 Hz, 6 H), 1.14 (d, 
J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  ppm 161.51, 159.52, 142.27, 116.93, 
69.14, 69.00, 27.22, 22.14, 22.11, 21.10.  m/z 238.9 (M+H)
+
. 
 
 
3-Isobutoxy-6-isopropoxy-4-isopropylpyridazine (1.13):  Synthesized from 1.9 (1.4 
mmol) using Method C, product purified by column chromatography on silica gel (5:95, 
N N
O O
NN
O O
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EtOAc/hexanes) which afforded pure 1.13 as a semi-viscous light yellow oil (0.26 g, 
73%).  Rƒ = 0.75 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (600 MHz, 
CDCl3)  ppm 6.71 (s, 1 H), 5.39 - 5.45 (spt, 1 H), 4.17 (d, J=6.45 Hz, 2 H), 3.01 - 3.08 
(m, 1 H), 2.07 - 2.12 (m, 1 H), 1.35 (d, J=4.69 Hz, 6 H), 1.19 (d, J=7.03 Hz, 6 H), 1.01 
(d, J=7.03 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 162.29, 160.50, 142.04, 
116.51, 73.31, 69.29, 28.07, 28.03, 22.16, 21.21, 19.48.  m/z 252.9 (M+H)
+
. 
 
 
3-(Benzyloxy)-6-isopropoxy-4-isopropylpyridazine (1.14):  Synthesized from 1.9 (1.9 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  1:9, EtOAc/hexanes) which afforded pure 1.14 as a semi-viscous 
light yellow oil (0.38 g, 72%).  Rƒ = 0.51 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.44 - 7.46 (m, 2 H), 7.34 - 7.39 (m, 2 H), 7.29 - 7.32 
(m, 1 H), 6.70 (s, 1 H), 5.48 (s, 2 H), 5.41 (spt, J=6.35 Hz, 1 H), 3.10 (spt, J=6.84 Hz, 1 
H), 1.37 (d, J=6.35 Hz, 6 H), 1.19 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  
ppm 162.18, 159.88, 142.11, 137.36, 128.56, 127.96, 127.94, 117.23, 69.27, 68.72, 
27.23, 22.14, 21.25.  m/z 287.0 (M+H)
+
. 
 
 
N N
OO
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3,6-Bis(benzyloxy)-4-isopropylpyridazine (1.15):  Synthesized using Method E and 
starting with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography 
on silica gel (gradient of 1:9  1:8, EtOAc/hexanes) which afforded pure 1.15 as a semi-
viscous darker yellow oil (0.63 g, 72%).  Rƒ = 0.58 (1:4 EtOAc/hexanes) UV TLC 
visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.45 - 7.49 (m, 4 H), 7.36 - 7.40 (m, 4 
H), 7.30 - 7.34 (m, 2 H), 6.83 (s, 1 H), 5.50 (s, 2 H), 5.45 (s, 2 H), 3.12 (spt, J=7.03 Hz, 1 
H), 1.20 (d, J=7.03 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 162.46, 160.39, 
142.40, 137.25, 136.96, 128.65, 128.59, 128.46, 128.23, 128.00, 116.82, 68.85, 68.84, 
27.31, 21.25.  m/z 334.8 (M+H)
+
. 
 
 
6-(Benzyloxy)-3-isopropoxy-4-isopropylpyridazine (1.16):  Synthesized from 1.10 (1.5 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.16 as a semi-viscous 
light yellow oil (0.20 g, 45%).  Rƒ = 0.67 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.45 (d, J=7.32 Hz, 2 H), 7.35 - 7.39 (m, 2 H), 7.29 - 
7.33 (m, 1 H), 6.70 (s, 1 H), 5.48 (s, 2 H), 5.41 (spt, J=6.35 Hz, 1 H), 3.10 (spt, J=6.84 
Hz, 1 H), 1.37 (d, J=5.86 Hz, 6 H), 1.19 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, 
CDCl3)  ppm 162.20, 159.90, 142.14, 137.38, 128.58, 127.97, 127.95, 117.26, 69.30, 
68.74, 27.24, 22.15, 21.27.  m/z 287.0 (M+H)
+
. 
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6-(Benzyloxy)-3-isobutoxy-4-isopropylpyridazine (1.17):  Synthesized from 1.10 (1.5 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.17 as a semi-viscous 
light yellow oil (0.05 g, 12%).  Rƒ = 0.65 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.45 (d, J=7.62 Hz, 2 H), 7.35 - 7.40 (m, 2 H), 7.29 - 
7.34 (m, 1 H), 6.76 (s, 1 H), 5.47 (s, 2 H), 4.16 (d, J=6.45 Hz, 2 H), 3.11 (spt, J=7.03 Hz, 
1 H), 2.10 (m, 1 H), 1.20 (d, J=7.03 Hz, 6 H), 1.00 (d, J=6.45 Hz, 6 H).  
13
C NMR (100 
MHz, CDCl3)  ppm 162.86, 160.07, 142.32, 137.30, 128.58, 128.05, 127.99, 116.81, 
73.44, 68.79, 28.05, 27.29, 21.27, 19.38.  m/z 301.0 (M+H)
+
. 
 
 
3,6-Diisobutoxy-4-isopropylpyridazine (1.18):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (1:9, EtOAc/hexanes) which afforded pure 1.18 as a semi-viscous yellow oil (0.56 g, 
80%).  Rƒ = 0.71 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, 
CDCl3) ppm 6.63 (s, 1 H), 4.10 (d, J=6.35 Hz, 2 H), 4.06 (d, J=6.84 Hz, 2 H), 2.97 (spt, 
J=6.84 Hz, 1 H), 2.04 (spt, J=6.84 Hz, 1 H), 2.00 (spt, J=6.84 Hz, 1 H), 1.11 (d, J=6.84 
Hz, 6 H), 0.92 (d, J=6.84 Hz, 7 H), 0.89 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, 
N N
OO
N N
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CDCl3)  ppm 162.41, 160.28, 141.72, 116.25, 73.11, 72.99, 27.88, 27.82, 27.23, 21.00, 
19.27, 19.15.  m/z 266.9 (M+H)
+
. 
 
 
6-Isobutoxy-3-isopropoxy-4-isopropylpyridazine (1.19):  Synthesized from 1.11 (1.3 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.19 as a light yellow oil 
(0.24 g, 71%).  Rƒ = 0.54 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 
MHz, CDCl3)  ppm 6.67 (s, 1 H), 5.31 - 5.35 (m, 1 H), 4.14 (d, J=6.84 Hz, 2 H), 2.98 - 
3.04 (m, 1 H), 2.04 - 2.10 (m, 1 H), 1.30 (d, J=4.88 Hz, 6 H), 1.16 (d, J=4.39 Hz, 6 H), 
0.96 (d, J=6.35 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  ppm 162.51, 160.40, 141.86, 
116.37, 73.21, 69.04, 27.98, 27.92, 22.04, 21.10, 19.37.  m/z 253.0 (M+H)
+
. 
 
 
3-(Benzyloxy)-6-isobutoxy-4-isopropylpyridazine (1.20):  Synthesized from 1.11 (1.3 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.20 as a semi-viscous 
yellow oil (0.18 g, 44%).  Rƒ = 0.53 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (500 MHz, CDCl3)  ppm 7.44 - 7.47 (m, 2 H), 7.34 - 7.38 (m, 2 H), 7.28 - 7.33 
(m, 1 H), 6.76 (s, 1 H), 5.47 (s, 2 H), 4.16 (d, J=6.84 Hz, 2 H), 3.11 (spt, J=6.84 Hz, 1 
N N
OO
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H), 2.07 - 2.12 (m, 1 H), 1.20 (d, J=6.84 Hz, 6 H), 1.00 (d, J=6.84 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 162.94, 160.10, 142.17, 137.37, 128.49, 128.04, 127.96, 
116.74, 73.45, 68.75, 28.06, 27.30, 21.28, 19.37.  m/z 301.0 (M+H)
+
. 
 
  
4-Isopropyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine (1.21):  Synthesized using 
Method E and starting with 0.5 g 3,6-dichloropyridazine, product purified by column 
chromatography on silica gel (gradient of 1:99  5:95, EtOAc/hexanes) which afforded 
pure 1.21 as a yellow-white crystalline solid (0.75 g, 62%).  Rƒ = 0.61 (1:4 
EtOAc/hexanes) UV TLC visualization.  Using Method F significantly increased 
production of product (0.90 g, 79%).  
1
H NMR (500 MHz, DMSO-d6)  ppm 8.08 - 8.12 
(m, 2 H), 7.98 (d, J=7.81 Hz, 2 H), 7.94 (d, J=8.30 Hz, 2 H), 7.71 (d, J=6.84 Hz, 2 H), 
7.50 - 7.58 (m, 6 H), 7.06 (s, 1 H), 5.93 (s, 2 H), 5.90 (s, 2 H), 2.92 (spt, J=6.84 Hz, 1 H), 
1.07 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, DMSO-d6)  ppm 162.00, 159.73, 
141.67, 133.30, 133.26, 132.41, 132.32, 131.28, 131.24, 128.78, 128.52, 128.49, 127.33, 
127.10, 126.53, 126.43, 125.96, 125.92, 125.37, 125.34, 123.74, 123.72, 116.70, 66.58, 
66.20, 26.81, 20.73.  m/z 434.8 (M+H)
+
. 
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4-Benzyl-3-chloro-6-isopropoxypyridazine (1.22):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (gradient of 1:99  6:94, EtOAc/hexanes) which afforded pure 1.22 as a semi-
viscous yellow oil (0.09 g, 12%).  Rƒ = 0.66 (1:4 EtOAc/hexanes) UV TLC visualization.  
Using Method B significantly increased production of product (0.36 g, 56%).  
1
H NMR 
(500 MHz, CDCl3)  ppm 7.26 - 7.37 (m, 4 H), 7.16 - 7.18 (m, 3 H), 6.94 (s, 1 H), 5.46 
(spt, J=6.35 Hz, 1 H), 3.95 (s, 2 H), 1.34 (d, J=6.35 Hz, 6 H).  
13
C NMR (125 MHz, 
CDCl3) ppm 164.67, 151.53, 143.4, 135.76, 129.54, 129.19, 127.49, 119.63, 70.60, 
38.42, 21.95.  m/z 262.9 (M+H)
+
. 
 
 
4-Benzyl-6-(benzyloxy)-3-chloropyridazine (1.23):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.23 as a 
viscous yellow-tan oil (0.41 g, 44%).  Rƒ = 0.44 (1:4 EtOAc/hexanes) UV TLC 
visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.43 (m, J=7.03 Hz, 2 H), 7.31 - 7.37 
(m, 6 H), 7.16 (m, J=7.62 Hz, 2 H), 6.58 (s, 1 H), 5.47 (s, 2 H), 3.97 (s, 2 H).  
13
C NMR 
(100 MHz, CDCl3)  ppm 164.80, 152.34, 143.80, 136.02, 135.49, 129.55, 129.24, 
128.76, 128.74, 128.58, 127.57, 119.32, 69.67, 38.45.  m/z 311.1 (M+H)
+
. 
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4-Benzyl-3-chloro-6-isobutoxypyridazine (1.24):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (gradient of 1:99  1:9, EtOAc/hexanes) which afforded pure 1.24 as a semi-
viscous yellow oil (0.21 g, 25%).  Rƒ = 0.44 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.29 (m, 2 H), 7.20 - 7.25 (m, 1 H), 7.17 (d, J=7.03 
Hz, 2 H), 6.52 (s, 1 H), 4.11 (d, J=6.45 Hz, 3 H), 3.83 (br. s., 3 H), 2.00 - 2.07 (m, 1 H), 
0.95 (d, J=7.62 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3) δ ppm 162.27, 160.66, 137.08, 
135.40, 129.39, 128.83, 126.94, 121.55, 119.76, 73.45, 35.38, 27.99, 19.31.  m/z 276.9 
(M+H)
+
. 
 
 
4-Benzyl-3,6-diisopropoxypyridazine (1.25):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.25 as a light yellow 
crystalline solid (0.25 g, 40%).  Rƒ = 0.55 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.27 - 7.30 (m, 2 H), 7.20 - 7.24 (m, 1 H), 7.18 (d, 
J=6.84 Hz, 2 H), 6.45 (s, 1 H), 5.41 (spt, J=6.35 Hz, 1 H), 5.36 (spt, J=6.35 Hz, 1 H), 
3.78 (s, 2 H), 1.35 (d, J=5.86 Hz, 6 H), 1.31 (d, J=6.35 Hz, 6 H).  
13
C NMR (125 MHz, 
N N
OO
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CDCl3)  ppm 161.26, 159.81, 137.30, 135.85, 129.53, 128.76, 126.87, 120.15, 69.58, 
69.17, 35.47, 22.15, 22.09.  m/z 287.0 (M+H)
+
. 
 
 
4-Benzyl-3-isobutoxy-6-isopropoxypyridazine (1.26):  Synthesized from 1.22 (0.57 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.26 as a semi-viscous 
bright yellow oil (0.08 g, 47%).  Rƒ = 0.61 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.27 - 7.32 (m, 2 H), 7.21 - 7.24 (m, 1 H), 7.16 - 7.20 
(m, 2 H), 6.52 (s, 1 H), 5.35 (spt, J=6.35 Hz, 1 H), 4.18 (d, J=6.35 Hz, 2 H), 3.83 (s, 2 
H), 2.07 - 2.14 (m, 1 H), 1.32 (d, J=5.86 Hz, 6 H), 0.97 (d, J=6.35 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 162.04, 161.60, 137.36, 135.83, 129.46, 128.86, 126.97, 
120.28, 73.48, 69.30, 35.38, 28.05, 22.09, 19.38.  m/z 301.2 (M+H)
+
. 
 
 
4-Benzyl-3-(benzyloxy)-6-isopropoxypyridazine (1.27):  Synthesized from 1.22 (0.57 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.27 as a semi-viscous 
dark yellow oil (0.09 g, 47%).  Rƒ = 0.51 (1:4 EtOAc/hexanes) UV TLC visualization.  
NN
O O
N N
OO
61 
 
1
H NMR (500 MHz, CDCl3)  ppm 7.25 - 7.34 (m, 7 H), 7.15 - 7.17 (m, 3 H), 6.47 (s, 1 
H), 5.38 - 5.54 (m, 3 H), 3.93 (s, 2 H), 1.33 (d, J=5.86 Hz, 6 H).  
13
C NMR (125 MHz, 
CDCl3)  ppm 164.52, 151.35, 143.27, 135.59, 134.82, 129.37, 129.31, 129.01, 128.82, 
127.30, 127.10, 119.49, 70.72, 70.40, 38.22, 21.79.  m/z 335.2 (M+H)
+
. 
 
 
4-Benzyl-3,6-bis(benzyloxy)pyridazine (1.28):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (gradient of 3:97  5:95, EtOAc/hexanes) which afforded pure 1.28 as a yellow 
crystalline solid (0.41 g, 52%).  Rƒ = 0.53 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (400 MHz, CDCl3) ppm 7.41 - 7.45 (m, 4 H), 7.34 - 7.39 (m, 5 H), 7.31 - 7.33 
(m, 1 H), 7.27 - 7.30 (m, 2 H), 7.24 - 7.27 (m, 1 H), 7.14 - 7.17 (m, 2 H), 6.60 (s, 1 H), 
5.51 (s, 2 H), 5.42 (s, 2 H), 3.88 (s, 2 H).  
13
C NMR (100 MHz, CDCl3)   ppm 162.18, 
160.58, 137.00, 136.79, 136.74, 135.88, 129.52, 128.91, 128.65, 128.56, 128.49, 128.26, 
128.14, 128.08, 127.06, 119.99, 68.99, 68.91, 35.43.  m/z 382.9 (M+H)
+
. 
 
 
4-Benzyl-6-(benzyloxy)-3-isopropoxypyridazine (1.29):  Synthesized from 1.23 (0.58 
mmol) using Method D, product purified by column chromatography on silica gel 
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(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.29 as an off-white 
crystalline solid (0.14 g, 73%).  Rƒ = 0.35 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.32 - 7.39 (m, 7 H), 7.15 - 7.18 (m, 3 H), 5.44 - 5.50 
(m, 3 H), 3.95 (s, 2 H), 1.34 (d, J=5.86 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  ppm 
161.88, 143.90, 143.42, 136.76, 135.76, 129.55, 129.20, 128.70, 128.48, 128.32, 127.50, 
121.87, 70.60, 69.15, 38.42, 21.95.  m/z 335.2 (M+H)
+
.   
 
 
4-Benzyl-6-(benzyloxy)-3-isobutoxypyridazine (1.30):  Synthesized from 1.23 (0.58 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  7:93, EtOAc/hexanes) which afforded pure 1.30 as a viscous darker 
yellow oil (0.08 g, 39%).  Rƒ = 0.51 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (500 MHz, CDCl3)  ppm 7.28 - 7.43 (m, 7 H), 7.15 - 7.19 (m, 3 H), 6.55 (s, 1 H), 
5.47 (s, 2 H), 4.19 (d, J=6.84 Hz, 2 H), 3.97 (s, 2 H), 2.06 (spt, J=6.84 Hz, 1 H), 0.97 (d, 
J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  ppm 165.31, 151.90, 143.35, 135.74, 
129.49, 129.36, 129.22, 129.18, 129.08, 127.49, 127.35, 119.17, 74.24, 74.08, 38.43, 
27.98, 19.26.  m/z 349.2 (M+H)
+
.  
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4-Benzyl-3,6-diisobutoxypyridazine (1.31):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.31 as a viscous 
bright yellow oil (0.43 g, 65%).  Rƒ = 0.63 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.27 - 7.31 (m, 2 H), 7.20 - 7.24 (m, 1 H), 7.17 (d, 
J=7.32 Hz, 2 H), 6.52 (s, 1 H), 4.18 (d, J=6.84 Hz, 2 H), 4.11 (d, J=6.84 Hz, 2 H), 3.84 
(s, 2 H), 2.07 - 2.14 (m, 1 H), 2.01 - 2.07 (m, 1 H), 0.964 (d, J=6.84 Hz, 6 H), 0.949 (d, 
J=7.32 Hz, 6H).  
13
C NMR (125 MHz, CDCl3)  ppm 162.29, 160.68, 137.12, 135.36, 
129.36, 128.82, 126.93, 119.75, 73.44, 73.26, 35.38, 27.99, 27.94, 19.34, 19.30.  m/z 
315.0 (M+H)
+
. 
 
 
4-Benzyl-6-isobutoxy-3-isopropoxypyridazine (1.32):  Synthesized from 1.24 (0.72 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.32 as a viscous darker 
yellow oil (0.11 g, 53%).  Rƒ = 0.58 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (500 MHz, CDCl3)  ppm 7.27 - 7.32 (m, 2 H), 7.21 - 7.25 (m, 1 H), 7.16 - 7.20 
(m, 2 H), 6.45 (s, 1 H), 5.41 (spt, J=6.35 Hz, 1 H), 4.18 (d, J=6.84 Hz, 2 H), 3.83 (s, 1 
H), 2.00 - 2.08 (m, 1 H), 1.35 (d, J=5.86 Hz, 6 H), 0.95 (d, J=6.84 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 161.60, 160.48, 137.11, 135.47, 129.46, 129.41, 126.90, 
120.28, 73.30, 69.62, 35.38, 28.05, 22.14, 19.33.  m/z 301.2 (M+H)
+
. 
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4-Benzyl-3-(benzyloxy)-6-isobutoxypyridazine (1.33):  Synthesized from 1.24 (0.90 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.33 as a viscous intense 
yellow oil (0.04 g, 12%).  Rƒ = 0.54 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (500 MHz, CDCl3)  ppm 7.42 (d, J=7.32 Hz, 2 H), 7.31 - 7.36 (m, 4 H), 7.15 - 
7.18 (m, 4 H), 6.57 (s, 1 H), 5.47 (s, 2 H), 4.19 (d, J=6.84 Hz, 2 H), 3.97 (s, 2 H), 2.01 - 
2.10 (m, 1 H), 0.97 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3)  ppm 164.82, 
152.35, 143.76, 136.07, 129.53, 129.38, 129.23, 129.19, 129.10, 127.56, 127.36, 119.31, 
74.09, 69.65, 38.45, 28.00, 19.27.  m/z 349.2 (M+H)
+
. 
 
 
4-Benzyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine (1.34):  Synthesized using Method 
F and starting with 0.5 g 3,6-dichloropyridazine, product purified by column 
chromatography on silica gel (gradient of 1:99  7:93, EtOAc/hexanes) which afforded 
pure 1.34 as a white crystalline solid (0.88 g, 87%).  Rƒ = 0.44 (1:4 EtOAc/hexanes) UV 
TLC visualization.  
1
H NMR (500 MHz, DMSO-d6)  ppm 8.07 (d, J=8.79 Hz, 2 H), 7.95 
- 8.00 (m, 2 H), 7.93 (d, J=8.30 Hz, 2 H), 7.67 (d, J=6.84 Hz, 1 H), 7.60 (d, J=7.32 Hz, 1 
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H), 7.53 - 7.58 (m, 4 H), 7.49 (q, J=7.32 Hz, 2 H), 7.10 - 7.19 (m, 5 H), 6.99 (s, 1 H), 
5.93 (s, 2 H), 5.87 (s, 2 H), 3.81 (s, 2 H).  
13
C NMR (125 MHz, DMSO-d6)  ppm 161.66, 
160.09, 137.25, 135.36, 133.25, 132.26, 132.21, 131.22, 131.11, 128.91, 128.80, 128.68, 
128.49, 128.47, 128.42, 127.28, 126.85, 126.52, 126.46, 125.93, 125.90, 125.33, 125.32, 
123.70, 123.69, 119.77, 66.52, 66.30, 34.36.  m/z 483.2 (M+H)
+
. 
 
 
3-Chloro-4-isobutyl-6-isopropoxypyridazine (1.35):  Synthesized using Method A and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (1:9, EtOAc/hexanes) which afforded pure 1.35 as a semi-viscous bright yellow 
oil (0.45 g, 42%).  Rƒ = 0.58 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 
MHz, CDCl3)  ppm 6.66 (s, 1 H), 5.44 (spt, J=6.35 Hz, 1 H), 2.46 (d, J=7.32 Hz, 2 H), 
1.96 (spt, J=6.84 Hz, 1 H), 1.34 (d, J=5.86 Hz, 6 H), 0.90 (d, J=6.84 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 164.37, 143.12, 129.71, 119.83, 70.40, 41.58, 27.60, 22.33, 
21.92.  m/z 228.9 (M+H)
+
. 
 
 
6-(Benzyloxy)-3-chloro-4-isobutylpyridazine (1.36):  Synthesized using Method A and 
starting with 0.95 g 3,6-dichloropyridazine, product purified by column chromatography 
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on silica gel (1:9, EtOAc/hexanes) which afforded pure 1.36 as a semi-viscous bright 
yellow oil (0.61 g, 52%).  Rƒ = 0.58 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (400 MHz, CDCl3)  ppm 7.42 - 7.47 (m, 1 H), 7.29 - 7.39 (m, 4 H), 6.80 (s, 1 H), 
5.49 (s, 2 H), 2.50 (d, J=7.42 Hz, 2 H), 1.93 - 2.04 (m, 1 H), 0.93 (d, J=6.64 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 164.50, 152.76, 143.42, 136.16, 128.64, 128.56, 
128.42, 119.48, 69.46, 41.62, 27.60, 22.33.  m/z 276.9 (M+H)
+
. 
 
 
3-Chloro-6-isobutoxy-4-isobutylpyridazine (1.37):  Synthesized using Method B and 
starting with 1 g 3,6-dichloropyridazine, product purified by column chromatography on 
silica gel (gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.37 as a very 
light yellow oil (0.57 g, 68%).  Rƒ = 0.68 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 6.73 (s, 1 H), 4.19 (d, J=6.84 Hz, 2 H), 2.48 (d, 
J=6.84 Hz, 2 H), 2.03 - 2.12 (m, 1 H), 1.93 - 2.02 (m, 1 H), 0.97 (d, J=6.84 Hz, 6 H), 
0.91 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, CDCl3) ppm 165.02, 152.30, 143.13, 
119.35, 73.91, 41.61, 27.97, 27.64, 22.33, 19.21.  m/z 243.1 (M+H)
+
. 
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4-Isobutyl-3,6-diisopropoxypyridazine (1.38):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (1:9, EtOAc/hexanes) which afforded pure 1.38 as a semi-viscous yellow oil (0.32 g, 
52%).  Rƒ = 0.62 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, 
CDCl3)  ppm 6.58 (s, 1 H), 5.36 - 5.40 (m, 2 H), 2.33 (d, J=6.84 Hz, 2 H), 1.88 - 1.96 
(m, 1 H), 1.34 (d, J=4.88 Hz, 12 H), 0.88 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, 
CDCl3)  ppm 161.49, 161.14, 135.75, 117.78, 69.21, 69.11, 38.68, 27.60, 22.59, 22.19, 
22.16.  m/z 253.9 (M+H)
+
. 
 
 
3-Isobutoxy-4-isobutyl-6-isopropoxypyridazine (1.39):  Synthesized from 1.35 (0.87 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.39 as a semi-viscous 
light yellow oil (0.19 g, 82%).  Rƒ = 0.54 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3) ppm 6.65 (d, J=3.42 Hz, 1 H), 5.34 - 5.41 (m, 1 H), 4.13 
(d, J=6.35 Hz, 2 H), 2.35 (d, J=6.84 Hz, 2 H), 2.06 – 2.13 (m, 1 H), 1.91 - 1.97 (m, 1 H), 
1.34 (d, J=5.37, 6 H), 0.98 (d, J=6.84 Hz, 6 H), 0.89 (d, J=5.86 Hz, 6 H).  
13
C NMR (125 
MHz, CDCl3) ppm 162.18, 161.26, 135.42, 120.18, 73.26, 69.29, 38.83, 28.02, 27.60, 
22.61, 22.14, 19.42.  m/z 267.0 (M+H)
+
. 
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3-(Benzyloxy)-4-isobutyl-6-isopropoxypyridazine (1.40):  Synthesized from 1.35 (0.87 
mmol) using Method C, product purified by column chromatography on silica gel 
(gradient of 1:99  8:92, EtOAc/hexanes) which afforded pure 1.40 as a semi-viscous 
bright yellow oil (0.15 g, 58%).  Rƒ = 0.53 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 7.43 - 7.48 (m, 2 H), 7.35 - 7.39 (m, 2 H), 7.30 - 7.33 
(m, 1 H), 6.64 (s, 1 H), 5.46 (s, 2 H), 5.40 (spt, J=6.35 Hz, 1 H), 2.41 (d, J=6.35 Hz, 2 
H), 1.95 - 1.99 (m, 1 H), 1.37 (d, J=6.35 Hz, 6 H), 0.90 (d, J=6.84 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 161.79, 160.66, 137.40, 135.50, 128.55, 128.41, 127.82, 
120.89, 69.36, 68.66, 38.71, 27.53, 22.57, 22.16.  m/z 301.2 (M+H)
+
. 
 
 
3,6-Bis(benzyloxy)-4-isobutylpyridazine (1.41):  Synthesized using Method E and 
starting with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography 
on silica gel (1:9, EtOAc/hexanes) which afforded pure 1.41 as a viscous bright yellow 
oil (0.58 g, 69%).  Rƒ = 0.71 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (400 
MHz, CDCl3)  ppm 7.44 - 7.48 (m, 4 H), 7.36 - 7.40 (m, 4 H), 7.29 - 7.34 (m, 2 H), 6.77 
(s, 1 H), 5.49 (s, 2 H), 5.45 (s, 2 H), 2.44 (d, J=7.03 Hz, 2 H), 1.99 (s, 1 H), 0.90 (d, 
J=6.64 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 162.03, 161.16, 137.27, 136.95, 
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135.74, 128.65, 128.58, 128.43, 128.22, 127.95, 127.85, 120.39, 68.84, 68.78, 38.63, 
27.53, 22.56.  m/z 348.8 (M+H)
+
. 
 
 
6-(Benzyloxy)-4-isobutyl-3-isopropoxypyridazine (1.42):  Synthesized from 1.36 (0.90 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  5:95, EtOAc/hexanes) which afforded pure 1.42 as a semi-viscous 
bright yellow oil (0.20 g, 75%).  Rƒ = 0.60 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (600 MHz, CDCl3)  ppm 7.43 - 7.48 (m, 2 H), 7.35 - 7.39 (m, 2 H), 7.30 - 7.34 
(m, 1 H), 6.77 (s, 1 H), 5.48 (s, 2 H), 5.40 (spt, J=5.86 Hz, 1 H), 2.44 (d, J=7.03 Hz, 2 
H), 1.97 - 2.01 (m, 1 H), 1.37 (d, J=6.45 Hz, 6 H), 0.90 (d, J=6.45 Hz, 6 H).  
13
C NMR 
(100 MHz, CDCl3)  ppm 162.01, 161.14, 137.24, 135.81, 128.67, 128.47, 127.86, 
120.42, 68.87, 68.79, 38.63, 27.52, 22.57, 22.15.  m/z 301.2 (M+H)
+
. 
 
 
6-(Benzyloxy)-3-isobutoxy-4-isobutylpyridazine (1.43):  Synthesized from 1.36 (0.90 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.43 as a semi-viscous 
light yellow oil (0.18 g, 63%).  Rƒ = 0.62 (1:4 EtOAc/hexanes) UV TLC visualization.  
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1
H NMR (500 MHz, CDCl3)  ppm 7.43 - 7.45 (m, 2 H), 7.34 - 7.38 (m, 2 H), 7.30 - 7.32 
(m, 1 H), 6.70 (s, 1 H), 5.46 (s, 2 H), 4.16 (d, J=6.84 Hz, 2 H), 2.42 (d, J=7.32 Hz, 2 H), 
2.08 - 2.13 (m, 1 H), 1.96 - 2.01 (m, 1 H), 0.99 (d, J=6.84 Hz, 6 H), 0.90 (d, J=6.84 Hz, 6 
H).  
13
C NMR (125 MHz, CDCl3)  ppm 162.51, 160.85, 137.38, 135.49, 128.62, 128.54, 
127.87, 120.35, 73.31, 68.66, 38.62, 28.04, 27.56, 22.57, 19.35.  m/z 315.2 (M+H)
+
. 
 
 
3,6-Diisobutoxy-4-isobutylpyridazine (1.44):  Synthesized using Method E and starting 
with 0.5 g 3,6-dichloropyridazine, product purified by column chromatography on silica 
gel (1:9, EtOAc/hexanes) which afforded pure 1.44 as a semi-viscous bright yellow oil 
(0.43 g, 63%).  Rƒ = 0.61 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (400 
MHz, CDCl3)  ppm 6.63 (s, 1 H), 4.12 (d, J=6.64 Hz, 2 H), 4.10 (d, J=6.64 Hz, 2 H), 
2.35 (d, J=7.42 Hz, 2 H), 2.02 - 2.12 (m, 2 H), 1.92 (m, 1 H), 0.96 (t, J=6.64 Hz, 12 H), 
0.87 (d, J=6.64 Hz, 6 H).  
1
H NMR (600 MHz, CDCl3)  ppm 6.63 (s, 1 H), 4.13 (d, 
J=6.45 Hz, 2 H), 4.10 (d, J=6.45 Hz, 2 H), 2.35 (d, J=7.03 Hz, 2 H), 2.03 - 2.09 (m, 2 H), 
1.88 - 1.96 (m, 1 H), 0.96 (d, J=7.03 Hz, 6 H), 0.95 (d, J=7.03 Hz, 6 H), 0.87 (d, J=7.03 
Hz, 6 H).  
13
C NMR (100 MHz, CDCl3)  ppm 162.11, 161.18, 135.31, 120.10, 73.18, 
73.13, 38.77, 28.02, 27.95, 27.53, 22.52, 19.36, 19.29.  m/z 281.0 (M+H)
+
. 
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6-Isobutoxy-4-isobutyl-3-isopropoxypyridazine (1.45):  Synthesized from 1.37 (1.03 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.45 as a semi-viscous 
light yellow oil (0.07 g, 24%).  Rƒ = 0.74 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, CDCl3)  ppm 6.57 (d, J=3.91 Hz, 1 H), 5.34 - 5.38 (m, 1 H), 4.14 
(d, J=6.84 Hz, 2 H), 2.35 (d, J=6.35 Hz, 2 H), 2.05 - 2.11 (m, 1 H), 1.89 - 1.96 (m, 1 H), 
1.33 (d, J=5.86 Hz, 6 H), 0.98 (d, J=6.35 Hz, 6 H), 0.88 (d, J=5.86 Hz, 6 H).  
13
C NMR 
(125 MHz, CDCl3)  ppm 162.15, 161.43, 135.35, 120.13, 73.21, 69.16, 38.79, 27.98, 
27.57, 22.57, 22.11, 19.38.  m/z 267.2 (M+H)
+
. 
 
 
3-(Benzyloxy)-6-isobutoxy-4-isobutylpyridazine (1.46):  Synthesized from 1.37 (1.03 
mmol) using Method D, product purified by column chromatography on silica gel 
(gradient of 1:99  3:97, EtOAc/hexanes) which afforded pure 1.46 as a semi-viscous 
yellow oil (0.18 g, 56%).  Rƒ = 0.67 (1:4 EtOAc/hexanes) UV TLC visualization.  
1
H 
NMR (500 MHz, CDCl3)  ppm 7.43 - 7.47 (m, 2 H), 7.35 - 7.38 (m, 2 H), 7.28 - 7.33 
(m, 1 H), 6.70 (s, 1 H), 5.46 (s, 2 H), 4.16 (d, J=6.84 Hz, 2 H), 2.42 (d, J=7.32 Hz, 2 H), 
2.08 - 2.12 (m, 1 H), 1.95 - 2.00 (m, 1 H), 0.99 (d, J=6.84 Hz, 6 H), 0.90 (d, J=6.35 Hz, 6 
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H).  
13
C NMR (125 MHz, CDCl3)  ppm 162.51, 160.86, 137.38, 135.51, 128.55, 128.46, 
127.88, 120.36, 73.32, 68.67, 38.63, 28.05, 27.57, 22.58, 19.36.  m/z 315.2 (M+H)
+
. 
 
 
4-Isobutyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine (1.47):  Synthesized using 
Method F and starting with 0.5 g 3,6-dichloropyridazine, product purified by column 
chromatography on silica gel (gradient of 1:99  5:95, EtOAc/hexanes) which afforded 
pure 1.47 as a light yellow crystalline solid (0.95 g, 87%).  Rƒ = 0.46 (1:4 
EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, DMSO-d6)  ppm 8.09 
(dd, J=6.84, 2.93 Hz, 2 H), 7.98 (d, J=6.84 Hz, 2 H), 7.93 - 7.95 (m, 2 H), 7.67 - 7.71 (m, 
2 H), 7.50 - 7.57 (m, 6 H), 7.08 (s, 1 H), 5.92 (s, 2 H), 5.89 (s, 2 H), 2.35 (d, J=7.32 Hz, 2 
H), 1.83 - 1.91 (m, 1 H), 0.75 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, DMSO-d6)  
ppm 161.59, 160.54, 135.12, 133.26, 132.44, 132.32, 131.25, 131.15, 128.78, 128.72, 
128.50, 126.53, 126.33, 125.94, 125.36, 123.75, 123.72, 120.21, 67.06, 66.23, 37.43, 
26.83, 22.07.  m/z 449.2 (M+H)
+
. 
 
 
3,6-Diisopropoxy-4-(naphthalen-2-ylmethyl)pyridazine (1.48):  Synthesized using 
Method F and starting with 0.2 g 3,6-dichloropyridazine, product purified by column 
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chromatography on silica gel (gradient of 1:99  8:92, EtOAc/hexanes) which afforded 
pure 1.48 as a white crystalline solid (0.09 g, 36%).  Rƒ = 0.53 (1:4 EtOAc/hexanes) UV 
TLC visualization.  
1
H NMR (400 MHz, DMSO-d6)  ppm 7.83 - 7.89 (m, 3 H), 7.78 (s, 
1 H), 7.46 - 7.50 (m, 2 H), 7.43 (dd, J=8.20, 1.56 Hz, 1 H), 6.89 (s, 1 H), 5.26 (spt, 
J=6.25 Hz, 1 H), 5.23 (spt, J=6.25 Hz, 1 H), 3.97 (s, 2 H), 1.28 (d, J=2.73 Hz, 6 H), 1.27 
(d, J=2.34 Hz, 6 H).  
13
C NMR (100 MHz, DMSO-d6)  ppm 160.78, 159.39, 135.26, 
135.21, 132.99, 131.76, 127.91, 127.60, 127.50, 127.48, 127.36, 126.18, 125.65, 119.90, 
68.86, 68.50, 34.71, 21.71.  m/z 337.2 (M+H)
+
. 
 
 
3,6-Diisobutoxy-4-(naphthalen-2-ylmethyl)pyridazine (1.49):  Synthesized using 
Method F and starting with 0.2 g 3,6-dichloropyridazine, product purified by column 
chromatography on silica gel (gradient of 1:99  5:95, EtOAc/hexanes) which afforded 
pure 1.49 as a viscous yellow oil (0.09 g, 33%).  Rƒ = 0.62 (1:4 EtOAc/hexanes) UV TLC 
visualization.  
1
H NMR (500 MHz, DMSO-d6)  ppm 7.81 - 7.88 (m, 3 H), 7.75 (s, 1 H), 
7.44 - 7.50 (m, 2 H), 7.41 (dd, J=8.30, 1.95 Hz, 1 H), 7.00 (s, 1 H), 4.08 (d, J=6.35 Hz, 2 
H), 4.06 (d, J=6.84 Hz, 2 H), 4.04 (s, 2 H), 1.97 - 2.06 (m, 2 H), 0.95 (d, J=6.84 Hz, 6 H), 
0.90 (d, J=6.84 Hz, 6 H).  
13
C NMR (125 MHz, DMSO-d6)  ppm 161.76, 160.27, 
135.17, 134.68, 133.03, 131.78, 128.00, 127.50, 127.38, 127.35, 127.23, 126.19, 125.64, 
119.70, 72.61, 72.43, 34.68, 27.39, 27.34, 19.00, 18.97.  m/z 365.2 (M+H)
+
. 
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3,6-Bis(benzyloxy)-4-(naphthalen-2-ylmethyl)pyridazine (1.50):  Synthesized using 
Method F and starting with 0.14 g 3,6-dichloropyridazine, product purified by column 
chromatography on silica gel (gradient of 1:99  8:92, EtOAc/hexanes) which afforded 
pure 1.50 as a darker yellow crystalline solid (0.06 g, 27%).  Rƒ = 0.41 (1:4 
EtOAc/hexanes) UV TLC visualization.  
1
H NMR (500 MHz, DMSO-d6)  ppm 7.84 - 
7.93 (m, 6 H), 7.75 (br. s., 1 H), 7.71 - 7.79 (m, 1 H), 7.26 - 7.51 (m, 9 H), 7.22 (s, 1 H), 
5.48 (br. s., 2 H), 5.47 (br. s., 2 H), 4.26 (s, 2 H).  
13
C NMR (125 MHz, DMSO-d6)  ppm 
164.50, 162.69, 156.81, 155.67, 143.64, 133.93, 133.38, 133.03, 131.93, 131.01, 128.37, 
128.33, 128.23, 127.56, 127.53, 127.52, 127.49, 127.23, 126.31, 125.95, 119.87, 68.77, 
68.72, 37.39.  m/z 433.2 (M+H)
+
. 
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Chapter Two: 
Novel Cyclic β-Sheets Targeting Integrin Mediated Cell Adhesion in Multiple 
Myeloma 
2.1 Introduction 
2.1.1 Overview of β-Sheets and β-Hairpins 
 
 β-sheets, or β-hairpins, are the second most abundant secondary structure found in 
naturally occurring proteins.  They account for roughly 28% of the total structure of 
proteins
1.  Similar to α-helices, β-sheets and β-hairpins play essential roles in the 
recognition domains of many proteins.  These domains, or motifs, are responsible for 
protein-protein, protein-RNA and protein-DNA interactions.  While such interactions are 
necessary for the proper function of many biological processes, they can also be 
responsible for many diseases
2
.   
 Structurally, β-sheets and β-hairpins share many commonalities.  In fact, β-
hairpins can be thought of as a motif, or subsection, of β-sheets.  β-sheets are formed 
when two or more β-strands pair up via backbone amide hydrogen bonding.  There are 
two possible β-sheet structures that can be formed by this pairing; parallel or antiparallel.  
The parallel β-sheets are formed when all of the N-termini of the individual β-strands are 
aligned in the same direction as shown by the blue arrows in Figure 2.1a.  However, 
antiparallel β-sheets are formed when the direction of the individual β-strands alternate as 
shown in Figure 2.1b by the blue and red arrows. 
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Figure 2.1: A) Structural depiction of parallel β-sheets; B) Antiparallel β-sheets.  
Hydrogen bonds drawn as dashed lines.  The arrow indicates the N to C terminus 
direction of the particular β-strand 
 
 Due to the staggered nature of the hydrogen bond donors and acceptors in parallel 
β-sheets, the length of these hydrogen bonds are longer than those found in antiparallel β-
sheets.  The shorter hydrogen bonds found in antiparallel sheets are planar in nature 
which results in stronger inter-strand stability.  Due to the extended conformation nature 
of both parallel and anti-parallel β-sheets, their side chains point above and below the 
plane of the sheet.  As a result, this produces three different recognition types for both 
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kinds of β-sheets.  Two of these types come from the two unique faces of the sheet 
created by the amino acid side chains; this means that both the top and the bottom faces 
can be used as separate binding sites.  The third type of interaction comes from the amide 
hydrogens and their ability to hydrogen bonding to receptors on both sides of the sheet. 
 As a β-sheet motif, β-hairpins are formed by two antiparallel strands that are 
joined by a short connecting loop as shown in Figure 2.2.  This loop is usually two to five 
residues in length and helps to stabilize the hairpin.  However, structural analysis has 
shown that most of the naturally occurring loops have less than 5 residues
3
.  These 
hairpins can either be found as separate individual motifs or found in groups which are 
linked together by hydrogen bonds.  When linked together, these groups of β-hairpins 
form a β-sheet.  Hairpins are important β-sheet motifs because they are used for 
biomolecular recognition in protein-protein interactions
4
. 
 
 
Figure 2.2: Ribbon diagram of β-hairpins  
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 The antiparallel β-strands in both β-hairpins and antiparallel β-sheets can be 
connected by structures known as β-turns.  As shown in Figure 2.3, β-turns generally 
contain four amino acids that are hydrogen bonding between the ith and i +3 residues.  
These turns allow the β-strands to quickly reverse direction which can allow the protein 
to assume a more globular compact shape
5
.   
 
 
Figure 2.3: Standard β-turn structure 
 
2.1.2 Various Known β-Turn Structures 
 
 The β-turn is an important structural aspect for many β-sheets and is often a 
critical element in the formation of β-hairpins5a.  The turn itself plays an important role in 
the sheet’s stability and can often initiate the formation of the β-hairpin or sheet.  As 
such, numerous groups have studied the effects of different turns on the β-sheet’s 
structure and stability.  By incorporating different natural and unnatural amino acids into 
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the turn, they have been able to study the turn’s ability to induce β-hairpin folding as well 
as its effects on the conformational stability of the peptide
6
. 
 Perhaps one of the simplest ways shown to create β-turns is to incorporate non-
bulky achiral amino acids such as Glycine.  Blanco and co-workers have shown that 
incorporating Asparagine and Glycine into the β-turn results in the successful formation 
of a β-hairpin in water.  This β-hairpin and the L-Asn-Gly dipeptide turn promoter can be 
seen in Figure 2.4. 
 
 
Figure 2.4: Blanco β-hairpin with Asn-Gly β-turn promoter 
 
 The Gellman group has produced successful β-turns by replacing the Asparagine 
residue with a D-Proline one
7
.  This new turn promoter was not only shown to be a better 
β-hairpin promoter than the Asn-Gly turn but that it also increased the likelihood of 
forming β-hairpins from linear peptides.  Figure 2.5 shows this Gellman peptide with this 
more successful turn. 
N
H
N
N
H
N
N
H
O
O
O H
O
HO
N
O
H
IleVal
LysThrSer
Ile
N
H
N
N
H
N
N
H
N
O
O
OH
O
H O
N
O
H
H
N
O
IleValTyrLys
Lys Thr Ser
N
Lys
H
O
Asp
HN
O
O
O
H
O
93 
 
 
Figure 2.5: Gellman peptide with D-Pro-Gly β-turn  
 
α-aminoisobutyric acid (Aib) is another achiral amino acid that has been used in 
the formation of β-turns.  Balaram and coworkers have shown that in organic solvents, β-
turns can be formed when Aib is combined with D-α-amino acids or achiral α-amino 
acids
8.  Expanding on this work, Hammer and coworkers synthesized β-turns from Aib 
and D-Alanine as well as from Aib and Gly.  They incorporated these turns into the same 
peptide used by Gellman (Figure 2.5) and found that in water, these new dipeptides 
function as β-turns.  NMR analysis of these β-sheets in water showed that these two turns 
adopted a type I′ β-turn9.  Figure 2.6 shows these peptides with their respective β-turns. 
 
  
Figure 2.6: A) Peptide with Aib-Gly β-turn; B) Peptide with Aib-D-Ala β-turn 
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 Balaram’s group has also investigated the combination of D-Proline with other 
unnatural amino acids to create a variety of expanded β-turns.  The peptides whose turns 
incorporated the α,β and α,γ residues (Figure 2.7) were shown to adopt hairpin 
conformations in methanol while the peptide with whose turn incorporated the α,δ 
residue only adopted the hairpin conformation when in the crystalline form
10
. 
 
 
Figure 2.7: A) Extended α,β turn promoter; B) Extended α,γ turn promoter; C) Extended 
α,δ turn promoter 
 
Other types of β-turns that have been shown to work include those that utilize 
either non-amino acids or amino acid-like compounds
11
 as shown in Figure 2.8.  The non-
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amino acid 1,2,3-trazole centered β-turn promoter has been shown to form hairpins in 
chloroform
12.  The tetrahydroisoquinoline based β-turn promoter is synthesized from L-
Dopa, an amino acid-like compound.  In chloroform, it has been shown to induce hairpin 
formation in smaller peptides
13
. 
 
 
Figure 2.8: Assorted β-turn promoters, A) 1,2,3-triazole β-turn promoter; B) cis-
azobenzene β-turn promoter; C) tetrahydroisoquinoline based β-turn promoter; D) 
diketopiperazine β-turn promoter 
 
 Up to this point, the β-turns discussed have all induced the formation of 
antiparallel β-sheets.  In 2008, the Gellman group reported on the first diacid linker to 
promote the formation of parallel β-sheets in water14.  Using the novel turn CHDA-Gly, 
the two β-strands are aligned in the parallel orientation as shown in Figure 2.9.  These 
types of turn promoter not only allow us to synthesize parallel β-sheets, but also may aid 
in the treatment of certain diseases.  This is due to the fact that parallel β-sheets play in 
important role in aggregation of peptides such as the Aβ peptide found in Alzhiemer’s 
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disease patients
2.  With the help of these turn promoters, parallel β-sheets that prevent 
peptide aggregation could be easily synthesized. 
 
 
Figure 2.9: Parallel β-sheet induced by novel CHDA-Gly β-turn promoter 
 
2.1.3 Cyclic β-Sheets and β-Hairpins 
 
 Usually, as with α-helices, only a certain small section of the β-sheet is 
responsible for the protein-protein interaction necessary for the biological activity to 
occur.  A potentially easy way to inhibit this interaction is by synthesizing a β-sheet 
similar to one of the ones responsible for the protein-protein interaction.  However, 
simply synthesizing a linear peptide with the proper residues in the correct locations may 
not produce a viable drug.  This is due to the linear peptide’s conformational flexibility 
which allows the peptide to assume random structures in aqueous solutions instead of the 
desired β-sheet.  Furthermore, the linear peptides are easily degraded by proteases, 
display poor bioavailability and poor pharmacological properties.  One solution to these 
problems is to cyclize the linear peptide.  Cyclization greatly reduces the peptide’s 
degrees of freedom which results in a peptide with a better defined and more fixed 
shape
15
.  Prearranging the peptide into the shape required for binding helps to increase 
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the peptide’s affinity for its target by removing the entropy loss associated with adopting 
the required shape.  Cyclization also helps to stabilize the bound conformation of the 
peptide
16
.  Finally, protease enzymes do not recognize cyclic peptides as well as linear 
peptides allowing them to remain bioactive longer than their linear counterparts. 
 Several research groups have designed cyclic β-sheets and have studied the 
effects of various turn promoters on the folding of these cyclized β-sheets17.  In 
particular, the Robinson group has designed a highly effective D-Pro-L-Pro β-turn 
promoter.  Figure 2.10 shows one of their p53/MDM2 inhibitors, a cyclic β-hairpin with 
the novel D-Pro-L-Pro turn incorporated
18.  This turn promoter adopts a stable type II′ β-
turn which is ideal for inducing β-hairpins.  The D-Pro-L-Pro turn has been used by the 
Kopple group to create cyclic hexapeptides which also display type II′ β-turns19.   
 
 
Figure 2.10: Cyclic β-hairpin utilizing D-Pro-L-Pro β-turn promoter 
 
 The utility of the Robinson turn (D-Pro-L-Pro) has been demonstrated by 
incorporating the turn into inhibitors for several different biological targets.  Figure 2.11 
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cationic antimicrobial peptide Protegrin I
20.  β-sheets that employ a mixed peptide-
peptoid backbone and display excellent antimicrobial activities have also been reported
21
 
(Figure 2.12).   
 
 
Figure 2.11: β-hairpin mimetic scaffold of antibiotic Protegrin I 
 
 
Figure 2.12: Antimicrobial β-sheets utilizing the D-Pro-L-Pro β-turn promoter 
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 Our group has designed two novel β-turn promoters used in the synthesis of cyclic 
β-hairpin peptidomimetics.  The methylsulfonamido aminoethyl glycine turn and the D-
Proline ether-peptidomimetic turn are shown in Figure 2.13 along with a general hairpin 
that has both types of turns.  We plan to use these peptidomimetics to inhibit protein-
protein interactions.  The recognition strand will mimic the core residues of the protein 
recognition surface while the non-recognition strand will house residues necessary for the 
optimization of the bioavailability and bioactivity of the peptide. 
 
 
Figure 2.13: A) Methylsulfonamido aminoethyl glycine β-turn promoter; B) D-Proline 
ether-peptidomimetic β-turn promoter; C) Generic cyclic β-hairpin peptidomimetic with 
the methylsulfonamido aminoethyl glycine β-turn promoter drawn in blue and the D-
Proline ether-peptidomimetic drawn in red 
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promoters should adopt a β-hairpin conformation, the binding affinity of these peptides 
may suffer due to the flexible nature of these turns.  We believe that that replacing one of 
these methylsulfonamido aminoethyl glycine turns with the D-Proline ether-
peptidomimetic turn will help to improve the peptide’s binding affinity by further 
constraining the number of available free conformations. 
 
2.1.4 Multiple Myeloma, Apoptosis, and Integrin Mediated Cell Adhesion 
 
 Multiple myeloma (MM) is the incurable cancer of the plasma cells which are the 
white blood cells responsible for producing antibodies
22
.  Relapse often occurs due to the 
unsuccessful eradication of all the cancerous cells.  These few remaining cancerous cells 
following treatment are referred to as minimal residual disease (MRD).  These tumor 
cells remain due to their development of strong multi-drug resistance mechanisms
23
.  As 
a result, the standard chemotherapy treatments have proven to be ineffective.  MRD is 
found in bone marrow which is rich in extracellular matrices; this microenvironment is 
critical for tumor survival
24
.  The adhesion of multiple myeloma to the extracellular 
matrix component fibronectin (FN) has been shown by Hazlehurst and coworkers to 
influence the tumor cell’s ability to survive and to inhibit drug induced apoptosis25.  
Several research groups have attacked this problem by targeting the integrin mediated 
cell adhesion process.  They have designed molecules that mimic the integrin recognition 
surfaces in order to prevent the integrin-fibronectin protein-protein interaction from 
occurring.  Inhibiting this interaction will increase the efficacy of standard apoptotic 
chemotherapeutic drugs which is exceptionally important given that the majority of 
101 
 
standard chemotherapeutic agents induce apoptosis.  While the majority of cancer cells 
are killed following an apoptotic pathway, the increasing number of multi-drug resistant 
tumors cells strongly implies that new chemotherapeutic agents should take advantage of 
different cellular death pathways. 
 While investigating the integrin mediated cell adhesion process, Kit Lam, Anne 
Cress, and co-workers identified several peptides capable of inhibiting this adhesion 
process.  Specifically, these peptides inhibited β1 integrin mediated adhesion of prostate 
cancer cells to the extracellular matrix components fibronectin, laminin and type-IV 
collagen
26
.  They also identified a synthetic peptide consisting of all D-amino acids that 
was able to block the binding of epithelial prostate carcinoma cells to ECM 
components
27
.  This synthetic peptide was named HYD1 and is composed of the 
following residues (in order): kikmviswkg.  HYD1 has also been used to block β1 
integrin mediated adhesion in Multiple myeloma.  In turn, this increased the efficiency of 
standard Multiple myeloma chemotherapy drugs
28
.  Interestingly, HYD1 has been shown 
to kill MM cells as a single agent both in vitro and in vivo.  Rather than following a 
standard apoptotic pathway (i.e. caspase activation), HYD1 killed MM cells by 
programmed cell necrosis.   
 Using the structure of the D-HYD1 peptide as a starting point, we plan to design 
and synthesize novel peptide analogs in an effort to improve the potency of the parent 
peptide.  These peptide analogs will be cyclized in order to improve their biological 
activity.  The recognition strand of these cyclic peptides will then be further constrained 
by the incorporation of our novel β-turn promoters (Figure 2.13).  These cyclic β-hairpins 
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are expected to block the adhesion of integrins to extracellular matrix components in 
prostate, Multiple myeloma, and lung tumor cells. 
 
2.1.5 Structural Determination and Analysis of Peptides 
 
 A variety of experimental spectroscopic techniques are available for the 3D 
structural determination of peptides and proteins.  Examples of such techniques include 
solution nuclear magnetic resonance spectroscopy (NMR), solid state NMR 
spectroscopy, X-ray crystallography, Fourier transformed infrared spectroscopy (FTIR), 
and circular dichroism spectroscopy (CD).  X-ray crystallography allows for the absolute 
structural elucidation of peptides and proteins.  While it is a widely favored spectroscopic 
technique, the requirement that the peptide be a crystalline solid during analysis is an 
extreme downfall.  Since peptides in the body are generally in solution, this technique 
cannot be used to study the dynamic interactions.   
Solution NMR studies of peptides can provide a great deal of information 
regarding the peptide’s structural characteristics.  The chemical shift values alone can 
provide a generalized 3D structural picture of the peptide of interest.  The explicit 3D 
conformation can be elucidated using the nuclear Overhauser effect (NOE).  NOE 
experiments observe the through space interactions between nuclei that are separated by 
distances of 5 Å or less.  The resulting distant constraint information obtained by the 
NOE measurements can then be incorporated into computational software.  This software 
then preforms energy minimization calculations to provide optimized solution structures 
of the peptide.  Solid state NMR is often preferred over solution state NMR when 
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studying proteins, especially larger proteins or those naturally found in membranes.  
Using solid state for such proteins provides a better idea of its 3D structure as well as 
how it interacts with other things in the cell.   
 FTIR spectroscopy can be used to examine peptides that display aggregation or 
self-association behavior.  Each functionality group produces its own unique set of 
absorption bands.  The amide bond found in peptides and proteins displays two types of 
characteristic bands.  The Amide I band arises from the stretching vibrations of the 
carbonyl double bond while the Amide II band is due to the bending vibrations from the 
amide N-H bonds
29.  The location of these two bands highly depends on the peptide’s 
secondary structure. 
 The conformation of peptides and proteins in solution can be determined by using 
circular dichroism spectroscopy.  This technique looks at the difference in absorbance of 
left and right circularly polarized light by a compound.  Each type of secondary structure 
produces a characteristic signal in the UV region between 190 and 260 nm which can be 
seen in Figure 2.14
30
. 
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Figure 2.14: CD spectrum of peptide secondary structures 
 
2.2 β-Sheet Construction 
2.2.1  Synthesis of Sulfonyl Chlorides for β-Turn Promoters 
 
A library of our novel sulfonamide aminoethyl glycine β-turn promoters were 
synthesized by incorporating different sulfonyl chlorides.  Figure 2.15 shows our generic 
sulfonamide aminoethyl glycine β-turn promoter.   
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Figure 2.15: Generic sulfonamide aminoethyl glycine β-turn promoter 
 
All sulfonyl chlorides were synthesized in a similar fashion to 
chloromethanesulfonyl chloride as shown in Scheme 2.1 and purified either via 
distillation or recrystallization.  Dichloromethane is added to an aqueous solution of 
sodium sulfite and phase-transfer catalyst tetrabutylammonium hydrogensulfate 
(TBAHS) in a large pressure vessel which is then heated for a period of time to give 
compound 2.1.  After thoroughly drying and powdering compound 2.1, it is then used in 
the next step without further purification.  Compound 2.1 is then chlorinated using PCl5 
to give sulfonyl chloride 2.2. 
 
 
Scheme 2.1: Synthesis of Chloromethanesulfonyl chloride 
 
The overall generic reactions for the preparation of the different sulfonyl 
chlorides is shown in Scheme 2.2, while Table 2.1 presents all sulfonyl chlorides 
prepared, their method of purification, and their overall reaction yields.   
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Scheme 2.2: Generic reactions for the synthesis of sulfonyl chlorides 
 
Table 2.1: Sulfonyl chlorides prepared, overall reaction yields, and method of 
purification 
 
Product R- Group Yield (%) Purification Method 
2.2 ClCH2 76-83 Distillation 
2.4 BrCH2 76-83 Distillation 
2.6 Methyl-d3 24 Distillation 
2.8 i-Propyl 19 Distillation 
2.10 i-Butyl 35 Distillation 
2.12 n-Butyl 4 Distillation 
2.14 Decyl 91 Recrystallization 
2.17 Octadecyl ---
a
 ---
a
 
2.19 Benzyl 55 Recrystallization 
2.21 1-Napthylmethyl 25 Recrystallization 
2.23 N-Boc Taurine 96
b
 ---
a
 
2.25 Ethyl 1,2-Disulfonyl 71.5 Recrystallization 
a
Not Purified, 
b
Taruine Sodium Salt Chlorinated with Triphosgene or SOCl
2
 
 
Chloromethanesulfonyl chloride has been prepared before by the direct 
chlorination of s-trithiane in acetic acid
31
, but the procedure described herein is easier, 
higher yielding and uses cheaper starting materials.  The procedures below are modified 
versions of that of Brienne and coworkers
32
.  The inherent problem of these previous 
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methods is that very lows yields of the intermediate sodium salt are obtained when 
refluxing the first reaction at atmospheric pressure due to the low boiling point of 
dichloromethane.  In order to remedy this problem, the reaction was performed in a 
pressure vessel.  The incorporation of a pressure vessel does two beneficial things for this 
synthesis.  First, it prevents the dichloromethane from being boiled out of solution; thus 
allowing for the use of the cheaper, more readily available dichloromethane as opposed to 
the heavier and more expensive dibromomethane, which has a higher boiling point, as the 
starting material.  Second, it takes advantage of Le Chatelier's principle, pushing the 
equilibrium more towards the product side, producing a greater quantity of the sodium 
sulfonate intermediate.  Furthermore, the incorporation of the pressure vessel broadens 
the scope of this reaction to encompass any halogenated precursor regardless of boiling 
point. 
It is important to note however, that the use of iodinated starting materials should 
be avoided for these reactions.  This is because during the chlorination step, diatomic 
Iodine is created as a by-product.  This by-product significantly complicates the 
purification process as Iodine will sublimate during the distillation process contaminating 
the pure product.  Additionally, it will also crash out as a solid when recrystallization is 
attempted.  Attempts to remove the Iodine by washing the product with an aqueous 
solution of sodium bisulfite proved highly ineffective as the sulfonyl chloride also reacted 
thus effectively eliminating the sulfonyl chloride product.  As evident for the deuterated 
product 2.6, the use of an aqueous bisulfite wash drastically reduced the reaction’s yield.  
It was much more practical however to use an iodinated starting material for this reaction 
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due to the fact that both bromomethane-d3 and chloromethane-d3 are gases at room 
temperature (bromomethane  b.p. 4°C, chloromethane -24.2°C). 
Methane-d3-sulfonyl chloride was synthesized in order to aid us in the 
determination of the metabolites that are produced from our peptides.  This deuterated 
version of mesyl chloride will be added to our novel turn promoter and then we will look 
for metabolite unknowns that are separated by three mass units for singly charged ions 
and 1.5 mass units for doubly charged ions. 
The synthesis of the remaining sulfonyl chlorides has also been reported at one 
time or another.  However, most of these reported methods usually involve more 
complicated reaction conditions or employ extremely stinky thiols. Such examples 
include the preparation and use of lithium reagents such as i-butyllithium at low 
temperatures to synthesize isobutylsulfonyl chloride
33
.  The oxidation and chlorination of 
thiols has been shown for a large variety of sulfonyl chlorides such as ethyl, i-propyl, 
benzyl, and 2-napthyl.  These reactions use a variety of oxidants such as hydrogen 
peroxide
34
 and metal nitrates
35
 to oxidize the thiols.  However, the obvious deterrent to 
utilizing these methods is the repulsive stech associated with thiols.  Thiocyanates have 
also been used as intermediates in the preparation of isobutyl, n-butyl, and decyl sulfonyl 
chlorides
36
.  Chlorination of these thiocyanates with sulfuryl chloride in the presence of 
acetic acid produces the desired sulfonyl chlorides.  However, these chlorination reagents 
are more expensive (1 L 97% for 122.50 USD and 1 L 99% for 45.90 USD
37
 
respectively) than the PCl5 (1 kg 95% for 67.30 USD
38
) used here in our procedure thus 
making this method much more costly.  Lastly, thionyl chloride has also been shown to 
109 
 
chlorinate the sodium salts of a variety of alkyl sulfonates to their respective sulfonyl 
chlorides
39
. 
While most of the halogenated starting materials were readily available, it was 
necessary to synthesize the alkyl halide used in first part of the octadecane-1-sulfonyl 
chloride synthesis. While there are several ways to accomplish this conversion
40
, the 
easiest and simplest was combine the 1-octadecanol with thionyl chloride and pyridine in 
benzene and allow the reaction to run overnight at room temperature.  The solvent was 
roto-evaporated from the resulting slurry and the alkyl halide was used directly in the 
next step without purification.  While it is possible to purify the alkyl halide from the 
alcohol either by distillation or by column chromatography, neither purification method is 
well suited for large scale research preparations such as the one described herein.  The 
difference in boiling points
41
 is minimal at best (Table 2.2).  All attempts to purify the 
alkyl halide via distillation failed and resulted in a stinky black charred mess in the 
bottom of the RBF. 
 
Table 2.2: Reported octadecyl boiling points at specific distillation pressures 
Octadecanol B.P. (°C) 1-Chlorooctadecane B.P. (°C) Pressure (Torr) 
--- 204 20 
210.5 --- 15 
203 199 10 
197-201 --- 9 
 
The other potential purification method that could have been used was column 
chromatography.  However, the extreme similarities between the two compound’s Rƒ 
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values (Table 2.3) indicated that using column chromatography was a poor choice to 
separate the two molecules.  Another possible common purification technique that could 
have been used was recrystallization.  However, given the extreme structural similarities 
between the alcohol and halide, recrystallization was dismissed as being implausible.  
The corresponding sulfonyl chloride was then synthesized following the same standard 
procedure as for the other sulfonyl chlorides. 
 
Table 2.3: Octadecyl Rƒ values 
Compound Rƒ (Hexanes) 
Octadecanol 0.94 
1-Chlorooctadecane 0.76 
 
 Finally, when synthesizing sodium sulfonate salts with longer aliphatic chains, 
such as decyl and octadecyl, care should be taken when roto-evaporating the water from 
the reaction as the sulfonate salts form micelles and reverse micelles with the water.  
These micelles and reverse micelles act as surfactants in the aqueous solution which then 
foam up almost uncontrollably when evaporation of the water is attempted.  Due to the 
extremely similar surfactant properties of these sulfonate salts, this foaming action is akin 
to the foam produced when washing ones hands with soap and water.  Additionally, the 
reverse micelles also trap water molecules inside them which can not only lead to vicious 
bumping when the water boils inside them but it can also make it very difficult to fully 
remove the water from these sulfonate salts.  It was found that using lower bath 
temperatures and reasonably moderate vacuum pressures helped to significantly reduce 
the foaming and bumping of the solution while removing the water.  Thus reducing 
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product lost due to bumping and foaming.  The trade-off for this reduced product loss is 
that the evaporation process now takes considerably longer. 
 
2.2.2  Synthesis of Novel β-turn Promoters† 
 
 These sulfonyl chlorides were then incorporated into our novel sulfonamide 
aminoethyl glycine β-turn promoter to produce a library of novel turn promoters.  The 
idea here is to increase the peptide’s hydrophobicity with these turn promoters that 
incorporate the different sulfonyl chlorides.  While we have varied the β-turn structure 
previously and seen basically the same biological activity, we expect to see a marked 
increase in the biological activity for peptides with this increased hydrophobicity due to 
the incorporation of these new sulfonyl groups. 
 
 
Scheme 2.3: Synthesis of sulfonamide aminoethyl glycine β-turn promoters 
 
Scheme 2.3 shows the synthesis of the sulfonamide aminoethyl glycine β-turn 
promoters.  The different sulfonyl chlorides were incorporated into step 3 of the turn 
promoter synthesis.  Selective mono-alkylation of excess ethylene diamine a with tert-
                                                 
†
 All turn promoters synthesized and characterized by Dr. Priyesh Jain 
H2N
NH2
BrCH2CO2tBu, THF
85% H2N
H
N
OtBu
O FmocNOsu, DIEA, DCM
90% FmocHN
H
N
OtBu
O·HCl
a b c
RSO2Cl, DIEA, THF
88% FmocHN
N
OtBu
O
d
O2S
R Dioxane, 4M HCl
quant. FmocHN
N
OH
OO2S
R
e
112 
 
butyl bromoacetate was carried out under dilute conditions to give compound b in 85% 
yield
42
.  Compound b is taken up in the next step without further purification and 
selective Fmoc protection of the primary amine is achieved to give crude fmoc-protected 
aminoethyl glycinate c.  The crude reaction mixture is then washed with dilute 
hydrochloric acid, stored overnight in the deep freezer, resulting in precipitation of pure 
compound c as the hydrochloride salt that can be stored for several months in the 
refrigerator.  Sulfonylation of the secondary amine with the appropriate sulfonyl chloride 
afforded compound d that precipitated from ethyl acetate solution under cold conditions.  
Deprotection of the t-butyl group was achieved by employing 4M HCl in dioxane to give 
the desired compound e in excellent yield. 
 
2.2.3  Design and Synthesis of Cyclic β-sheets† 
 
 Using the N and C terminal truncation studies previously done by Hazlehurst and 
co-workers as a starting point, we know that the sequence MVISW is most likely the core 
region of the linear D-HYD1 peptide that is required for biological activity.  It was then 
found that replacing the Isoleucine with Valine produced a more active D-HYD1 peptide.  
Knowing that cyclization of a linear peptide restricts the number of available low energy 
conformations as well as increasing the affinity of the cyclized peptide for its target and 
stabilizing the bound conformation of the peptide
16
; we chose to develop and synthesize 
cyclized versions of our peptides.  In our cyclized version of D-HYD1, the recognition 
strand contains the more active core sequence (MVVSW) while the non-recognition 
strand contains a repeating pair of residues (KLKLK) to help improve solubility and to be 
                                                 
†
 All work regarding peptide synthesis performed by Dr. Priyesh Jain 
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amphipathic in an extended conformation.  Energy minimization studies then showed that 
these cyclic peptides exhibited β-sheet like conformations (Figure 2.16). 
 
 
 
Figure 2.16: Stereo drawings of cyclic peptides obtained after energy minimization 
procedures.  (a) β-Sheet containing L-Pro-D-Pro and methylsulfonamido aminoethyl 
glycine turn promoters.  (b) β-Sheet containing two methylsulfonamido aminoethyl 
glycine turn promoters 
 
 These energy minimization studies indicated that incorporating the Robinson β-
turn promoter (D-Pro-L-Pro) and our novel methylsulfonamido aminoethyl glycine turn 
a) 
b) 
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promoter would produce a stable β-hairpin with all of the internal H-bonds intact43.  The 
β-sheet peptide sequence was then optimized in a number of ways and Alanine scans 
were utilized to reveal the key residues critical for binding to integrins (previously 
described
43
).  Following the determination of these essential residues responsible for the 
bioactivity, we focused on enhancing the peptide’s bioactivity through other minor 
alterations such as adjusting the peptide’s hydrophobicity.  This was accomplished in one 
of two ways.  The first was to make adjustments to the non-critical residues in the 
recognition strand such as changing a Methionine to a Norleucine.  The second way 
involved the incorporation of the different sulfonyl chlorides into our novel sulfonamide 
aminoethyl glycine β-turn promoter as discussed above. 
Peptides were also designed with a constrained oxygenated turn promoter in an 
effort to further reduce the β-sheet’s degrees of freedom and potentially increase its 
affinity for the target.  Using energy minimization studies to assist in the determination of 
the optimal constrained turn promoter, we chose the D-Proline ether-peptidomimetic 
derivative shown in Figure 2.17.  β-sheets were then synthesized using the D-Proline 
derived ether-peptidomimetic for one of the turns and methylsulfonamido aminoethyl 
glycine for the other turn. 
 
 
Figure 2.17: D-Proline derived ether-peptidomimetic β-turn promoter 
  
O
OHN
Fmoc
O
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The synthesis of the β-sheets was accomplished by first synthesizing them as 
linear peptides and then cyclizing them under dilute conditions.  The linear peptides were 
synthesized with a peptide synthesizer using 2-chlorotrityl chloride resin as a solid 
support.  The peptides were created using the Fmoc solid phase peptide synthesis strategy 
shown in Scheme 2.4.  The linear peptides were then cleaved from the resin and then 
cyclized in solution under dilute conditions.   
 
 
Scheme 2.4: Solid-Phase synthesis of cyclic peptides 
 
2.2.4 Biological Activity Results 
  
All of the peptides our group has made thus far (Figure 2.18) and their respective 
biological activity data for binding to integrins of H929 multiple myeloma tumor cells are 
shown in Table 2.4.  Of the 29 peptides listed, only the following 7 peptides were 
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structurally analyzed by 2D NMR; 2.26, 2.27, 2.30, 2.32, 2.33, 2.36, and 2.43.  Since the 
biological activity for many of these peptides has already been reviewed
43
, discussion 
pertaining to the biological activity results will be primarily centered around the 7 
peptides structurally analyzed by 2D NMR. 
  
 
Figure 2.18.  Generic cyclic HYD1 peptide 
 
Table 2.4.  Structure-Activity relationships of cyclic HYD1 peptide derivatives  
 
Peptide R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 IC50(µM) 
2.26 K L K L K M V V S W T1 T2 15 
2.27 K L K L K M V V S W T1 T1 15 
2.28 K L K L K M V V S A T1 T1 57.1±2.2 
2.29 K L K L K M V V A W T1 T1 4.1±1.9 
2.30 K L K L K M V A S W T1 T1 19±6.9 
2.31 K L K L K M A V S W T1 T1 6.2±2.7 
2.32 K L K L K A V V S W T1 T1 31.1±7.6 
2.33 K L K L K N* V V S W T1 T1 2.6±1.3 
2.34 K L K L K N* V V Y W T1 T1 2.9±1.3 
2.35 K L K L K W V V A W T1 T1 5.9 
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Table 2.4 (cont.).  Structure-Activity relationships of cyclic HYD1 peptide derivatives 
Peptide R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 IC50(µM) 
2.36 K L K L K W S V V M T1 T1 5.9±3.4 
2.37 K L K L K W A V V N* T1 T1 12.3 
2.38 K L K L K W A V V A T1 T1 21.9 
2.39 K L K L K W A V A N* T1 T1 25.9 
2.40 K L K L K W A A V N* T1 T1 41.3 
2.41 K L K L K A A V V N* T1 T1 2.8 
2.42 K L K L K W A V V F T1 T1 9.7 
2.43 K L K L K N* V V A W T3 T1 1 
2.44 K L K L K N* V L A W T3 T1 10 
2.45 K L K L K N* V I A W T3 T1 10 
2.46 K L K L K N* V F A W T3 T1 9 
2.47 Q L K L K N* V V A W T3 T1 38 
2.48 K Q K L K N* V V A W T3 T1 18 
2.49 K L Q L K N* V V A W T3 T1 13 
2.50 K L K Q K N* V V A W T3 T1 25 
2.51 K L K L Q N* V V A W T3 T1 19 
2.52 K L K L K N* A V A W T3 T1 11 
2.53 K L K L K N* V V A W T1 T3 14 
2.54 K L K L K N* V V A W T3 T3 36 
T1= NH2CH2CH2N(SO2Me)CH2COOH; T2= LPro-DPro; T3= N(CH2)3CHCH2OCH2COOH; N*= Nle;  
X=Sarcosine 
 
Methionine, Valine, and Tryptophan at residues 6, 8, and 10 respectively have all 
been shown to be key binding residues
43
.  The difference in binding activities between 
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peptides can be seen in Table 2.4.  When Methionine in peptide 2.27 is replaced by 
Norleucine in 2.33, a dramatic increase in the peptide’s biological activity is observed.  
This serves to reinforce the fact that this is a crucial binding residue. 
The identical IC50 value seen for both 2.26 and 2.27 suggests that the structure of 
the turn at the end of the β-sheet is not critical to its biological activity.  As long as the 
turn is able to induce and/or allow a β-sheet to be formed, the structure of the turn does 
not appear to be important to the β-sheet’s biological activity.  So far, we have observed 
that you can vary the β-turn structure and see basically the same biological activity.  The 
difference in biological activities has more to do with the recognition strand sequence and 
the hydrophobicity of the peptide. 
Given that our results indicated that the β-turn structure doesn’t matter, we 
incorporated our new constrained ring to help reduce the peptide’s degrees of freedom.  
Installing both the D-Proline derived ether-peptidomimetic turn (T3) and our 
methylsulfonamido aminoethyl glycine turn (T1) into peptide 2.43 gave us a β-sheet with 
the best biological activity so far of 1 μM.  Although we may have succeeded in 
decreasing the degrees of freedom using this constrained ring turn, it is most likely not 
the source of the peptide’s improved bioactivity.  The source of this improved bioactivity 
is most likely due to the modification of residue 9 from Serine in 2.33, with two T1 turns, 
to Alanine in 2.43.  Whether this enhancement is due to improved side chain interactions 
with the target or simply due to the increased hydrophobicity of the residue (and the 
peptide) is unknown at the moment. 
Analysis of peptides containing the T3 turn suggests that while the turn’s primary 
structure does not directly interact with the target, its rigidity and placement has a large 
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effect on the peptide’s biological activity.  Both the recognition sequence and non-
recognition sequence are identical in peptides 2.43, 2.53, and 2.54.  In peptide 2.43, the 
T3 turn occupies residue 11 while the T1 turn occupies residue 12.  The turns in peptide 
2.53 are on opposite sides in relationship to 2.43 while peptide 2.54 employs two T3 
turns.  If the turn’s structure does not matter, then peptides 2.43 and 2.53 should have the 
same IC50 values and peptide 2.54 should display the best biological activity of the three.  
Clearly, this is not the case as peptide 2.54’s IC50 is about 2.5 times that of 2.53 and both 
peptides have larger values than 2.43.   
When T3 is put in the same location as the Robinson turn (T2) in peptides 2.53 and 
2.26 respectively, the two peptides display nearly identical activity data despite the fact 
that Norleucine replaced Methionine in residue 6.  If the structure of the turns were 
irrelevant, the activity of 2.53 should be identical to 2.43, which is substantially better 
than 2.26’s activity.  This suggests that the rigidity of the turn plays an important role in 
the peptide’s ability to properly bind to the target.  Specifically, the location of the rigid 
turn is integral to the peptide’s success.  The IC50 data for peptides 2.43 – 2.46 clearly 
demonstrates that as long as the rigid turn is only found in residue 11, the peptide will 
display great biological activity.  This is regardless of the fact that the key Valine residue 
in position 8 has been replaced in three of these peptides.  Therefore, the foundation of 
this enhanced activity data for these peptides must be due to the β-turn in residue 12. 
While the T2 and the T3 turn are both fairly rigid, their primary structures adjacent 
to the recognition domain, residues 6 – 10, are not very similar.  This indicates that the 
rigidity of the turn is responsible for the changes seen in the activity data rather than the 
turn’s primary structure.  Therefore, ensuring that a flexible turn is installed in position 
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12 should produce peptides that display optimal biological activities.  These flexible β-
turns allow nearby residues to move and twist as necessary to best fit the binding target 
which results in improved biological activity data.  However, when rigid turns are used, 
such as T3, the nearby residues cannot move as well which means they cannot adapt the 
best binding conformation and the activity values suffer as a result.   
Taking into account the very similar IC50 values for peptides 2.33 and 2.43, we 
can see that the recognition residues on the right side of the peptide (residues 6 and 7) are 
the only ones that require some flexibility in order to adapt their optimal binding 
conformation.  This implies that the structure and mobility of both residues 6 and 7 are 
critical to the peptide’s biological activity.  Combining this with the improved activity 
data found when Methionine was replaced by Norleucine in residue 6 effectively 
demonstrates that residue 6 is the most essential residue to the peptide’s success.   
Finally, we have synthesized some peptides with the T1 turns that incorporate the 
various sulfonyl chlorides described above.  Some of these peptides have been submitted 
for biological testing.  However, we do not have any SAR data to report at this time.  We 
plan to incorporate the remaining sulfonyl derivatized T1 turns in the future. 
 
2.3 β-Sheet Structural Analysis 
2.3.1  Circular Dichroism Studies 
 
Circular dichroism (CD) is a sensitive measure of the secondary structure of 
peptides and proteins
44
.  Peptides with a β-sheet structure usually exhibit an absorption 
minimum around 210 nm and a relatively strong absorption maximum around 190 nm.  
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As seen in Figure 2.19, the CD spectra of peptide 2.26 shows an absorption minima 
around 215 nm, which suggests a more stable β-sheet conformation for this peptide 
whereas peptide 2.27 displays a negative band around 202-204 nm, which suggests that 
this peptide deviates from a stable β-sheet conformation and moves towards a more 
random structure.  This can be attributed to the D-Pro-L-Pro turn in peptide 2.26 which is 
very structurally rigid thus forcing the peptide into a β-hairpin conformation.  The 
methylsulfonamido linker in peptide 2.27 is more flexible, allowing the residues to be 
less structurally rigid and thereby deviates from an ideal β-hairpin conformation.  All 
cyclic HYD1 peptides display similar CD bands: negative absorption minima around 202 
nm and strong positive absorption maxima around 190 nm.  Therefore, we can conclude 
that all of our cyclic peptides have adopted a semi β-sheet structure. 
 
Figure 2.19: Circular dichroism studies for cyclic HYD1 peptides 2.26, 2.27, 2.30, 2.32, 
2.33 in 7 mM sodium acetate buffer at a concentration of 200 µM at pH 7 
 
 
Peptide 2.26 
Peptide 2.27 
Peptide 2.30 
Peptide 2.32 
Peptide 2.33 
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2.3.2  NMR Studies for Structural Determination of Cyclic Peptides in Solution 
 
Complete peak assignments were only done for cyclic peptides 2.26, 2.30, and 
2.43.  Assignments for both the recognition sequence and the non-recognition sequence, 
omitting the turns, were done for the remainder of the peptides.  In an effort to reduce 
spectral overlap of the 2D spectra sets, the NMR experiments were run in 100% D2O to 
remove the exchangeable amide and Lys ε-NH protons from the spectrum.  Even without 
information from the amide and Lys ε-NH protons, the results from our NMR 
experiments clearly show that the peptides have all adopted a β-hairpin structure. 
Supporting our CD results, the chemical shifts of the amino acid α-hydrogen 
protons (Hα) and the NOE data indicate that the peptides are in a β-hairpin conformation.  
Our NMR results agree with previous empirical analysis which has shown that when β-
sheets are formed, there is a downfield shift in the Hα resonances
45
.  The majority of the 
amino acid Hα’s in our peptides are shifted significantly downfield such that their values 
indicate a β-hairpin conformation (Table 2.5).   
Hα and NOE NMR analysis of peptide 2.26, which contains both the Robinson β-
hairpin turn promoter template (D-Pro-L-Pro)
46
 and the methylsulfonamido aminoethyl 
glycine turn, confirms the structure of this peptide as a β-sheet.  This peptide was 
cyclized using a methylsulfonamido aminoethyl glycine in place of the D-Pro-L-Pro as 
the β-hairpin turn promoter to give peptide 2.27.  A comparison between the Hα shifts of 
these two peptides reveals many similarities.  Most of the Hα’s on the non-recognition 
side of peptide 2.27 have shifted upfield relative to 2.26, suggesting that the structure is 
less like a β-sheet.  While three of these residues have only shifted about 0.2 ppm or less 
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upfield, Leu4’s shift of about 0.7 ppm suggests a fair amount of structural change.  
Interestingly, the only Hα on the non-recognition strand that has a downfield shift is Lys5.  
More importantly however, all but one of the Hα’s on the recognition side of the peptide 
have shifted downfield indicating a β-sheet conformation.  The Hα of Ser9 is the only one 
that has shifted upfield.  Looking at the fact that the Hα’s on residues Met6 and Lys5 have 
shifted downfield after the β-hairpin turn promoter was changed from the D-Pro-L-Pro to 
our methylsulfonamido aminoethyl glycine turn, it suggests that our turn promoter allows 
for more β-hairpin-like character at this end of the peptide.  Thus, our turn may be a 
better β-hairpin promoter for certain peptide sequences. 
 
Table 2.5: α-Proton Chemical Shifts (ppm) of selective cyclic peptide analogs 
     Position   
 R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 
2.26 4.38 4.54 4.29 4.99 4.54 4.48 4.13 4.27 4.60 4.69 
3.56
S
 
3.86
R
 
L-Pro  4.53 
D-Pro 4.74 
2.27 4.26 4.35 4.08 4.28 4.57 4.64 4.66 4.32 4.46 4.70 ---- ---- 
2.30 4.31 4.16 4.07 4.04 4.42 4.60 4.58 4.53 4.60 4.61 
3.89
S
 
4.06
R
 
3.47
S 
4.05
R
 
2.32 4.44 4.31 4.08 4.28 4.52 4.42 4.63 4.18 4.70 4.67 ---- ---- 
2.33 4.29 4.29 4.09 4.38 4.59 4.45 4.67 4.64 4.45 4.60 ---- ---- 
2.36 4.17 4.53 4.05 4.37 4.35 4.83 4.51 4.52 4.10 4.45 ---- ---- 
2.43 4.55 4.78 4.32 4.63 4.17 4.34 4.44 4.55 4.70 5.05 4.232 
3.94
S 
4.08
R
 
R = Pro-R, S = Pro-S 
 
Although most of the Hα shifts were small, about 0.2 ppm or less, there was a 
large shift in two of the Hα’s which appears to be highly structurally significant.  While 
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the Leu4’s Hα shifted upfield 0.704 ppm, Val7’s Hα shifted downfield 0.532 ppm.  This 
suggests that the Leu4 is not adopting a predominantly β-sheet conformation.  This is 
most likely due to steric interactions from the γ-protons of Val7 which is directly across 
from Leu4.  Presumably as a direct result of Leu4’s structural conformational change, 
Lys3’s Hα is shifted 0.215 ppm (the second largest shift) upfield which removes a small 
amount of its β-sheet character and thus is further evidence supporting this interpretation.   
An examination of the other peptides reveals a similar phenomenon.  The Leu4 
Hα is shifted upfield and the residue in position 7 is always shifted downfield, with the 
exception of peptide 2.36, in comparison with peptide 2.26.  This can be explained by the 
fact that the D-Pro-L-Pro turn in the Robinson template is very structurally rigid, forcing 
those residues proximate it into a β-hairpin conformation.  However, our 
methylsulfonamido aminoethyl glycine turn is much more flexible, thus allowing the 
residues close to the turn to be less rigid in their orientations.  It is probably this 
flexibility that allows the Leu4 Hα to deviate from the β-sheet configuration.  NOE 
analysis supports this view.  In peptide 2.26, strong NOEs were observed between the 
Hα’s of Leu4 and Val7.  However, in peptide 2.27 the NOE between the Hα’s of Leu4 and 
Val7 was only of low intensity.  In its place, there was a semi-strong NOE between the 
Hα of Leu4 and only one γ-CH3 group of Val7.  This significant reduction in the NOE 
cross-peak intensity between the Leu and Val Hα’s combined with the appearance of a 
new strong cross-peak between the Leu Hα’s is strong evidence in support of the 
flexibility of our turn relative to the D-Pro-L-Pro turn. 
We also investigated the use of our ether peptidomimetic amino acid linker (T3) 
as a β-turn promoter.  This promoter is similar to the D-Pro-L-Pro turn in that they both 
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contain pyrrolidine rings however; T3 has a higher degree of flexibility than the D-Pro-L-
Pro turn due to the fact that T3 contains only one ring and lacks the additional carbonyl 
group.  An empirical analysis of the Hα’s in peptide 2.43 shows more resonances 
adopting a β-sheet conformation than any other peptide.  This suggests that the rigid T3 
linker is capable of promoting a β-turn while retaining sufficient flexibility to allow all of 
the other residues to adopt a β-sheet.  
Comparing the Hα’s of peptides 2.26 and 2.43 reveals a number of striking 
similarities and further demonstrates linker T3’s ability to induce a β-turn.  Focusing on 
the non-recognition strands, a comparison of the Hα of the Lys residues closest to their 
respective turns (2.26 Lys5 vs. 2.43 Lys1) reveals almost no chemical shift difference; 
2.43 Lys1 is shifted downfield by only 0.009 ppm.  Moving further away from the 
respective turns, the chemical shift difference between the two Lys3 Hα’s increases 
slightly to 0.029 ppm implying 2.43 has slightly more β-sheet character at this residue.  
Generally, as is the case for 2.26, the Hα of the Lys furthest from the turn is slightly 
downfield of Lys3’s Hα.  In peptide 2.43, however, Lys5’s Hα is considerably upfield of 
Lys3. Additionally the Hα’s of both Lys5 and Nle6 in 2.43 are significantly upfield of the 
same protons in peptide 2.33.  Combined, these facts show that this end of the turn, from 
Lys5 through the turn to Nle6, adopts slightly less of a β-sheet conformation in 2.43.  
This is most likely caused relieving a conformational strain generated by either the 
methylsulfonamido aminoethyl glycine turn or by Lys side chain interactions with the 
other residues.  It should be noted however that all of the protons in the T1 linker of 2.43 
have been significantly shifted downfield of those in the T1 linker of 2.26, further 
confirming the superiority of the T3 linker over the Robinson template. 
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The Leu residues in the non-recognition strand are in striking contrast the Lys 
residues.  In 2.43 the Hα of Leu2, the one closest to the constrained ring turn, is upfield 
(by about 0.205 ppm) from the corresponding Hα of Leu4 in 2.26.  However, given the 
fact that the chemical shifts of the Lys Hα’s right next to the rigid turns in each peptide 
are almost exactly identical, it is expected that the Leu Hα’s should not be all that 
different.  This is most likely due to the difference in rigidity between the two linkers as 
discussed above. 
Moving on to the recognition strand, as is expected, there is a downfield shift of 
Trp’s Hα in 2.43 vs. 2.26 which is probably due to its proximity to the rigid β-turn.  With 
regards to the Val residues, we would expect them to follow a similar trend.  Taking into 
consideration the fact that in peptide 2.26, the Val at residue 7 is very close (two residues 
away) to the D-Pro-L-Pro turn, it stands to reason that it’s Hα should be much more 
downfield than the same residue on peptide 2.43 which is much further away (four 
residues away, twice as far) from its constrained ring turn.  However, the Hα’s for both 
Val7 and Val8 in 2.43 are shifted significantly downfield (0.28 and 0.31 ppm 
respectively) from those in peptide 2.26.  In a comparison of the Hα’s of the Val8 
residues between the two peptides, we would expect their Hα chemical shifts to be fairly 
similar given their central location on the recognition strand of the peptide.  This however 
is clearly not the case, which indicates that 2.43’s recognition strand contains more β-
sheet character at this residue than in peptide 2.26.  Therefore, extrapolation of these 
findings indicates that the entire recognition strand in peptide 2.43 has adopted a β-sheet 
conformation.   
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The replacement of the Robinson template by our turn T1 slightly increases the 
distance between the two sides of the β-sheet.  This is due to the fact that this turn isn’t 
rigidly fixed into a certain conformation thereby allowing the chain to expand and 
contract, somewhat like an accordion.  It is this accordion-like action that allows the 
distance between the two sides of the β-sheet to change.  This change in distance can be 
seen by the decrease in NOE intensity between the Leu and Val residues mentioned 
previously.  NOEs also show the disappearance of the following; a strong NOE between 
the ε protons of Met6 and the Hα of Lys5, a strong NOE between the γ1 protons of Val8 
and the β and β′ protons of Lys3.  Also, the intensity of the NOE interaction between the 
γ2 protons of Val8 and the β proton of Lys3 dropped from being semi-strong to being 
very weak upon replacement of the Robinson turn. 
The methylsulfonamido aminoethyl glycine turn itself can be broken down into 
two parts for discussions sake.  The first part is the CH2 side between the carbonyl and 
the N-Mesyl group, which we will refer to as the α-protons.  The second part is the CH2-
CH2 side between the N-Mesyl group and the amide NH, which will be referred to as the 
γ and δ-protons as shown in Figure 2.20a.  The flexibility of the turn is not just limited to 
adjusting the distance between the two sides.  Rather, NOE analysis shows the existence 
of 2 distinct conformations.  Newman projections of the two different conformations 
viewed down the δ-γ bond showing specific steric interactions can be seen in Figure 2.20.  
The first conformation (2.20b) exists as an eclipsed conformer which puts it in the higher 
energy state of the two. 
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Figure 2.20: (a) Labeled positions on the methylsulfonamido aminoethyl glycine turn.  
Newman projection of the β-turn viewed down the δ-γ bond:  (b) N-Ms pointing down 
and away from the β-sheet; (c) N-Ms pointing into the center of the β-sheet 
 
However, the bulky N-Ms group points down and away from the β-sheet, 
eliminating all steric interactions and placing it in the lowest energy state.  The second 
conformation (2.20c) exists as the staggered conformer, thus being the lower energy of 
the two.  This time however, the bulky N-Ms group points directly into the center of the 
β-sheet causing large amounts of steric interactions with the sheet’s backbone forcing the 
N-Ms group into a very high energy state.  Therefore, it can be assumed that the bulky N-
Ms group drives the turn’s preference for the (2.20b) conformation, picking the lower 
total energy conformer with the least amount of steric interactions. 
Interestingly, conformer (2.20b) may also be slightly favored because the Pro-R 
γ-proton (labeled as H′) is eclipsed with the amide NH and the Pro-R δ-proton is eclipsed 
with the nitrogen from the N-Ms group.  The proton attached to the amide NH is pointed 
out away from the backbone of the peptide while the lone pair on this nitrogen is pointed 
upwards towards the inside of the β-sheet.  Additionally, the lone pair on the nitrogen 
from the N-Ms group points out towards the middle of the two δ-protons.  There is the 
potential for a favorable attractive interaction between the lone pairs on these nitrogens 
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and their respective eclipsed protons
47
.  This would forgive some of the strain caused 
from being in the eclipsed conformation further reducing the total energy of the (2.20b) 
conformation making it the more favorable one. 
Indeed, this favorable attractive interaction is supported by the chemical shifts of 
the respective protons.  In peptide 2.30 for both turns, the Pro-R γ-protons are shifted 
downfield relative to the Pro-S γ-protons meaning a decrease in shielding as is expected 
with the interaction of the lone pair of electrons on the amide nitrogen. 
 For all but one of the peptides, the turn’s geminal γ-protons are non-identical 
giving rise to a Pro-R proton and a Pro-S proton.  Peptide 2.26 is the only one where 
these protons are identical.  This is most likely caused by the Robinson turn locking the 
methylsulfonamido aminoethyl glycine turn into a more rigid conformation.  
Observations that support this analysis can be seen by the significant (0.08 ppm and 
greater) upfield shift of both the γ and δ resonances in 2.26 vs. those in 2.30.  The α 
protons of peptide 2.26 also experience large (0.18 ppm and greater) upfield shift in 
comparison to those in peptide 2.30, with the exception of the Pro-S α proton in residue 
12 of peptide 2.30.  Thus, this side of the peptide looks less like a β-sheet when the 
Robinson turn is used to induce the β-hairpin.   
Because only one peak is seen for the γ-protons in peptide 2.26’s turn, they must 
exist in somewhat similar environments and the turn’s conformation must be different 
enough from the two mentioned above.  Supported by NOEs, Figure 2.21 is a Newman 
projection viewed down the δ-γ bond of the T1 linker and shows what this altered 
conformation might look like.  
 
130 
 
 
Figure 2.21: Newman Projection of the structurally locked β-turn viewed down the δ-γ 
bond 
 
The final turn promoter, T3, contains characteristics of both turns T1 and T2.  In 
T3, the CH2 α to the carbonyl (herein referred to as α′) has a Pro-R and Pro-S proton 
much like the α-position in the T1 linker.  However, the chemical shifts of these two 
protons are opposite of those in any of the T1 linkers such that in T3, the Pro-S proton is 
the more downfield one rather than being the more upfield one.  As shown in Figure 2.22, 
this has to do with the two lone pairs on the ether oxygen which are pointing away from 
the center of the β-sheet and encompass the Pro-S proton causing its chemical shift to 
move downfield.  Additionally, the difference here in chemical shifts between the Pro-R 
and Pro-S protons is only 0.044 ppm while the differences between the T1 α protons are 
between 0.13 and 0.58 ppm.  Therefore, this means that the Pro-R and Pro-S protons are 
in fairly similar chemical environments.  This is clearly the case as the Newman 
projection shows because one of the lone pairs on the oxygen is also close to the Pro-R 
proton which would also account for the significant downfield shift of this proton as well. 
 
H
N H
H
NHH
MeO2S
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Figure 2.22: Newman Projection of the T3 β-turn viewed down the O- α′ bond.  The Pro-
R α′ proton is labeled as H′ 
 
2.3.3 Peptide Structural Characterization via NOE   
 
In conjunction with the chemical shifts of the α-protons, the NOE data was used 
to help determine the 3D structure of peptides.  Analysis of peptide 2.30 was used as a 
general model for all the peptides.  Cross-strand analysis reveals many NOEs between the 
Trp10 and Lys1 residues, specifically between Trp4H-LysεH, Trp5H-LysβH, Trp5H-
LysεH, Trp6H-LysγH and TrpβH-LysεH to name a few.  These suggest that the 
Tryptophan ring sits between the two strands at an angle with the indole ring facing the 
rest of the peptide.  Additionally, peptide 2.27 also shows a NOE between TrpβH-LysβH, 
evidence that the ring spends part of its time in an alternate position between the two 
strands.            
Chemical shift analysis supports these two Trp positions, showing that the 
Tryptophan ring occupies one of the two positions depending on the adjacent residues.  
With the exception of the Hα’s, all of the protons in Lys1 are downfield of their 
respective ones in either Lys3 or Lys5 even though Lys1 is cross-strand from Trp10 
H H

CO
CH2
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which would suggest an upfield shift due to an interaction with the face of the aromatic 
rings
48
.  The first, and main, position Trp occupies is one that deals with those peptides 
that contain a Valine at residue 8.  Here, the aromatic ring of Trp10 and the hydrophobic 
γ-methyl groups of Val8 are oriented with each other such that one face of the 
Tryptophan ring is interacting with the Valine via intra-pair Van der Waal’s contacts 
while the other face is interacting slightly with the Lys1 protons via cation-π interaction 
causing the γ-methyl’s to slightly shift upfield49.  This is confirmed by the chemical shifts 
of the Valine in position 8 because the protons interacting with the Tryptophan ring shift 
a certain amount upfield relative to their proximity to the Tryptophan ring as is expected 
due to the increased shielding from the ring.  However, peptide 2.32 does not follow this 
model.  While the Val8 Hα does shift upfield, the β and γ-protons shift downfield which 
means the face of the Tryptophan ring is not interacting with that Valine to the same 
extent as the other peptides.  This downfield shift is also seen in peptide 2.43.  In peptide 
2.32, all of Lys3’s protons shift upfield with the exception of the Hα and new prominent 
NOEs can be seen between Lys3 and Trp10.  This combined with the fact that there was 
very little shift, up or downfield, of Lys1’s protons means the faces of the Tryptophan 
ring are now interacting with Lys 1 and Lys3 rather than with Lys1 and Val8.  This is 
probably due to the replacement of the Methionine with an Alanine at position 6 thus 
reducing the Van der Waal’s interactions and eliminating the hydrogen bonding between 
positions 3 and 6. 
 The second position Trp occupies is found in peptide 2.30, which lacks a Valine 
at residue 8.  Here, the Tryptophan ring sits between the two strands partially over the 
turn and is at an angle with the indole ring facing the rest of the peptide.  In this 
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orientation, there is less interaction between the face of the Tryptophan ring and the 
protons of Lys1.  Therefore, the Lys1 resonances are shifted slightly downfield.  
Regardless of the presence or absence of a Valine at residue 8, the Lys5 and Lys3 
resonances are more upfield due to interactions with each other and the Methionine. 
 Interestingly, peptide 2.30 shows only a small NOE between the Hα’s of Leu2 and 
Ser9, much like the Leu4-Val7 interaction mentioned above.  There are however a few 
notable NOEs between Leu2 and Ser9 which include SerβH-LeuδH, SerβH-LeuβH and 
SerβH-Leuβ′H.  These imply that the Leucine is oriented such that the β-protons point 
into the β-sheet while the δ-methyl’s are pointing down and away from the β-sheet.  It is 
also important to note the chemical shift of the Serine Hα.  There is no difference in the 
Serine Hα chemical shift between peptides 2.26 and 2.30.  This is due to the fact that in 
2.26, the Robinson turn helps to keep everything in a tight β-sheet and so the Serine Hα is 
most likely artificially changed due to the Tryptophan ring current effects while in 2.30, 
the Tryptophan ring is over the turn.  However, in peptides 2.27 and 2.33, the Tryptophan 
ring is above the Serine Hα shielding it and causing an upfield shift.  In peptide 2.32, the 
Serine Hα is significantly downfield suggesting that the Tryptophan ring isn’t sitting 
above it; this is supported by the NOE data.  NOE data for peptide 2.43 suggests that 
while the Tryptophan ring is over the β-sheet, it may be in a more vertical position over 
Leu2 and Ala9 interacting with the Lys1 and Lys3 side chains.  This possible ring 
orientation is supported by the downfield shift of Alanine’s Hα. 
In peptide 2.30, the NOEs between the Ala8 and Lys3 residues are of significant 
intensity.  The Alanine β-proton shows an NOE with the β, β′, γ and δ-protons of Lys3.  
Although the other peptides possess a Valine at position 8, they show the same NOEs 
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with Lys3 and some even show NOEs to Lys1 and Lys5.  These cross-strand and 
diagonal cross-strand NOEs imply that all of the Lysine’s are oriented over the β-sheet 
itself and that when there is a Valine in position 8, it’s γ-methyl groups are aligned with 
the β-sheet and point in opposite directions. 
 The Valine in position 7 has several cross-strand NOEs, while most are with Leu4 
there is one with Leu2 which is quite intense.  A few of those with Leu4 include Valγ2H-
LeuγH, Valγ2H-LeuδH, Valγ2H-LeuβH, ValβH-LeuαH and ValαH-LeuδH.  The NOE 
with Leu2 is between Valγ1H and LeuδH.  Although the intensity of the NOE between 
the Hα’s of Val7 and Leu4 is quite low, the strengths of the NOEs just mentioned provide 
compelling evidence that the structure of this part of the peptide is indeed a β-sheet. 
 NOEs from peptide 2.30’s Met6 describe an interesting side-chain conformation 
and a particular orientation with Lys5.  Some of these include MetεH-LysαH, Metβ′H-
Lysβ′H, Metβ′H-LysεH and MetαH-LysεH.  Since these residues are attached to either 
side of the turn, their cross-strand NOEs are proof that the turn does in fact make a β-
sheet rather than a random coil.  Additionally, NOEs are also observed between Met6 and 
Lys3.  Some of the most significant ones are MetεH-LysεH, MetγH-LysεH and MetβH-
LysεH.  These diagonal cross-strand NOEs help to reinforce the fact that these peptides 
exist as β-sheets despite the lack of a strong NOE between the Hα’s of Leu4 and Val7.  
These NOEs suggest that the Methionine side chain is specifically interacting with these 
two Lysine side chains.  In addition to the standard Van der Waals interactions, weak 
hydrogen bonding may exist between the Methionine sulfur and the Lysine ε-NH protons 
holding the chains closer in space thus giving rise to more and stronger NOEs between 
the chains
50
.  This idea is supported by the fact that when Methionine is replaced by 
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Norleucine in 2.33, both the amount and the intensity of the cross-strand NOEs decrease 
significantly.  Furthermore, both the ε and γ-methylenes of Lys5 experience a significant 
downfield shift upon the replacement with Norleucine.  Replacing the Methionine residue 
with a more hydrophobic one removes the hydrogen bonding and causes a change in the 
side chain conformation, which is evident in peptide 2.33.  
  
2.3.4 Constrained Conformation Search with MacroModel
† 
 
Structures of peptides 2.26 and 2.30 were built with Maestro
51
.  NOE-derived 
distance constraints were applied to optimize the peptide structures with MacroModel
52
 
to produce 891 and 920 structures within a 100 kJ/mol range for peptides 2.26 and 2.30, 
respectively.  The conformations were reduced in number based on RMSD to 61 and 87 
structures of which the 20 lowest energy representative structures shown in Figure 2.23 
were analyzed.  Both sets of calculated structures reveal a twisting of the β-hairpin 
structure.  Further, peptide 2.26 has a more subtle twist close to its rigid D-Pro-L-Pro 
linker while the β-hairpin is more contorted near linker T1.  The Ramachandran plot 
places all phi/psi angles of peptide 2.30 in the β-sheet region while 2 amino acids, L-Pro 
and Val 7, of peptide 2.26 are in the disallowed region (Figure 2.24).  The averaged 
energies offer explanation to these structural differences: solvation and electrostatics 
contribute 80% of the difference in the average energies of the calculated structures 
(Table 2.6).  The flexibility of the  linker T1 in comparison to the rigid D-Pro-L-Pro 
linker allow for a more solvated conformation when in solution, an entropic gain (from 
less ordered waters) that translates into lower electrostatic and solvation energies.  
                                                 
†
 Molecular modeling work performed by Daniel Santiago 
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Further, peptide 2.30 has lower stretch, bend, and torsion energies than peptide 2.26 
accounting for less than 20% of the average energy difference (Table 2.6).  Overall, the 
average energies from the calculated structures indicate more conformational flexibility 
of peptide 2.30 over peptide 2.26. 
 
 
Figure 2.23: Stereoviews of the 20 lowest energy structures for NOE-constrained 
calculated structure of peptides 2.26 (green carbon atoms) and 2.30 (gold carbon atoms).  
N = blue, O = red, S = yellow; hydrogens omitted for clarity.  Thin wire representations 
prepared with Maestro 
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Figure 2.24: Ramachandran plot of peptides 2.26 and 2.30.  All of  the peptide 2.30 
amino acids are in the Beta-sheet region while two amino acids (Val7, L-Pro) of peptide 
2.26 are in the “disallowed regions”53.  The L-Pro phi/psi angles are consistent with the 
L-Pro phi-psi angles of the cyclic peptide structure published by Fasan et al (PDB 
2AXI)
54 
 
 
 
 
Peptide 2.26       Peptide 2.30 
Peptides 2.26 & 2.30 
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Table 2.6: Average difference in Cα atom distances between the 20 lowest energy 
structures of peptides 2.26 and 2.30  
 
  
Residue Number 
Recognition Strand 
  10 9 8 7 6 
R
es
id
u
e 
N
u
m
b
er
 
N
o
n
-r
ec
o
g
n
it
io
n
 S
tr
an
d
 
1 -0.66±0.03 -0.33±0.01 -2.46±0.15 -0.9±0.04 -2.78±0.14 
2 0.3±0.02 -0.26±0.01 -0.57±0.02 0.91±0.01 -0.31±0.01 
3 3.53±0.12 0.41±0.01 -0.53±0.01 -0.68±0.02 -2±0.08 
4 2.85±0.05 -0.32±0.00 0.31±0.01 0.04±0.00 0.01±0.00 
5 4.56±0.11 1.71±0.04 2.32±0.09 0.75±0.03 0.19±0.01 
 
2.4 Conclusion 
 
 The novel sulfonamido aminoethyl glycine β-turn promoters described in this 
chapter provide a new way to induce β-sheets while allowing for the manipulation of the 
peptide’s hydrophobicity.  In the case of our cyclic HYD1 peptides, alteration of the 
primary sequence does not affect the peptide’s propensity to adopt a β-sheet 
conformation.  The cyclic HYD1 peptides displayed optimal biological activity results 
when using a flexible turn promoter in residue 12.  These results do not stem from the 
turn promoter’s primary structure but rather are directly related to the side chain and 
flexibility of the amino acid in residue 6.  Modification of this residue from Methionine 
to Norleucine produced a peptide that is 5.8 times more biologically active.  The NOE 
data shows that Methionine interacts with the non-recognition strand Lysine’s through 
both hydrogen bonding and Van der Waal’s interactions.  However, Norleucine cannot 
hydrogen bond with the non-recognition strand Lysine’s which means these two residue 
side chains are less attracted to one another thus allowing Norleucine to be more flexible.  
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This shows that Norleucine, residue 6, needs to be flexible so that it can adopt the optimal 
binding orientation.  The combination of these results clearly demonstrates that residue 6 
is the most important residue in the peptide with respect to biological activity. 
 
2.5 Experimental Procedures 
2.5.1 Materials and Methods 
 
All starting materials, organic and inorganic reagents (ACS grade), and solvents 
were obtained from commercial sources and used as received unless otherwise noted.  All 
deuterated solvents were purchased from Cambridge Isotopes.  Moisture- and air-
sensitive reactions were carried out in oven dried glassware and under an atmosphere of 
argon.  Thin layer chromatography (TLC) was performed on glass plates (EMD or 
Whatman) precoated with 0.25 mm thickness of silica gel (60Å F-254) and visualized 
with ultraviolet light (254 nm).  Column chromatographic purifications were performed 
using silica gel 60Å, 63-200 μm mesh (Dynamic Adsorbents).  Organic and specified 
aqueous solutions were concentrated under reduced pressure on a Büchi rotary 
evaporator.  
1
H NMR and 
13
C NMR spectra were obtained using either a 400 MHz 
Varian INOVA equipped with a 5-mm B.B. RT probe with Z-axis PFGs, a 500 MHz 
Varian INOVA equipped with a 3-mm B.B. RT probe with Z-axis PFGs or a 600 MHz 
Varian INOVA instrument equipped with a 5-mm I.D. RT probe with Z-axis PFGs 
running VnmrJ 2.2D software at 25 °C in CDCl3 unless otherwise specified.  Spectra 
were then analyzed using ACD labs NMR Manager version 11.0.  Chemical shifts (δ) are 
reported in parts per million ppm (ppm) relative to residual solvent signal; either 
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chloroform (δ 7.24) or DMSO (δ 2.50) for 1H NMR and either chloroform (δ 77.16) or 
DMSO (δ 39.52) for 13C NMR.  Multiplicity is expressed as (s = singlet, br s = broad 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, spt = septet, or m = multiplet) and 
the values of the coupling constants (J) are given in Hertz (Hz) followed by the 
integration.  Mass Spectrometry (MS) spectra were carried out on an Agilent LC/MSD 
VL single quadrupole system.   
 
2.5.2 Sulfonyl Chloride Synthesis 
 
Sodium Chloromethanesufonate (2.1):  In a 420 mL round bottom glass pressure vessel 
equipped with a 2 cm long football shaped stir bar, anhydrous sodium sulfite (94.5 g, 
0.75 mol, 1 eq.) is added to 275 mL DI water.  After the sodium sulfite dissolves, 
TBAHS (3.82 g, 11.25 mmol, 0.015 eq.) is added followed by dichloromethane (96.5 
mL, 1.5 mol, 2 eq.).  The flask is then heated to 110°C for 24hrs.  Afterwards, the flask is 
allowed to cool to RT and the solvent is evaporated on a rotary evaporator at 60-80°C.  
The residue is then put under high vacuum for 24 hrs. to yield snow-white clumps of 
crude sodium chloromethanesulfonate salt that was used directly in the next step. 
 
 
Chloromethanesulfonyl Chloride (2.2):  The crude sodium chloromethanesulfonate salt 
2.1 is ground to a fine powder with a mortar and pestle and then dried under high vacuum 
for an additional 12-24 hrs. as needed to remove any residual water.  The crude sodium 
Cl SO3 Na
Cl S
Cl
O O
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salt is then split into two 80 g portions.  A single portion is added to a flame dried 500 
mL 3-neck round bottom flask equipped with a 4 cm long football shaped stir bar and a 
reflux condenser which is capped with a calcium chloride drying tube that is connected to 
a 10 M NaOH bath.  One of the outer two necks of the flask is equipped with a gas inlet 
adapter attached to an argon source and the other with a rubber septa.  The flask was 
chilled to 0°C in an ice-salt bath and then 1.25 eq. phosphorus pentachloride was added 
quickly (Adequate stirring is necessary to ensure a thorough mixing of the two solids.  It 
may be necessary to mix the two powders at first with a spatula by hand for a brief 
amount of time).  About 3-4 minutes after the addition of PCl5, there is a vigorous 
exothermic reaction which liquefies the two powders.  Occasionally the two solids will 
not liquefy at 0°C but will instead begin to liquefy once the reaction has reached room 
temperature (This is generally seen for smaller scale reactions).  The reaction is stirred at 
0°C for 30 minutes and heated in an oil bath at 140°C for 45 minutes followed by 70°C 
for 30 minutes.  The reaction is then cooled in an ice bath and quenched slowly with 
cracked ice (Cracked ice should be added piecewise and very slowly at first as an 
extremely vigorous exothermic reaction occurs).  When the hydrolysis is complete and 
the reaction has been warmed to RT, the reaction is extracted with two 500-mL portions 
of dichloromethane.  The first portion is then washed with 400 mL of distilled water and 
the two organic layers are combined.  The majority of the solvent is then evaporated on a 
rotary evaporator (For optimum yields, the water bath temperature should not exceed 
40°C with a vacuum pressure not exceeding 450 mm).  The residue is transferred to a 200 
mL flask and the product distilled.  Chloromethanesulfonyl chloride is collected as a 
colorless, lachrymatory liquid with a considerably strong odor (85-93 g, 76-83% based on 
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sodium sulfite).  b.p. 80-81°C (25 mm.).  
1
H NMR (400MHz, CDCl3): δ ppm 5.00 (s, 
2H).  
13
C NMR (100MHz, CDCl3) δ ppm 65.75.  
 
 
Sodium Bromomethanesufonate (2.3):  This product was synthesized in the same manner 
as product 2.1 using dibromomethane (104.72 mL, 1.5 mol, 2 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Bromomethanesulfonyl Chloride (2.4):  This product was synthesized in the same 
manner as product 2.2.  Bromomethanesulfonyl chloride was collected as a colorless, 
lachrymatory liquid with a considerably strong odor (110-120 g, 76-83% based on 
sodium sulfite).  b.p. 80-81°C (25 mm.).   
1
H NMR (400 MHz, CDCl3) δ ppm 4.94 (s, 2 
H).  
13
C NMR (100 MHz, DMSO-d6) δ ppm 43.31. 
 
 
Sodium Methane-d3-sulfonate (2.5):  This product was synthesized in the same manner as 
product 2.1 using iodomethane-d3 (9.33 mL, 0.15 mol, 1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Br SO3 Na
Br S
Cl
O O
SO3 NaD3C
D3C SO2Cl
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Methane-d3-sulfonyl Chloride
55
 (2.6):  The dried and powdered sulfonate 2.5 was added 
to a flame dried 250 mL 3-neck round bottom flask equipped with a 4 cm long football 
shaped stir bar and a reflux condenser which was capped with a calcium chloride drying 
tube that was connected to a 10 M NaOH bath.  One of the outer two necks of the flask 
was equipped with a gas inlet adapter attached to an argon source and the other with a 
rubber septa.  The flask was chilled to 0°C in an ice-salt bath and then PCl5 (40.6 g, 0.195 
mol, 1.3 eq.) was added quickly. (Adequate stirring is necessary to ensure a thorough 
mixing of the two solids.  It may be necessary to mix the two powders at first with a 
spatula by hand for a brief amount of time).  The two solids were then heated and 
liquefied into a purple goo around 60°C.  The reaction was heated further to 90°C for 1.5 
hrs.  The reaction was then cooled in an ice bath and quenched slowly with cracked ice 
(Cracked ice should be added piecewise and very slowly at first as an extremely vigorous 
exothermic reaction occurs).  When the hydrolysis is complete and the reaction has been 
warmed to RT, the reaction was extracted with two 250-mL portions of diethyl ether.  
The combined organic layers were then washed 3x with a 20% NaHSO3 (aq) solution.  
These water layers were then combined and extracted once with diethyl ether.  All ether 
layers were then combined and dried over anhydrous MgSO4, filtered and then the 
majority of the solvent was evaporated on a rotary evaporator (For optimum yields, the 
water bath temperature should not exceed 38°C with a vacuum pressure not exceeding 
300 mm).  The residue was transferred to a 100 mL flask and the product distilled.  
Methane-d3-sulfonyl chloride was collected as a yellow tinted lachrymatory oil (4.3 g, 
24% based on sodium sulfite).  b.p. 42°C (5-6 mm.).  
13
C NMR (100 MHz, CDCl3) δ 
ppm 51.81 (spt, J=21.91 Hz).  
2
H NMR (61 MHz, CDCl3) δ ppm 3.60 (s, 3 D). 
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Sodium Propane-2-sufonate (2.7):  This product was synthesized in the same manner as 
product 2.1 using 2-bromopropane (51.64 mL, 0.55 mol, 1.1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Propane-2-sulfonyl Chloride (2.8):  This product was synthesized in the same manner as 
product 2.2.  Following the addition of PCl5, the reaction was heated to 75 °C for 4 hrs. 
and then worked up as for product 2.2.  Propane-2-sulfonyl chloride was collected as a 
colorless semi-viscous lachrymatory oil (14.4 g, 19% based on sodium sulfite).  b.p. 53°C 
(5 mm.).  
1
H NMR (400 MHz, CDCl3) δ ppm 3.73 (spt, J=6.64 Hz, 1 H), 1.56 (d, J=6.64 
Hz, 6 H).  
13
C NMR (100 MHz, Acetone-d6) δ ppm 67.46, 17.32. 
 
 
Sodium 2-Methylpropane-1-sulfonate (2.9):  This product was synthesized in the same 
manner as product 2.1 using isobutyl chloride (72.16 mL, 0.69 mol, 1.1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
SO3Na
SO2Cl
SO3 Na
SO2Cl
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2-Methylpropane-1-sulfonyl Chloride (2.10):  This product was synthesized in the same 
manner as product 2.2.  Following the addition of PCl5, the reaction was heated to 70-75 
°C for 5 hrs. and then worked up as for product 2.2.  2-Methylpropane-1-sulfonyl 
chloride was collected as a colorless, considerably lachrymatory liquid with a smell 
similar to that of an onion (34.3 g, 35% based on sodium sulfite).  b.p. 61°C (5 mm.).  
1
H 
NMR (400 MHz, CDCl3) δ ppm 3.60 (d, J=6.64 Hz, 2 H), 2.39 - 2.53 (m, 1 H), 1.13 (d, 
J=6.64 Hz, 6 H).  
13
C NMR (100 MHz, CDCl3) δ ppm 73.57, 26.12, 21.95. 
 
 
Sodium Butane-1-sulfonate (2.11):  This product was synthesized in the same manner as 
product 2.1 using 1-chlorobutane (86.2 mL, 0.825 mol, 1.1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Butane-1-sulfonyl Chloride (2.12):  This product was synthesized in the same manner as 
product 2.2.  Following the addition of PCl5, the reaction was heated to 75 °C for 6 hrs. 
and then worked up as for product 2.2.  Butane-1-sulfonyl chloride was collected as a 
colorless, lachrymatory liquid (4.7 g, 4% based on sodium sulfite).  b.p. 65°C (5 mm.).  
1
H NMR (400 MHz, Acetone-d6) δ ppm 3.97 (t, J=7.81 Hz, 2 H), 1.94 - 2.03 (m, 2 H), 
1.55 (sxt, J=7.50 Hz, 2 H), 0.98 (t, J=7.22 Hz, 3 H).  
13
C NMR (100 MHz, Acetone-d6) δ 
ppm 65.65, 27.13, 21.30, 13.65. 
  
 
SO3 Na
SO2Cl
SO3 Na
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Sodium Decane-1-sulfonate (2.13):  This product was synthesized in the same manner as 
product 2.1 using 1-bromodecane (114.12 mL, 0.55 mol, 1.1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Decane-1-sulfonyl Chloride (2.14):  This product was synthesized in the same manner as 
product 2.2.  Following the addition of PCl5, the reaction was heated to 75-85 °C for 2 
hrs. and then worked up as for product 2.2.  However, diethyl ether must be used as the 
extraction solvent for this product because dichloromethane will not work for this 
product.  Butane-1-sulfonyl chloride was recrystallized from diethyl ether as a yellow 
solid (109.56 g, 91% based on sodium sulfite).  Rƒ = 0.70 (1:4 EtOAc/hexanes) I2 TLC 
visualization.  
1
H NMR (600 MHz, CDCl3) δ ppm 3.63 (t, J=7.62 Hz, 2 H), 2.00 (quin, 
J=7.62 Hz, 2 H), 1.42 - 1.49 (m, 2 H), 1.22 - 1.27 (m, 12 H), 0.85 (t, J=7.03 Hz, 3 H).  
13
C NMR (150 MHz, CDCl3) δ ppm 65.53, 31.89, 29.44, 29.26, 29.22, 28.93, 27.57, 
24.34, 22.69, 14.12.  m/z 242.2 (M+H)
+
. 
 
 
1-Chlorooctadecane
40b
 (2.15):  In a 1 L RBF, 1-octadecanol (132.25 g, 0.5 mol, 1 eq.) 
was dissolved in 500 mL benzene followed by the addition of pyridine (40.36 mL, 0.5 
mol, 1 eq.) at RT.  Thionyl chloride (47.3 mL, 0.65 mol, 1.3 eq.) was then added 
dropwise to the reaction over 30-45 minutes.  The mixture was then allowed to react for 
24 hrs. and then the solvent was roto-evaporated.  Once the majority of the solvent was 
removed, diethyl ether was added and the reaction was roto-evaporated once more.  
SO2Cl
Cl
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Following the removal of the diethyl ether, dichloromethane was added to the reaction 
and then roto-evaporated.  After the majority of the liquid was removed, the residue was 
dried on the high vacuum and the crude product was used in the next step without further 
purification.  Rƒ = 0.76 (Hexanes) I2 TLC visualization. 
 
 
Sodium Octadecane-1-sulfonate (2.16):  This product was synthesized in the same 
manner as product 2.1 using 1-Chlorooctadecane (49 g, 0.17 mol, 1 eq.) in place of 
dichloromethane.  The reaction was heated to 140 °C for 16 hrs. in the pressure vessel.  
When cooling the reaction, the crude product solidified in the pressure vessel around 60 
°C and was scooped out and added to a large RBF for evaporation.  The residual product 
in the pressure vessel was collected with DI water and combined with the product in the 
large RBF.  The crude salt was dried and powdered before using in the next step. 
 
 
Octadecane-1-sulfonyl Chloride
56
 (2.17):  This product was synthesized in the same 
manner as product 2.2.  A suitably large enough RBF must be used (larger than for other 
chlorinations) due to the fact that the reaction will foam as the PCl5 reacts!  Following the 
addition of PCl5, the reaction was heated to 100-110 °C for 1.5 hrs. and then worked up 
as for product 2.2.  Diethyl ether was used as the extraction solvent for this product 
instead of dichloromethane.  Evaporation of the diethyl ether left crude 2.17 as a brown 
crystalline solid. 
 
SO3Na
SO2Cl
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Sodium Phenylmethanesulfonate (2.18):  This product was synthesized in the same 
manner as product 2.1 using benzyl chloride (94.94 mL, 0.825 mol, 1.1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
Phenylmethanesulfonyl Chloride
57
 (2.19):  This product was synthesized in the same 
manner as product 2.2.  Following the addition of PCl5, the reaction was heated to 75-80 
°C for 5.5 hrs. and then worked up as for product 2.2.  Phenylmethanesulfonyl chloride 
was recrystallized from dichloromethane as a white solid (35.6 g, 25% based on sodium 
sulfite).  The solid product was washed with hexanes during the filtration step of 
recrystallization to avoid product loss.  
1
H NMR (400 MHz, CDCl3) δ ppm 7.42 - 7.50 
(m, 5 H), 4.85 (s, 2 H).  
13
C NMR (100 MHz, CDCl3) δ ppm 131.44, 130.26, 129.19, 
126.20, 70.87. 
 
 
Sodium Naphthalen-1-ylmethanesulfonate (2.20):  This product was synthesized in the 
same manner as product 2.1 using 1-chloromethylnapthalene (37.7 mL, 0.25 mol, 1.1 eq.) 
in place of dichloromethane.  The crude salt was dried and powdered before using in the 
next step. 
SO3 Na
SO2Cl
SO3 Na
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Naphthalen-1-ylmethanesulfonyl Chloride
58
 (2.21):  This product was synthesized in the 
same manner as product 2.2.  Following the addition of PCl5, the reaction was heated to 
60 °C for 9 hrs. and then worked up as for product 2.2.  Naphthalen-1-ylmethanesulfonyl 
chloride was recrystallized from dichloromethane and diethyl ether as a light brown 
crystalline solid (14.1 g, 25% based on sodium sulfite).  
1
H NMR (500 MHz, CDCl3) δ 
ppm 8.17 (d, J=8.30 Hz, 1 H), 7.90 (d, J=7.81 Hz, 1 H), 7.86 (d, J=8.30 Hz, 1 H), 7.62 (t, 
J=7.32 Hz, 1 H), 7.53 (d, J=6.34 Hz, 1 H), 7.55 (d, J=7.81 Hz, 1 H), 7.43 (t, J=7.32 Hz, 1 
H), 5.06 (s, 2 H).  
13
C NMR (125 MHz, CDCl3) δ ppm 123.80, 123.02, 121.48, 120.38, 
120.36, 119.62, 118.65, 117.41, 116.71, 115.34, 70.06.  m/z 242.2 (M+H)
+
. 
 
 
N-Boc Taurine Tetrabutylammonium Salt
59
 (2.22):  In a 100 mL RBF, Taurine (4 g, 32 
mmol, 1 eq.) was dissolved in 16 mL 2M NaOH.  Boc anhydride (6.98 g, 32 mmol, 1 
eq.), dissolved in 10 mL THF, was then added dropwise to the reaction at RT and then 
the reaction was allowed to react for 24 hrs.  The reaction was then diluted with 20 mL 
DI water followed by the addition of LiOH (0.77 g, 32 mmol, 1 eq.) and TBAHS (10.86 
g, 32 mmol, 1 eq.).  After stirring for 30 minutes, the reaction was further diluted with 20 
mL DI water and then extracted 2x with DCM.  The organic layer was dried over 
anhydrous MgSO4, filtered, and then roto-evaporated.  The crude clear viscous oily 
SO2Cl
S
N
H
OtBu
O
Bu4NO
O O
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product was used in the next step without further purification.  
1
H NMR (400 MHz, 
CDCl3) δ ppm 6.08 (br. s., 1 H), 3.39 - 3.45 (m, 2 H), 3.14 - 3.20 (m, 8 H), 2.74 - 2.78 
(m, 2 H), 1.50 - 1.57 (m, 8 H), 1.31 - 1.38 (m, 8 H), 1.29 (s, 9 H), 0.89 (t, J=7.22 Hz, 12 
H).  
13
C NMR (100 MHz, CDCl3) δ ppm 155.99, 78.27, 58.60, 50.65, 36.95, 28.38, 
23.89, 19.62, 13.57. 
 
 
N-Boc Taurine Chloride
59
 (2.23):  In a 200 mL RBF, the crude salt 2.22 (15.9 g, 32 
mmol, 2.5 eq.) was dissolved in 100 mL DCM followed by the addition of DMF (0.25 
mL, 3.2 mmol, 0.25 eq.).  Triphosgene (3.83 g, 12.8 mmol, 1 eq.) was then added to the 
reaction at RT in portions as it quickly elicited a vigorous response.  After stirring for 4.5 
hrs., the reaction was roto-evaporated.  The residue was the taken up in DCM and washed 
1x with DI water.  The DCM was dried over anhydrous MgSO4, filtered, and then roto-
evaporated.  The residue was then dried on the high vacuum and the crude product was 
obtained as a slightly yellow solid.  m/z 242.2 (M+H)
+
. 
  
 
Sodium Ethane-1,2-disulfonate (2.24):  This product was synthesized in the same manner 
as product 2.1 using 1,2-dichloroethane (23.75 mL, 0.3 mol, 1 eq.) in place of 
dichloromethane.  The crude salt was dried and powdered before using in the next step. 
 
 
S
N
H
OtBu
O
Cl
O O
SO3 Na
NaO3S
ClO2S
SO2Cl
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Ethane-1,2-disulfonyl Dichloride
60
 (2.25):  This product was synthesized in the same 
manner as product 2.2.  Following the addition of PCl5, the reaction was heated to 100-
115 °C for 3 hrs. and then worked up as for product 2.2.  Diethyl ether was used as the 
extraction solvent for this product instead of dichloromethane.  Evaporation of the diethyl 
ether afforded pure 2.24 as a white fluffy lachrymatory powder (48.7 g, 71% based on 
dichloroethane).  Recrystallization from Toluene afforded analytically pure product.  
1
H 
NMR (600 MHz, Benzene-d6) δ ppm 3.24 (s, 4 H).  
13
C NMR (150 MHz, Benzene-d6) δ 
ppm 57.72. 
 
2.5.3 Circular Dichroism Measurements 
Circular dichroism experiments were carried out at room temperature on the Aviv (Model 
# 210) spectropolarimeter flushed with nitrogen. The samples were prepared as stock 
solutions in sodium acetate buffer and diluted to the desired concentration for 
measurements. Each spectra was collected from 250 to 184 nm using a 0.1 cm path 
length cylindrical quartz cell. Each spectrum was recorded as an average of three scans 
taken at a spectral bandwidth of 1 nm. All spectra were corrected for buffer contributions 
and presented in units of molar ellipticity. 
 
2.5.4 NMR Spectroscopy  
 
All deuterated reagents and solvents were purchased from Cambridge Isotopes.  
All 1D 
1
H and 
13
C NMR spectra were recorded on a Bruker 250 MHz or a Varian 
INOVA 400 MHz spectrometer in CDCl3 unless otherwise specified and chemical shifts 
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are reported in ppm (δ) relative to internal standard tetramethylsilane (TMS).  2D NMR 
samples were prepared by dissolving 1-2 mg peptide in 100 μL D2O and then adjusting 
the pD to 4.0 (uncorrected) with either 50 mM NaOAc-d3 or 50 mM AcOH-d4 to yield a 
final concentration between 3-7 mM.  Chemical shifts are reported in parts per million 
(ppm) relative to 0.5 mM DSS.  NMR experiments were run and processed on a three-
channel Varian Inova 500 MHz instrument at 298.1 K using a 3-mm I.D. RT probe 
equipped with Z-axis PFGs running VnmrJ 2.2D.  Spectra were then analyzed using 
ACD labs NMR Manager version 11.0.  1D NMR spectra were collected using 32K data 
points, between 16 and 64 scans were collected using a 0.5 s delay and 1 s presaturation.  
2D TOCSY and NOESY experiments were run with a 5000 Hz window in both 
dimensions.  TOCSY experiments were run with a mixing time of 60 ms, a 0.5 s 
relaxation delay followed by 1 s of presaturation and 512 increments in the ƒ1 dimension 
with 32 transients per increment (collecting 4096 data points per transient in the ƒ2 
dimension).  Zero-filling was then applied using 4096 points for each dimension.  
NOESY experiments were performed using a 500 ms mixing time, 1 s of presaturation 
and 512 increments of 32 transients each (collecting 4096 data points per transient in the 
ƒ2).  Zero-filling was then applied using 4096 points for each dimension.  Presaturation 
was used to suppress the water resonance both during the relaxation delay and during the 
mixing time.  All spectra were analyzed using standard window functions (Gaussian 
without shifting).  Assignments were made by using standard methods as described by 
Wüthrich
61
. 
 
2.5.5 2D NMR Data 
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Table 2.7: NMR assignments for peptide 2.26 
 
α Β γ δ ε 
L-Pro-T2 4.531 2.219, 2.111 2.077, 1.940 3.949, 3.705  
D-Pro-T2 4.741 2.287, 2.155 2.004, 1.896 3.793, 3.539  
Lys-1 4.379 1.784, 1.745 1.403 1.667 2.977 
Leu-2 4.536 1.569 1.505 0.812, 0.811 
 
Lys-3 4.291 1.794, 1.667 1.403, 1.261 1.564 2.947 
Leu-4 4.985 1.730 1.530 0.851, 0.777 
 
Lys-5 4.541 1.789, 1.662 1.349, 1.242 1.564 2.864 
Turn T1-11 3.563
S
, 3.866
R
 
 
3.348 3.162 SO2Me = 3.030 
Met-6 4.482 2.107 2.551, 2.434 
 
2.121 
Val-7 4.130 1.940 0.875, 0.665 
  
Val-8 4.267 1.989 0.880, 0.802 
  
Ser-9 4.599 3.837 
   
Trp-10 4.692 3.226, 3.128 7.121, 7.146, 7.229, 7.473, 7.561 (5H, 2H, 6H, 7H, 4H) 
S = Pro-S, R = Pro-R 
 
Table 2.8: NMR assignments for peptide 2.27 
 
α β γ δ ε 
Lys-1 4.262 1.823, 1.774 1.432, 1.402 1.642 2.976 
Leu-2 4.349 1.554 1.427 0.782, 0.767 
 
Lys-3 4.076 1.759, 1.642 1.373, 1.285 1.588 2.874 
Leu-4 4.281 1.945 1.622 0.923, 0.845 
 
Lys-5 4.574 1.765, 1.657 1.286 1.589 2.879 
Met-6 4.643 2.155, 1.989 2.575, 2.522 
 
2.072 
Val-7 4.662 1.637 0.874, 0.801 
  
Val-8 4.320 1.911 0.816, 0.772 
  
Ser-9 4.462 3.778 
   
Trp-10 4.701 3.172 7.140, 7.121, 7.238, 7.473, 7.590 (5H, 2H, 6H, 7H, 4H) 
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Table 2.9: NMR assignments for peptide 2.30 
 
α β γ δ ε 
Turn T1-12 3.891
S
, 4.062
R
 
 
3.500
S
, 3.612
R
 3.236 SO2Me = 3.045 
Lys-1 4.311 1.823 1.452 1.691 2.996 
Leu-2 4.160 1.525, 1.418 1.359 0.768, 0.645 
 
Lys-3 4.072 1.740, 1.613 1.281, 1.149 1.506 2.776 
Leu-4 4.042 1.994 1.955 0.929, 0.904 
 
Lys-5 4.423 1.770, 1.657 1.305 1.589 2.879 
Turn T1-11 3.465
S
, 4.047
R
 
 
3.490
S
, 3.529
R
 3.334 SO2Me = 3.050 
Met-6 4.599 2.234, 1.999 2.664, 2.532 
 
2.077 
Val-7 4.575 1.618 0.924, 0.797 
  
Ala-8 4.531 1.183 
   
Ser-9 4.599 3.822, 3.720 
   
Trp-10 4.609 3.206, 3.123 7.151, 7.160, 7.239, 7.473, 7.654 (5H, 2H, 6H, 7H, 4H) 
S = Pro-S, R = Pro-R 
 
Table 2.10: NMR assignments for peptide 2.32 
 
α β γ δ ε 
Lys-1 4.438 1.823, 1.779 1.423 1.662 2.977 
Leu-2 4.311 1.946 1.892 0.836, 0.763 
 
Lys-3 4.081 1.750, 1.638 1.339, 1.261 1.555 2.845 
Leu-4 4.282 1.540 1.427 0.787, 0.768 
 
Lys-5 4.516 1.745, 1.647 1.291 1.564 2.869 
Ala-6 4.419 1.383 
   
Val-7 4.629 1.623 0.865, 0.792 
  
Val-8 4.184 1.950 0.934, 0.860 
  
Ser-9 4.697 3.803, 3.754 
   
Trp-10 4.668 3.172, 3.153 7.146, 7.141, 7.244, 7.478, 7.615 (5H, 2H, 6H, 7H, 4H) 
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Table 2.11: NMR assignments for peptide 2.33 
 
α β γ δ ε 
Lys-1 4.287 1.799, 1.691 1.437, 1.379 1.623 2.943 
Leu-2 4.292 1.579 1.467 0.821, 0.807 
 
Lys-3 4.086 1.750, 1.682 1.369, 1.266 1.584 2.869 
Leu-4 4.375 1.985 1.618 0.914, 0.836 
 
Lys-5 4.590 1.731, 1.638 1.388, 1.310 1.589 2.943 
Nor-6 4.453 1.794 1.711 1.276 0.851 
Val-7 4.673 2.038 0.895, 0.880 
  
Val-8 4.639 1.589 0.861, 0.811 
  
Ser-9 4.453 3.802 
   
Trp-10 4.595 3.246, 3.207 7.112, 7.141, 7.239, 7.483, 7.581 (2H, 5H, 6H, 7H, 4H) 
 
Table 2.12: NMR assignments for peptide 2.36 
 
α β γ δ ε 
Lys-1 4.174 1.770, 1.652 1.345 1.379 2.967 
Leu-2 4.531 1.657 1.535 0.895, 0.851 
 
Lys-3 4.052 1.731, 1.608 1.354 1.535 2.943 
Leu-4 4.365 1.633 1.525 0.905, 0.875 
 
Lys-5 4.345 1.819, 1.770 1.437, 1.393 1.687 2.977 
Trp-6 4.834 3.436, 3.212 7.141, 7.234, 7.268, 7.493, 7.630 (5H, 6H, 2H, 7H, 4H) 
Ser-7 4.512 3.774, 3.754 
   
Val-8 4.517 1.496 0.816, 0.782 
  
Val-9 4.096 2.009 0.939, 0.924 
  
Met-10 4.453 2.048, 1.941 2.562, 2.498 
 
2.083 
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Table 2.13: NMR assignments for peptide 2.43 
 
α β γ δ ε 
Turn T3-11 4.232 3.426 1.544 1.754 α-CH2-O: 3.704 
O-CH2-CO 4.022
S
, 3.978
R
 
    
Lys-1 4.550 1.994, 1.935 1.525, 1.495 1.730 3.010 
Leu-2 4.780 1.725, 1.642 1.427 0.889, 0.792 
 
Lys-3 4.320 1.852, 1.759 1.393, 1.344 1.627 2.918 
Leu-4 4.634 1.701 1.564 0.831, 0.816 
 
Lys-5 4.169 1.828, 1.715 1.422, 1.383 1.661 2.971 
Turn T1-12 3.944
S
, 4.076
R
 
 
3.538
S
, 3.445
R
 3.284 SO2Me = 3.064 
Nor-6 4.340 1.720 1.647 1.281 0.860 
Val-7 4.442 2.106 0.938, 0.928 
  
Val-8 4.545 1.950 0.933, 0.875 
  
Ala-9 4.697 1.285 
   
Trp-10 5.054 3.309, 2.952 7.223, 7.175, 7.258, 7.497, 7.658 (5H, 6H, 2H, 7H, 4H) 
S = Pro-S, R = Pro-R 
 
2.5.6 NOE Enhancement Pictures 
 
In the NOE figures shown below, arrows drawn in black represent a strong NOE 
enhancement.  Arrows drawn in green represent a medium NOE enhancement while 
arrows drawn in red represent a weak NOE enhancement. 
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Figure 2.25: Peptide 2.26 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
 
c) 
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Figure 2.26: Peptide 2.27 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
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Figure 2.27: Peptide 2.30 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
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Figure 2.28: Peptide 2.32 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
 
c) 
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Figure 2.29: Peptide 2.33 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
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Figure 2.30: Peptide 2.36 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
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Figure 2.31: Peptide 2.43 NOEs: (a) Intra-residue NOEs; (b) Same-strand NOEs; (c) 
Cross-strand NOEs 
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Figure A1: A) Proton NMR; B) Carbon NMR of 4-Benzyl-3,6-dichloropyridazine (1.1) 
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Figure A2: A) Proton NMR; B) Carbon NMR of 3,6-Dichloro-4-isopropylpyridazine 
(1.2) 
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Figure A3: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 1-(3,6-
Dichloropyridazin-4-yl)-3-methylbutan-1-ol (1.3) 
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Figure A4: A) Proton NMR; B) Carbon NMR of 3,6-Dichloro-4-isobutylpyridazine (1.4) 
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Figure A5: A) Proton NMR; B) Carbon NMR of 3,6-Dichloro-4-(naphthalen-2-
ylmethyl)pyridazine (1.5) 
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Figure A6: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of (S)-Ethyl 2-(6-
chloropyridazin-3-ylamino)-3-phenylpropanoate (1.6) 
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Figure A7: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of (S)-
Methyl 2-(5-benzyl-6-chloropyridazin-3-ylamino)-4-methylpentanoate (1.7) 
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Figure A8: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of (S)-methyl 2-(5-
benzyl-6-chloropyridazin-3-ylamino)-3-phenylpropanoate (1.8) 
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Figure A9: A) Proton NMR; B) Carbon NMR of 3-Chloro-6-isopropoxy-4-
isopropylpyridazine (1.9) 
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Figure A10: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 6-(Benzyloxy)-3-
chloro-4-isopropylpyridazine (1.10) 
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Figure A11: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
Chloro-6-isobutoxy-4-isopropylpyridazine (1.11) 
 
*Note* The black arrow in the 1D NOESY spectra indicates the irradiated peak while the 
red arrows indicate the peaks arising from the NOE enhancement. 
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Figure A12: A) Proton NMR; B) Carbon NMR of 3,6-Diisopropoxy-4-
isopropylpyridazine (1.12) 
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Figure A13: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
Isobutoxy-6-isopropoxy-4-isopropylpyridazine (1.13) 
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Figure A14: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
(Benzyloxy)-6-isopropoxy-4-isopropylpyridazine (1.14) 
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Figure A15: A) Proton NMR; B) Carbon NMR of 3,6-Bis(benzyloxy)-4-
isopropylpyridazine (1.15) 
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Figure A16: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
(Benzyloxy)-3-isopropoxy-4-isopropylpyridazine (1.16) 
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Figure A17: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
(Benzyloxy)-3-isobutoxy-4-isopropylpyridazine (1.17) 
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Figure A18: A) Proton NMR; B) Carbon NMR of 3,6-Diisobutoxy-4-
isopropylpyridazine (1.18) 
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Figure A19: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 6-Isobutoxy-3-
isopropoxy-4-isopropylpyridazine (1.19) 
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Figure A20: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
(Benzyloxy)-6-isobutoxy-4-isopropylpyridazine (1.20) 
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Figure A21: A) Proton NMR; B) Carbon NMR of 4-Isopropyl-3,6-bis(naphthalen-1-
ylmethoxy)pyridazine (1.21) 
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Figure A22: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 4-
Benzyl-3-chloro-6-isopropoxypyridazine (1.22) 
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Figure A23: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 4-Benzyl-6-
(benzyloxy)-3-chloropyridazine (1.23) 
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Figure A24: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 4-
Benzyl-3-chloro-6-isobutoxypyridazine (1.24) 
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Figure A25: A) Proton NMR; B) Carbon NMR of 4-Benzyl-3,6-diisopropoxypyridazine 
(1.25) 
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Figure A26: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 4-Benzyl-3-
isobutoxy-6-isopropoxypyridazine (1.26) 
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Figure A27: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 4-
Benzyl-3-(benzyloxy)-6-isopropoxypyridazine (1.27) 
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Figure A28: A) Proton NMR; B) Carbon NMR of 4-Benzyl-3,6-
bis(benzyloxy)pyridazine (1.28) 
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Figure A29: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 4-Benzyl-6-
(benzyloxy)-3-isopropoxypyridazine (1.29) 
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Figure A30: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 4-
Benzyl-6-(benzyloxy)-3-isobutoxypyridazine (1.30) 
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Figure A31: A) Proton NMR; B) Carbon NMR of 4-Benzyl-3,6-diisobutoxypyridazine 
(1.31) 
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Figure A32: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 4-Benzyl-6-
isobutoxy-3-isopropoxypyridazine (1.32) 
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Figure A33: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 4-Benzyl-3-
(benzyloxy)-6-isobutoxypyridazine (1.33) 
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Figure A34: A) Proton NMR; B) Carbon NMR of 4-Benzyl-3,6-bis(naphthalen-1-
ylmethoxy)pyridazine (1.34) 
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Figure A35: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
Chloro-4-isobutyl-6-isopropoxypyridazine (1.35) 
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Figure A36: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
(Benzyloxy)-3-chloro-4-isobutylpyridazine (1.36) 
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Figure A37: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
Chloro-6-isobutoxy-4-isobutylpyridazine (1.37) 
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Figure A38: A) Proton NMR; B) Carbon NMR of 4-Isobutyl-3,6-diisopropoxypyridazine 
(1.38) 
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Figure A39: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
Isobutoxy-4-isobutyl-6-isopropoxypyridazine (1.39) 
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Figure A40: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 3-
(Benzyloxy)-4-isobutyl-6-isopropoxypyridazine (1.40) 
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Figure A41: A) Proton NMR; B) Carbon NMR of 3,6-Bis(benzyloxy)-4-
isobutylpyridazine (1.41) 
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Figure A42: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
(Benzyloxy)-4-isobutyl-3-isopropoxypyridazine (1.42) 
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Figure A43: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
(Benzyloxy)-3-isobutoxy-4-isobutylpyridazine (1.43) 
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Figure A44: A) Proton NMR; B) Carbon NMR of 3,6-Diisobutoxy-4-isobutylpyridazine 
(1.44) 
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Figure A45: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY; D) 1D NOESY of 6-
Isobutoxy-4-isobutyl-3-isopropoxypyridazine (1.45) 
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Figure A46: A) Proton NMR; B) Carbon NMR; C) 1D TOCSY of 3-(Benzyloxy)-6-
isobutoxy-4-isobutylpyridazine (1.46) 
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Figure A47: A) Proton NMR; B) Carbon NMR of 4-Isobutyl-3,6-bis(naphthalen-1-
ylmethoxy)pyridazine (1.47) 
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Figure A48: A) Proton NMR; B) Carbon NMR of 3,6-Diisopropoxy-4-(naphthalen-2-
ylmethyl)pyridazine (1.48) 
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Figure A49: A) Proton NMR; B) Carbon NMR of 3,6-Diisobutoxy-4-(naphthalen-2-
ylmethyl)pyridazine (1.49) 
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Figure A50: A) Proton NMR; B) Carbon NMR of 3,6-Bis(benzyloxy)-4-(naphthalen-2-
ylmethyl)pyridazine (1.50) 
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Figure A51: A) Proton NMR; B) Carbon NMR of Chloromethanesulfonyl Chloride (2.2) 
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Figure A52: A) Proton NMR; B) Carbon NMR of Bromomethanesulfonyl Chloride (2.4) 
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Figure A53: A) Proton NMR; B) Carbon NMR of Methane-d3-sulfonyl Chloride (2.6) 
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Figure A54: A) Proton NMR; B) Carbon NMR of Propane-2-sulfonyl Chloride (2.8) 
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Figure A55: A) Proton NMR; B) Carbon NMR of 2-Methylpropane-1-sulfonyl Chloride 
(2.10) 
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Figure A56: A) Proton NMR; B) Carbon NMR of Butane-1-sulfonyl Chloride (2.12) 
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Figure A57: A) Proton NMR; B) Carbon NMR of Decane-1-sulfonyl Chloride (2.14) 
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Figure A58: A) Proton NMR; B) Carbon NMR of Phenylmethanesulfonyl Chloride 
(2.19) 
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Figure A59: A) Proton NMR; B) Carbon NMR of Naphthalen-1-ylmethanesulfonyl 
Chloride (2.21) 
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Figure A60: A) Proton NMR; B) Carbon NMR of N-Boc Taurine Tetrabutylammonium 
Salt (2.22) 
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Figure A61: A) Proton NMR; B) Carbon NMR of Ethane-1,2-disulfonyl Dichloride 
(2.25) 
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Appendix B:  
Selected 2D NMR Spectra 
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Figure B1: Peptide 2.26 TOCSY 
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PJ-6-62 NOESY REPROCESSED.ESP
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Figure B2: Peptide 2.26 NOESY 
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Figure B3: Peptide 2.27 TOCSY 
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Figure B4: Peptide 2.27 NOESY 
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TOCSY 6-106.ESP
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Figure B5: Peptide 2.30 TOCSY 
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PJ-6-106 NOESY REPROCESSED.ESP
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Figure B6: Peptide 2.30 NOESY 
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Figure B7: Peptide 2.32 TOCSY 
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PJ-6-108 NOESY 2ND TRIAL.ESP
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Figure B8: Peptide 2.32 NOESY 
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PJ-6-110 TOCSY TRIAL 2.ESP
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Figure B9: Peptide 2.33 TOCSY 
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Figure B10: Peptide 2.33 NOESY 
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PJ-7-04 TOCSY.ESP
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Figure B11: Peptide 2.36 TOCSY 
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PJ-7-04 NOESY TRIAL 2.ESP
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Figure B12: Peptide 2.36 NOESY 
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PJ-8-73 TOCSY.ESP
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Figure B13: Peptide 2.43 TOCSY 
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PJ-8-73 NOESY BEST LOOKING REDONE.ESP
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Figure B14: Peptide 2.43 NOESY 
325 
 
 
 
Appendix C:  
Selected Mass Spectra 
 
 
 
Figure C1: Mass spectra of 4-benzyl-3,6-dichloropyridazine (1.1) 
N N
ClCl
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Figure C2: Mass spectra of 3,6-dichloro-4-isopropylpyridazine (1.2) 
 
 
 
 
 
 
 
NN
Cl Cl
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Figure C3: Mass spectra of 1-(3,6-dichloropyridazin-4-yl)-3-methylbutan-1-ol (1.3) 
N N
ClCl
HO
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Figure C4: Mass spectra of 3,6-dichloro-4-isobutylpyridazine (1.4) 
 
 
 
 
 
N N
ClCl
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Figure C5: Mass spectra of 3,6-dichloro-4-(naphthalen-2-ylmethyl)pyridazine (1.5) 
N N
ClCl
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Figure C6: Mass spectra of (S)-ethyl 2-(6-chloropyridazin-3-ylamino)-3-
phenylpropanoate (1.6) 
N N
O
H
N
O
Cl
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Figure C7: Mass spectra of (S)-methyl 2-(5-benzyl-6-chloropyridazin-3-ylamino)-4-
methylpentanoate (1.7) 
 
 
 
 
 
 
 
 
 
 
 
 
N N
Cl
O
H
N
O
332 
 
 
 
 
Figure C8: Mass spectra of (S)-methyl 2-(5-benzyl-6-chloropyridazin-3-ylamino)-3-
phenylpropanoate (1.8) 
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Figure C9: Mass spectra of 3-chloro-6-isopropoxy-4-isopropylpyridazine (1.9) 
NN
O Cl
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Figure C10: Mass spectra of 6-(benzyloxy)-3-chloro-4-isopropylpyridazine (1.10) 
N N
ClO
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Figure C11: Mass spectra of 3-chloro-6-isobutoxy-4-isopropylpyridazine (1.11) 
N N
ClO
336 
 
 
 
Figure C12: Mass spectra of 3,6-diisopropoxy-4-isopropylpyridazine (1.12) 
N N
O O
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Figure C13: Mass spectra of 3-isobutoxy-6-isopropoxy-4-isopropylpyridazine (1.13) 
NN
O O
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Figure C14: Mass spectra of 3-(benzyloxy)-6-isopropoxy-4-isopropylpyridazine (1.14) 
N N
OO
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Figure C15: Mass spectra of 3,6-bis(benzyloxy)-4-isopropylpyridazine (1.15) 
 
N N
OO
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Figure C16: Mass spectra of 6-(benzyloxy)-3-isopropoxy-4-isopropylpyridazine (1.16) 
 
N N
OO
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Figure C17: Mass spectra of 6-(benzyloxy)-3-isobutoxy-4-isopropylpyridazine (1.17) 
N N
OO
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Figure C18: Mass spectra of 3,6-diisobutoxy-4-isopropylpyridazine (1.18) 
N N
OO
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Figure C19: Mass spectra of 6-isobutoxy-3-isopropoxy-4-isopropylpyridazine (1.19) 
N N
OO
344 
 
 
 
  
Figure C20: Mass spectra of 3-(benzyloxy)-6-isobutoxy-4-isopropylpyridazine (1.20) 
N N
OO
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Figure C21: Mass spectra of 4-isopropyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine 
(1.21) 
N N
OO
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Figure C22: Mass spectra of 4-benzyl-3-chloro-6-isopropoxypyridazine (1.22) 
N N
ClO
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Figure C23: Mass spectra of 4-benzyl-6-(benzyloxy)-3-chloropyridazine (1.23) 
N N
ClO
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Figure C24: Mass spectra of 4-benzyl-3-chloro-6-isobutoxypyridazine (1.24) 
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Figure C25: Mass spectra of 4-benzyl-3,6-diisopropoxypyridazine (1.25) 
N N
OO
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Figure C26: Mass spectra of 4-benzyl-3-isobutoxy-6-isopropoxypyridazine (1.26) 
NN
O O
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Figure C27: Mass spectra of 4-benzyl-3-(benzyloxy)-6-isopropoxypyridazine (1.27) 
N N
OO
352 
 
 
 
Figure C28: Mass spectra of 4-benzyl-3,6-bis(benzyloxy)pyridazine (1.28) 
N N
OO
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Figure C29: Mass spectra of 4-benzyl-6-(benzyloxy)-3-isopropoxypyridazine (1.29) 
N N
OO
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Figure C30: Mass spectra of 4-benzyl-6-(benzyloxy)-3-isobutoxypyridazine (1.30) 
N N
OO
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Figure C31: Mass spectra of 4-benzyl-3,6-diisobutoxypyridazine (1.31) 
N N
OO
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Figure C32: Mass spectra of 4-benzyl-6-isobutoxy-3-isopropoxypyridazine (1.32) 
N N
OO
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Figure C33: Mass spectra of 4-benzyl-3-(benzyloxy)-6-isobutoxypyridazine (1.33) 
N N
OO
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Figure C34: Mass spectra of 4-benzyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine (1.34) 
N N
OO
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Figure C35: Mass spectra of 3-chloro-4-isobutyl-6-isopropoxypyridazine (1.35) 
N N
ClO
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Figure C36: Mass spectra of 6-(benzyloxy)-3-chloro-4-isobutylpyridazine (1.36) 
N N
ClO
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Figure C37: Mass spectra of 3-chloro-6-isobutoxy-4-isobutylpyridazine (1.37) 
N N
ClO
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Figure C38: Mass spectra of 4-isobutyl-3,6-diisopropoxypyridazine (1.38) 
N N
OO
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Figure C39: Mass spectra of 3-isobutoxy-4-isobutyl-6-isopropoxypyridazine (1.39) 
NN
O O
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Figure C40: Mass spectra of 3-(benzyloxy)-4-isobutyl-6-isopropoxypyridazine (1.40) 
N N
OO
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Figure C41: Mass spectra of 3,6-bis(benzyloxy)-4-isobutylpyridazine (1.41) 
N N
OO
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Figure C42: Mass spectra of 6-(benzyloxy)-4-isobutyl-3-isopropoxypyridazine (1.42) 
N N
OO
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Figure C43: Mass spectra of 6-(benzyloxy)-3-isobutoxy-4-isobutylpyridazine (1.43) 
N N
OO
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Figure C44: Mass spectra of 3,6-diisobutoxy-4-isobutylpyridazine (1.44) 
N N
OO
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Figure C45: Mass spectra of 6-isobutoxy-4-isobutyl-3-isopropoxypyridazine (1.45) 
N N
OO
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Figure C46: Mass spectra of 3-(benzyloxy)-6-isobutoxy-4-isobutylpyridazine (1.46) 
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Figure C47: Mass spectra of 4-isobutyl-3,6-bis(naphthalen-1-ylmethoxy)pyridazine 
(1.47) 
N N
OO
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Figure C48: Mass spectra of 3,6-diisopropoxy-4-(naphthalen-2-ylmethyl)pyridazine 
(1.48) 
N N
OO
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Figure C49: Mass spectra of 3,6-diisobutoxy-4-(naphthalen-2-ylmethyl)pyridazine 
(1.49) 
N N
OO
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Figure C50: Mass spectra of 3,6-bis(benzyloxy)-4-(naphthalen-2-ylmethyl)pyridazine 
(1.50) 
N N
OO
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Figure C51: Mass spectra of decane-1-sulfonyl Chloride (2.14) 
 
SO2Cl
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Figure C52: Mass spectra of naphthalen-1-ylmethanesulfonyl Chloride (2.21) 
 
SO2Cl
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Figure C53: Mass spectra of N-Boc Taurine Chloride (2.23) 
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